var images_info;if (!images_info) images_info =[]; images_info["102"]={"102213":{"type":"graphic_table","displayName":"Measles exanthem ddx","title":"Differential diagnosis of measles exanthem","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of measles exanthem</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Viral infections associated with rash</td> </tr> <tr> <td class=\"indent1\">Rubella</td> <td>Rubella infection is characterized by rash (resembling measles), fever, and lymphadenopathy (postauricular, posterior cervical, and/or suboccipital adenopathy); in general, symptoms are relatively mild. </td> </tr> <tr> <td class=\"indent1\">Erythema infectiosum or \"fifth disease\" (human parvovirus B19)</td> <td>Children often develop a characteristic rash with a \"slapped cheeks\" appearance.</td> </tr> <tr> <td class=\"indent1\">Roseola infantum or exanthem subitum (human herpesvirus 6 or 7)</td> <td>Primarily seen in infants and young children; roseola infantum&nbsp;is characterized by high fever (three to four days) followed by generalized maculopapular rash that spreads from the trunk to the face and extremities.</td> </tr> <tr> <td class=\"indent1\">Infectious mononucleosis (Epstein-Barr virus or cytomegalovirus)</td> <td>Infectious mononucleosis is characterized by pharyngitis, fever, and&nbsp;lymphadenopathy. Maculopapular rash usually occurs following administration of ampicillin.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">HIV infection</td> <td>Primary HIV infection is characterized by fever, sore throat, malaise, headache, lymphadenopathy, and mucocutaneous ulceration. A transient, maculopapular, nonpruritic rash, located on the trunk or face, may occur two to four weeks after the primary HIV infection. </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Bacterial infections associated with rash</td> </tr> <tr> <td class=\"indent1\">Scarlet fever</td> <td>Scarlet fever is characterized by pharyngitis due to group A <em>Streptococcus </em>infection, accompanied by&nbsp;a coarse, sandpaper-like, erythematous, blanching rash.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Mycoplasma</em> infection</td> <td><em>Mycoplasma</em> infection is characterized by respiratory tract infection; in some cases, there may be associated mild erythematous maculopapular or vesicular rash. Rarely, erythema multiforme or Stevens-Johnson syndrome occurs.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Autoimmune connective tissue disease associated with rash</td> </tr> <tr> <td class=\"indent1\">Juvenile idiopathic arthritis and adult-onset Still disease</td> <td>Rash consists of evanescent, salmon pink maculopapular rash occurring with fever. The rash predominantly involves the trunk and extremities but can also involve the palms, soles, and occasionally the face.</td> </tr> <tr> <td class=\"indent1\">Acute cutaneous lupus erythematosus</td> <td>Rash consists of widespread eruption, often focused over the extensor aspects of the arms and hands; it is typically precipitated or exacerbated by exposure to ultraviolet light.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 102213 Version 1.0</div></div></div>"},"102215":{"type":"graphic_movie","displayName":"Cleft-like indentation of posterior mitral leaflet","title":"Cleft-like indentation of the posterior mitral leaflet","html":"<div class=\"graphic normal\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Cleft-like indentation of the posterior mitral leaflet</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/102215_Cleftmitralleafletvid.mp4\" style=\"width:688px;height:288px\"></div><img style=\"width:800px; height:307px;\" src=\"images/CARD/102215_Cleftmitralleafletimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-dimensional transesophageal echocardiography of the mitral valve demonstrates a large cleft-like indentation of the posterior leaflet between the P1 and P2 scallops (arrows). This is visible on both left atrial and left ventricular views of the valve.</div><div id=\"graphicVersion\">Graphic 102215 Version 1.0</div></div></div>"},"102220":{"type":"graphic_picture","displayName":"Hallux limitus","title":"Hallux limitus","html":"<div class=\"graphic\"><div style=\"width: 828px\" class=\"figure\"><div class=\"ttl\">Hallux limitus</div><div class=\"cntnt\"><img style=\"width:808px; height:349px;\" src=\"images/SM/102220_Halluxlimitus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows hallux limitus in the foot of an asymptomatic patient. Although no signs of degenerative joint disease are apparent, only 30 degrees of passive extension can be obtained at the metatarsophalangeal joint.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 102220 Version 1.0</div></div></div>"},"102223":{"type":"graphic_picture","displayName":"Plantar fibromatosis of foot (Ledderhose disease)","title":"Plantar fibromatosis of foot (Ledderhose disease)","html":"<div class=\"graphic\"><div style=\"width: 714px\" class=\"figure\"><div class=\"ttl\">Plantar fibromatosis of foot (Ledderhose disease)</div><div class=\"cntnt\"><img style=\"width:694px; height:722px;\" src=\"images/SM/102223_Plntrfbrmtfootlddrhsdss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These photographs from the same patient show a normal left foot and a right foot with plantar fibromatosis. The plantar lesion is accentuated by extension of the metatarsophalangeal joint.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 102223 Version 1.0</div></div></div>"},"102224":{"type":"graphic_table","displayName":"Post-ERCP perforation incidence","title":"Incidence of post-ERCP perforation and outcomes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of post-ERCP perforation and outcomes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Reference/year</td> <td class=\"subtitle1\" rowspan=\"2\">Country</td> <td class=\"subtitle1\" rowspan=\"2\">Study period</td> <td class=\"subtitle1\" rowspan=\"2\">Design</td> <td class=\"subtitle1\">ERCP procedures</td> <td class=\"subtitle1\">Perforation</td> <td class=\"subtitle1\">Type I*</td> <td class=\"subtitle1\">Type II, III, IV<sup>&#182;</sup></td> <td class=\"subtitle1\">Surgery</td> <td class=\"subtitle1\">Fatalities</td> </tr> <tr> <td class=\"subtitle2\">n</td> <td class=\"subtitle2\">n (%)</td> <td class=\"subtitle2\">n</td> <td class=\"subtitle2\">n</td> <td class=\"subtitle2\">n</td> <td class=\"subtitle2\">n</td> </tr> <tr> <td>Howard et al, 1999</td> <td class=\"centered\">United States</td> <td class=\"centered\">1994 to 1998</td> <td class=\"centered\">R</td> <td class=\"centered\">6060</td> <td class=\"centered\">40 (0.66)</td> <td class=\"centered\">4</td> <td class=\"centered\">36</td> <td class=\"centered\">7</td> <td class=\"centered\">2</td> </tr> <tr> <td>Stapler et al, 2000</td> <td class=\"centered\">United States</td> <td class=\"centered\">1993 to 1998</td> <td class=\"centered\">R</td> <td class=\"centered\">1417</td> <td class=\"centered\">14 (1.0)</td> <td class=\"centered\">5</td> <td class=\"centered\">9</td> <td class=\"centered\">9</td> <td class=\"centered\">2</td> </tr> <tr> <td>Enns et al, 2002</td> <td class=\"centered\">United States</td> <td class=\"centered\">1987 to 1999</td> <td class=\"centered\">R</td> <td class=\"centered\">9314</td> <td class=\"centered\">33 (0.35)</td> <td class=\"centered\">5</td> <td class=\"centered\">28</td> <td class=\"centered\">7</td> <td class=\"centered\">1</td> </tr> <tr> <td>Preetha et al, 2003</td> <td class=\"centered\">Singapore</td> <td class=\"centered\">1994 to 2003</td> <td class=\"centered\">R</td> <td class=\"centered\">4030</td> <td class=\"centered\">18 (0.45)</td> <td class=\"centered\">5</td> <td class=\"centered\">13</td> <td class=\"centered\">18</td> <td class=\"centered\">3</td> </tr> <tr> <td>Kayhan et al, 2004</td> <td class=\"centered\">Turkey</td> <td class=\"centered\">Two years</td> <td class=\"centered\">R</td> <td class=\"centered\">3124</td> <td class=\"centered\">17 (0.54)</td> <td class=\"centered\">2</td> <td class=\"centered\">15</td> <td class=\"centered\">9</td> <td class=\"centered\">0</td> </tr> <tr> <td>Assalia et al, 2007</td> <td class=\"centered\">Israel</td> <td class=\"centered\">1996 to 2003</td> <td class=\"centered\">P</td> <td class=\"centered\">3104</td> <td class=\"centered\">22 (0.71)</td> <td class=\"centered\">2</td> <td class=\"centered\">20</td> <td class=\"centered\">3</td> <td class=\"centered\">1</td> </tr> <tr> <td>Wu et al, 2006</td> <td class=\"centered\">Canada</td> <td class=\"centered\">1996 to 2002</td> <td class=\"centered\">R</td> <td class=\"centered\">6620</td> <td class=\"centered\">30 (0.45)</td> <td class=\"centered\">5</td> <td class=\"centered\">25</td> <td class=\"centered\">12</td> <td class=\"centered\">2</td> </tr> <tr> <td>Fatima et al, 2007</td> <td class=\"centered\">United States</td> <td class=\"centered\">1994 to 2004</td> <td class=\"centered\">R</td> <td class=\"centered\">12,427</td> <td class=\"centered\">75 (0.61)</td> <td class=\"centered\">8</td> <td class=\"centered\">67</td> <td class=\"centered\">22</td> <td class=\"centered\">5</td> </tr> <tr> <td>Mao et al, 2008</td> <td class=\"centered\">China</td> <td class=\"centered\">2004 to 2007</td> <td class=\"centered\">R</td> <td class=\"centered\">2432</td> <td class=\"centered\">9 (0.37)</td> <td class=\"centered\">0</td> <td class=\"centered\">9</td> <td class=\"centered\">3</td> <td class=\"centered\">0</td> </tr> <tr> <td>Knudson et al, 2008</td> <td class=\"centered\">United States</td> <td class=\"centered\">2000 to 2007</td> <td class=\"centered\">R</td> <td class=\"centered\">4919</td> <td class=\"centered\">32 (0.65)</td> <td class=\"centered\">6</td> <td class=\"centered\">26</td> <td class=\"centered\">12</td> <td class=\"centered\">0</td> </tr> <tr> <td>Cotton et al, 2009</td> <td class=\"centered\">United States</td> <td class=\"centered\">1994 to 2006</td> <td class=\"centered\">R</td> <td class=\"centered\">11,497</td> <td class=\"centered\">16 (0.14)</td> <td class=\"centered\">12</td> <td class=\"centered\">4</td> <td class=\"centered\">11</td> <td class=\"centered\">1</td> </tr> <tr> <td>Avgerinos et al, 2009</td> <td class=\"centered\">United States</td> <td class=\"centered\">1999 to 2008</td> <td class=\"centered\">R</td> <td class=\"centered\">4358</td> <td class=\"centered\">15 (0.34)</td> <td class=\"centered\">9</td> <td class=\"centered\">6</td> <td class=\"centered\">13</td> <td class=\"centered\">3</td> </tr> <tr> <td>Kim JH et al, 2009</td> <td class=\"centered\">Korea</td> <td class=\"centered\">2003 to 2007</td> <td class=\"centered\">R</td> <td class=\"centered\">2247</td> <td class=\"centered\">18 (0.80)</td> <td class=\"centered\">8</td> <td class=\"centered\">10</td> <td class=\"centered\">7</td> <td class=\"centered\">1</td> </tr> <tr> <td>Morgan et al, 2009</td> <td class=\"centered\">United States</td> <td class=\"centered\">1995 to 2008</td> <td class=\"centered\">R</td> <td class=\"centered\">12,817</td> <td class=\"centered\">24 (0.19)</td> <td class=\"centered\">12</td> <td class=\"centered\">12</td> <td class=\"centered\">10</td> <td class=\"centered\">1</td> </tr> <tr> <td>Polydorou et al, 2011</td> <td class=\"centered\">Greece</td> <td class=\"centered\">1989 to 2010</td> <td class=\"centered\">R</td> <td class=\"centered\">9880</td> <td class=\"centered\">44 (0.44)</td> <td class=\"centered\">7</td> <td class=\"centered\">37</td> <td class=\"centered\">12</td> <td class=\"centered\">2</td> </tr> <tr> <td>Kim BS et al, 2011</td> <td class=\"centered\">Korea</td> <td class=\"centered\">1994 to 2009</td> <td class=\"centered\">R</td> <td class=\"centered\">7638</td> <td class=\"centered\">13 (0.17)</td> <td class=\"centered\">4</td> <td class=\"centered\">9</td> <td class=\"centered\">7</td> <td class=\"centered\">0</td> </tr> <tr> <td>Dubecz et al, 2012</td> <td class=\"centered\">Germany</td> <td class=\"centered\">2001 to 2009</td> <td class=\"centered\">R</td> <td class=\"centered\">12,232</td> <td class=\"centered\">11 (0.09)</td> <td class=\"centered\">3</td> <td class=\"centered\">8</td> <td class=\"centered\">4</td> <td class=\"centered\">2</td> </tr> <tr> <td>Kim J et al, 2012</td> <td class=\"centered\">Korea</td> <td class=\"centered\">2001 to 2011</td> <td class=\"centered\">R</td> <td class=\"centered\">11,048</td> <td class=\"centered\">68 (0.61)</td> <td class=\"centered\">13</td> <td class=\"centered\">55</td> <td class=\"centered\">9</td> <td class=\"centered\">4</td> </tr> <tr> <td>Li et al, 2012</td> <td class=\"centered\">China</td> <td class=\"centered\">2003 to 2011</td> <td class=\"centered\">R</td> <td class=\"centered\">8504</td> <td class=\"centered\">16 (0.19)</td> <td class=\"centered\">7</td> <td class=\"centered\">9</td> <td class=\"centered\">4</td> <td class=\"centered\">0</td> </tr> <tr> <td>Kwon et al, 2012</td> <td class=\"centered\">Korea</td> <td class=\"centered\">2000 to 2010</td> <td class=\"centered\">R</td> <td class=\"centered\">8381</td> <td class=\"centered\">53 (0.63)</td> <td class=\"centered\">21</td> <td class=\"centered\">32</td> <td class=\"centered\">18</td> <td class=\"centered\">3</td> </tr> <tr> <td>Rabie et al, 2013</td> <td class=\"centered\">Saudi Arabia</td> <td class=\"centered\">2008 to 2011</td> <td class=\"centered\">R</td> <td class=\"centered\">597</td> <td class=\"centered\">10 (1.67)</td> <td class=\"centered\">0</td> <td class=\"centered\">10</td> <td class=\"centered\">3</td> <td class=\"centered\">1</td> </tr> <tr> <td>Miller et al, 2013</td> <td class=\"centered\">Israel</td> <td class=\"centered\">1995 to 2011</td> <td class=\"centered\">R</td> <td class=\"centered\">1638</td> <td class=\"centered\">27 (1.65)</td> <td class=\"centered\">5</td> <td class=\"centered\">22</td> <td class=\"centered\">16</td> <td class=\"centered\">8</td> </tr> <tr> <td>Jin, 2013</td> <td class=\"centered\">South Korea</td> <td class=\"centered\">2000 to 2007</td> <td class=\"centered\">R</td> <td class=\"centered\">22,998</td> <td class=\"centered\">59 (0.27)</td> <td class=\"centered\">17</td> <td class=\"centered\">42</td> <td class=\"centered\">18</td> <td class=\"centered\">5</td> </tr> <tr> <td>Kodali et al, 2014</td> <td class=\"centered\">United States</td> <td class=\"centered\">2002 to 2012</td> <td class=\"centered\">R</td> <td class=\"centered\">8264</td> <td class=\"centered\">12 (0.14)</td> <td class=\"centered\">2</td> <td class=\"centered\">10</td> <td class=\"centered\">4</td> <td class=\"centered\">0</td> </tr> <tr> <td>Turner et al, 2014</td> <td class=\"centered\">Australia</td> <td class=\"centered\">2005 to 2006</td> <td class=\"centered\">R</td> <td class=\"centered\">211</td> <td class=\"centered\">5 (2.4)</td> <td class=\"centered\">0</td> <td class=\"centered\">5</td> <td class=\"centered\">4</td> <td class=\"centered\">1</td> </tr> <tr> <td>Koc et al, 2014</td> <td class=\"centered\">Turkey</td> <td class=\"centered\">2007 to 2013</td> <td class=\"centered\">R</td> <td class=\"centered\">2972</td> <td class=\"centered\">28 (0.94)</td> <td class=\"centered\">0</td> <td class=\"centered\">28</td> <td class=\"centered\">14</td> <td class=\"centered\">2</td> </tr> <tr> <td>Motomura et al, 2014</td> <td class=\"centered\">Japan</td> <td class=\"centered\">2008 to 2013</td> <td class=\"centered\">R</td> <td class=\"centered\">2674</td> <td class=\"centered\">6 (0.22)</td> <td class=\"centered\">1</td> <td class=\"centered\">5</td> <td class=\"centered\">3</td> <td class=\"centered\">0</td> </tr> <tr> <td>Katsinelos et al, 2014</td> <td class=\"centered\">Greece</td> <td class=\"centered\">2005 to 2012</td> <td class=\"centered\">R</td> <td class=\"centered\">2715</td> <td class=\"centered\">3 (0.11)</td> <td class=\"centered\">0</td> <td class=\"centered\">3</td> <td class=\"centered\">1</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td>Prachayakul et al, 2014</td> <td class=\"centered\">Thailand</td> <td class=\"centered\">2009 to 2013</td> <td class=\"centered\">R</td> <td class=\"centered\">4082</td> <td class=\"centered\">12 (0.29)</td> <td class=\"centered\">10</td> <td class=\"centered\">2</td> <td class=\"centered\">10</td> <td class=\"centered\">0</td> </tr> <tr> <td><strong>Total</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> <td class=\"centered\"><strong>188,200</strong></td> <td class=\"centered\"><strong>730<br /> (0.39%)</strong></td> <td class=\"centered\"><strong>173<br /> (23.7%)</strong></td> <td class=\"centered\"><strong>557<br /> (76.3%)</strong></td> <td class=\"centered\"><strong>270<br /> (37.0%)</strong></td> <td class=\"centered\"><strong>50<br /> (6.8%)</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">P: prospective study; R: retrospective study; ERCP: endoscopic retrograde cholangiopancreatography.<br />* Type I, free bowel wall perforation.<br />&para; Type II, periampullary injuries; Type III, pancreatic or bile duct injuries; Type IV, retroperitoneal air alone.</div><div id=\"graphicVersion\">Graphic 102224 Version 3.0</div></div></div>"},"102225":{"type":"graphic_picture","displayName":"Hammertoes and claw toes","title":"Hammertoes and claw toes","html":"<div class=\"graphic\"><div style=\"width: 790px\" class=\"figure\"><div class=\"ttl\">Hammertoes and claw toes</div><div class=\"cntnt\"><img style=\"width:770px; height:307px;\" src=\"images/SM/102225_Hammertoesclawtoes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photographs above depict several examples of hammertoes (arrowheads) and claw toes (arrow). These conditions may be associated with neurologic or medical conditions, and the patient in the photograph had lumbar spinal stenosis.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 102225 Version 1.0</div></div></div>"},"102226":{"type":"graphic_figure","displayName":"Nasal valve anatomy","title":"Nasal valve anatomy","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Nasal valve anatomy</div><div class=\"cntnt\"><img style=\"width:535px; height:435px;\" src=\"images/SLEEP/102226_Nasal_valve_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nasal valve anatomy (internal). Speculum examination of the right internal nasal valve (V), the space bounded by the caudal aspect of the upper lateral cartilage (ULC), the anterior part of the inferior turbinate (T), and the septum (S). Nasal valve collapse occurs when the upper lateral cartilage collapses medially (arrow) during nasal inspiration.</div><div class=\"graphic_reference\">Original figure modified for this publication. Weaver EM. Nasal valve stabilization. Oper Tech Otolaryngol 2012; 23:67. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 102226 Version 2.0</div></div></div>"},"102228":{"type":"graphic_figure","displayName":"Dorsum of the foot: Superficial dissection","title":"Dorsum of the foot: Superficial dissection","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Dorsum of the foot: Superficial dissection</div><div class=\"cntnt\"><img style=\"width:586px; height:645px;\" src=\"images/SM/102228_Dorsum_ft_sprfc_dssc.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 102228 Version 2.0</div></div></div>"},"102231":{"type":"graphic_picture","displayName":"Shoe wear from varus foot strike","title":"Shoe wear from varus foot strike","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Shoe wear from varus foot strike</div><div class=\"cntnt\"><img style=\"width:720px; height:632px;\" src=\"images/SM/102231_Shoe_wear_varus_foot_strike.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows the running shoes of a patient with an excessive varus forefoot strike (ie, excessive supination during strike phase). Note the extensive wear at the outer, or lateral, portion of the soles (arrows).</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 102231 Version 1.0</div></div></div>"},"102233":{"type":"graphic_picture","displayName":"Calcaneal valgus and pronation of foot","title":"Calcaneal valgus and pronation of foot","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Calcaneal valgus and pronation of foot</div><div class=\"cntnt\"><img style=\"width:590px; height:472px;\" src=\"images/SM/102233_Calcaneal_valgu_pronat_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a patient with significant calcaneal valgus and pronation of the left foot.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 102233 Version 1.0</div></div></div>"},"102244":{"type":"graphic_table","displayName":"SCIT maintenance extracts","title":"Preparation of allergen immunotherapy extracts for subcutaneous immunotherapy (SCIT): Overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preparation of allergen immunotherapy extracts for subcutaneous immunotherapy (SCIT): Overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Allergens</td> <td class=\"subtitle1\">Effective doses</td> <td class=\"subtitle1\">Available extracts<br /> (in United States)</td> <td class=\"subtitle1\">Dosing recommended in practice parameters</td> <td class=\"subtitle1\">Amount to add to 10 mL vial<br /> (maintenance solution) (maintenance dose = 0.5 mL)</td> <td class=\"subtitle1\">Mixing limitations</td> </tr> <tr class=\"divider_bottom\"> <td><em>Dermatophagoides pteronyssinus</em></td> <td>3.25 to 12 mcg Der p 1*</td> <td>10,000 AU/mL</td> <td>500 to 2000 AU</td> <td>2 mL (to deliver 1000 AU per dose)</td> <td>Do not mix with fungal or cockroach</td> </tr> <tr class=\"divider_bottom\"> <td><em>Dermatophagoides farinae</em></td> <td>10 mcg Der f 1*</td> <td>10,000 AU/mL</td> <td>500 to 2000 AU</td> <td>2 mL (to deliver 1000 AU per dose)</td> <td>Do not mix with fungal or cockroach</td> </tr> <tr class=\"divider_bottom\"> <td>Short ragweed</td> <td>4 to 24 mcg Amb a 1*</td> <td>1:10 w/v (100,000 AU/mL)</td> <td>1000 to 4000 BAU</td> <td>0.5 mL (to deliver 2500 BAU per dose)</td> <td>Do not mix with fungal or cockroach</td> </tr> <tr class=\"divider_bottom\"> <td>Timothy grass</td> <td>15 and 20 mcg Phl p 5*</td> <td>100,000 BAU/mL</td> <td>1000 to 4000 AU</td> <td>0.6 mL (to deliver 3000 BAU per dose)</td> <td>Do not mix with fungal or cockroach</td> </tr> <tr class=\"divider_bottom\"> <td>Bermuda grass</td> <td>Not determined</td> <td>10,000 BAU/mL</td> <td>300 to 1500 BAU</td> <td>2 mL (to deliver 1000 BAU per dose)</td> <td>Do not mix with fungal or cockroach</td> </tr> <tr class=\"divider_bottom\"> <td>Cat hair or pelt</td> <td>11 to 17 mcg Fel d 1*</td> <td>10,000 BAU/mL</td> <td>1000 to 4000 BAU</td> <td>6 mL (to deliver 3000 BAU per dose)</td> <td>Do not mix with fungal or cockroach</td> </tr> <tr class=\"divider_bottom\"> <td>Dog (acetone-precipitated)</td> <td>15 mcg Can f 1*</td> <td>1:100 w/v</td> <td>0.04 to 0.19 mL, 1:100 w/v</td> <td>2 mL</td> <td>Do not mix with fungal or cockroach</td> </tr> <tr class=\"divider_bottom\"> <td>Birch</td> <td>3.25 to 12 mcg Bet v 1*</td> <td>1:10 to 1:40 w/v, 10,000 to 40,000 PNU/mL</td> <td>1:100 w/v or 4000 PNU</td> <td>1 to 4 mL depending on stock extract concentration</td> <td>Do not mix with fungal or cockroach</td> </tr> <tr class=\"divider_bottom\"> <td>Olive</td> <td>Not determined</td> <td>1:10 to 1:40 w/v, 10,000 to 40,000 PNU/mL</td> <td>1:100 w/v or 4000 PNU</td> <td>1 to 4 mL depending on stock extract concentration</td> <td>Do not mix with fungal or cockroach</td> </tr> <tr class=\"divider_bottom\"> <td>Sagebrush</td> <td>Not determined</td> <td>1:10 to 1:40 w/v, 10,000 to 40,000 PNU/mL</td> <td>1:100 w/v or 4000 PNU</td> <td>1 to 4 mL depending on stock extract concentration</td> <td>Do not mix with fungal or cockroach</td> </tr> <tr class=\"divider_bottom\"> <td><em>Alternaria alternata</em></td> <td>1.6 and 8 mcg Alt a 1*</td> <td>1:10 to 1:40 w/v, 10,000 to 40,000 PNU/mL</td> <td>Highest tolerated dose</td> <td>Variable depending on potency of the stock extract</td> <td>Do not mix with pollens, dust mite, danders, or cockroach</td> </tr> <tr class=\"divider_bottom\"> <td><em>Aspergillus fumigatus</em></td> <td>Not determined</td> <td>1:10 to 1:40 w/v, 10,000 to 40,000 PNU/mL</td> <td>Highest tolerated dose</td> <td>Variable depending on potency of the stock extract</td> <td>Do not mix with pollens, dust mite, danders, or cockroach</td> </tr> <tr class=\"divider_bottom\"> <td>Cockroach</td> <td>Not determined</td> <td>1:10 to 1:40 w/v, 10,000 to 40,000 PNU/mL</td> <td>Highest tolerated dose</td> <td>Variable depending on potency of the stock extract</td> <td>Do not mix with pollens, dust mite, danders, or molds</td> </tr> <tr class=\"divider_bottom\"> <td>Hymenoptera venoms (except fire ant)</td> <td>100 mcg*</td> <td>100 mcg/mL single venom or 300 mcg/mL mixed vespid</td> <td>50 to 200 mcg of each venom</td> <td>Not applicable, use undiluted</td> <td>Do not mix with any other allergen extract</td> </tr> <tr> <td>Imported fire ant whole body extract</td> <td>0.5 mL of a 1:100 w/v to 0.5 mL of a 1:10 w/v</td> <td>1:10 w/v and 1:20 w/v</td> <td>None</td> <td>1 to 10 mL</td> <td>Do not mix with any other allergen extract</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AU: allergy units; BAU: bioequivalent allergy units; w/v: weight/volume; PNU: protein nitrogen units.<br />* Based upon double-blind, placebo-controlled studies.</div><div class=\"graphic_reference\">Data from: Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 2011; 127:S1.</div><div id=\"graphicVersion\">Graphic 102244 Version 1.0</div></div></div>"},"102246":{"type":"graphic_table","displayName":"Differential diagnosis for pelvic inflammatory disease","title":"Differential diagnosis for pelvic inflammatory disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis for pelvic inflammatory disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Suggestive&nbsp;features</td> </tr> <tr> <td>Ectopic pregnancy</td> <td>History of missed menses, positive pregnancy test</td> </tr> <tr> <td>Ovarian cyst rupture/torsion&nbsp;</td> <td>Sudden onset of severe pain</td> </tr> <tr> <td>Endometriosis&nbsp;</td> <td>Cyclical or chronic pain&nbsp;</td> </tr> <tr> <td>Cystitis</td> <td>Urinary frequency and/or dysuria</td> </tr> <tr> <td>Appendicitis</td> <td>Pain localized to the right iliac fossa, vomiting</td> </tr> <tr> <td>Diverticulitis</td> <td>Bowel symptoms in older women</td> </tr> <tr> <td>Irritable bowel syndrome</td> <td>Generalized abdominal pain, constipation, diarrhea</td> </tr> <tr> <td>Functional pain</td> <td>Other causes have been excluded</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 102246 Version 1.0</div></div></div>"},"102267":{"type":"graphic_picture","displayName":"Trichotillomania on scalp","title":"Trichotillomania","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Trichotillomania</div><div class=\"cntnt\"><img style=\"width:648px; height:470px;\" src=\"images/DERM/102267_Trichotillomania_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Alopecia, broken hairs, and signs of scalp trauma in a patient with trichotillomania.</div><div class=\"graphic_reference\">Courtesy of Nonhlanhla P Khumalo, MBChB, FCDerm, PhD, and Paradi Mirmirani, MD.</div><div id=\"graphicVersion\">Graphic 102267 Version 1.0</div></div></div>"},"102269":{"type":"graphic_table","displayName":"Traction alopecia clinical features and differential diagnoses","title":"Traction alopecia: Common clinical features and differential diagnoses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Traction alopecia: Common clinical features and differential diagnoses</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Differential diagnoses</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Traction folliculitis</strong></td> <td> <ul> <li>Pustules, erythema, inflamed papules, or scale in areas of traction </li> <li>Hair casts may be seen along hair shaft </li> </ul> </td> <td> <ul> <li>Bacterial folliculitis </li> <li>Tinea capitis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Marginal traction alopecia</strong></td> <td> <ul> <li>Hair loss on hairline, often predominantly above temples; may be more extensive </li> <li>\"Fringe sign\" (retention of vellus hairs [short, fine hairs] at the hair line) </li> </ul> </td> <td> <ul> <li>Alopecia areata (ophiasis pattern) </li> <li>Frontal fibrosing alopecia </li> </ul> </td> </tr> <tr> <td><strong>Non-marginal traction alopecia</strong></td> <td> <ul> <li>Patchy hair loss </li> <li>May exhibit geometric patterns, particularly in patients with traction alopecia from hair extensions or weaves </li> </ul> </td> <td> <ul> <li>Trichotillomania </li> <li>Syphilis </li> <li>Alopecia areata </li> <li>Tinea capitis </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 102269 Version 1.0</div></div></div>"},"102271":{"type":"graphic_algorithm","displayName":"Algorithm indications for ICD placement in HCM","title":"Algorithm showing the indications for implantable cardioverter-defibrillator (ICD) placement in patients with hypertrophic cardiomyopathy (HCM)","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Algorithm showing the indications for implantable cardioverter-defibrillator (ICD)&nbsp;placement in patients with hypertrophic cardiomyopathy&nbsp;(HCM)</div><div class=\"cntnt\"><img style=\"width:538px; height:392px;\" src=\"images/CARD/102271_Indicatn_ICD_placement_HCM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Regardless of the level of recommendation put forth in these guidelines, the decision for placement of an ICD must involve prudent application of individual clinical judgment, thorough discussions of the strength of evidence, the benefits, and the risks (including but not limited to inappropriate discharges, lead and procedural complications) to allow active participation of the fully informed patient in ultimate decision making.</div><div class=\"graphic_footnotes\">ICD: implantable cardioverter defibrillator; HCM: hypertrophic cardiomyopathy; VT: ventricular tachycardia; SD: sudden death; LV: left ventricular; BP: blood pressure; SCD: sudden cardiac death.<br />* SCD risk modifiers include established risk factors and emerging risk modifiers.</div><div class=\"graphic_reference\">Reproduced from: Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 58:e212. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 102271 Version 1.0</div></div></div>"},"102272":{"type":"graphic_picture","displayName":"Odontogenic abscess","title":"Odontogenic abscess","html":"<div class=\"graphic\"><div style=\"width: 663px\" class=\"figure\"><div class=\"ttl\">Odontogenic abscess</div><div class=\"cntnt\"><img style=\"width:643px; height:480px;\" src=\"images/PALC/102272_Odontogenic_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Odontogenic abscess in relation to tooth number 30.</div><div id=\"graphicVersion\">Graphic 102272 Version 1.0</div></div></div>"},"102273":{"type":"graphic_picture","displayName":"Gross decay of tooth","title":"Gross decay of tooth","html":"<div class=\"graphic\"><div style=\"width: 673px\" class=\"figure\"><div class=\"ttl\">Gross decay of tooth</div><div class=\"cntnt\"><img style=\"width:653px; height:499px;\" src=\"images/PALC/102273_Gross_decay_tooth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross decay of tooth number 30 with an associated periapical radiolucency.</div><div id=\"graphicVersion\">Graphic 102273 Version 1.0</div></div></div>"},"102274":{"type":"graphic_picture","displayName":"Gingivitis with focal marginal erythema and edema","title":"Gingivitis with focal marginal erythema and edema","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Gingivitis with focal marginal erythema and edema</div><div class=\"cntnt\"><img style=\"width:644px; height:429px;\" src=\"images/PALC/102274_Gngvts_fcl_marg_eryth_edema.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 102274 Version 1.0</div></div></div>"},"102275":{"type":"graphic_picture","displayName":"Herpes labialis","title":"Recurrent herpes simplex type I (HSV-1) infection of the lower lip, herpes labialis","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Recurrent herpes simplex type I (HSV-1) infection of the lower lip, herpes labialis</div><div class=\"cntnt\"><img style=\"width:644px; height:483px;\" src=\"images/PALC/102275_Herpes_labialis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 102275 Version 1.0</div></div></div>"},"102276":{"type":"graphic_picture","displayName":"Primary HSV-1 infection with multiple ulcerations","title":"Primary infection with herpes simplex virus type I (HSV-1), with multiple ulcerations on the undersurface of the tongue and labial mucosa","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Primary infection with herpes simplex virus type I (HSV-1), with multiple ulcerations on the undersurface of the tongue and labial mucosa</div><div class=\"cntnt\"><img style=\"width:644px; height:483px;\" src=\"images/PALC/102276_Primary_herpes_mult_ulcerat.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 102276 Version 1.0</div></div></div>"},"102277":{"type":"graphic_picture","displayName":"Recrudescent HSV infection of tongue dorsum","title":"Recrudescent infection with herpes simplex virus type 1 (HSV-1) presenting on the tongue dorsum","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Recrudescent infection with herpes simplex virus type 1 (HSV-1) presenting&nbsp;on the tongue dorsum</div><div class=\"cntnt\"><img style=\"width:644px; height:483px;\" src=\"images/PALC/102277_Recrudescent_infect_dorsum.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 102277 Version 1.0</div></div></div>"},"102278":{"type":"graphic_picture","displayName":"Pseudomembranous candidiasis left ventrolateral tongue","title":"Pseudomembranous candidiasis left ventrolateral tongue","html":"<div class=\"graphic\"><div style=\"width: 666px\" class=\"figure\"><div class=\"ttl\">Pseudomembranous candidiasis left ventrolateral tongue</div><div class=\"cntnt\"><img style=\"width:646px; height:430px;\" src=\"images/PALC/102278_Pseudom_candidiasis_ventrlt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 102278 Version 1.0</div></div></div>"},"102279":{"type":"graphic_picture","displayName":"Angular cheilitis erythematous fissures","title":"Angular cheilitis erythematous fissures","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Angular cheilitis erythematous fissures</div><div class=\"cntnt\"><img style=\"width:644px; height:483px;\" src=\"images/PALC/102279_Angular_cheilitis_fissures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angular cheilitis with erythematous fissures at the commissures.</div><div id=\"graphicVersion\">Graphic 102279 Version 1.0</div></div></div>"},"102280":{"type":"graphic_picture","displayName":"Black hairy tongue","title":"Black hairy tongue","html":"<div class=\"graphic\"><div style=\"width: 665px\" class=\"figure\"><div class=\"ttl\">Black hairy tongue</div><div class=\"cntnt\"><img style=\"width:645px; height:547px;\" src=\"images/PALC/102280_Black_hairy_tongue.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 102280 Version 1.0</div></div></div>"},"102281":{"type":"graphic_picture","displayName":"Henoch-Schönlein purpura - leg","title":"Henoch-Schönlein purpura","html":"<div class=\"graphic\"><div style=\"width: 666px\" class=\"figure\"><div class=\"ttl\">Henoch-Schönlein purpura</div><div class=\"cntnt\"><img style=\"width:646px; height:484px;\" src=\"images/DERM/102281_Henoch_Schonlein_purpra_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palpable purpuric lesions on the legs of a child with Henoch-Sch&ouml;nlein purpura.</div><div class=\"graphic_reference\">Courtesy of Moise L Levy, MD.</div><div id=\"graphicVersion\">Graphic 102281 Version 1.0</div></div></div>"},"102285":{"type":"graphic_picture","displayName":"Swinging flashlight test","title":"Swinging flashlight test for Marcus-Gunn pupil","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Swinging flashlight test for Marcus-Gunn pupil</div><div class=\"cntnt\"><img style=\"width:490px; height:731px;\" src=\"images/NEURO/102285_Swng_flshlght_tst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) In bright light, each eye perceives the same amount of light on average. As such, the pupils are equal in size.<br />(B) When the light is shone in the unaffected eye, it constricts normally.<br />(C) When the light is swung from the unaffected&nbsp;eye and shone in the affected eye, it perceives less light and both pupils paradoxically dilate.</div><div id=\"graphicVersion\">Graphic 102285 Version 5.0</div></div></div>"},"102288":{"type":"graphic_picture","displayName":"Epidermodysplasia verruciformis neck","title":"Epidermodysplasia verruciformis","html":"<div class=\"graphic\"><div style=\"width: 875px\" class=\"figure\"><div class=\"ttl\">Epidermodysplasia verruciformis</div><div class=\"cntnt\"><img style=\"width:855px; height:552px;\" src=\"images/DERM/102288_Epdrmdyspls_vrrcfrm_ nck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical pityriasis versicolor-like lesions on the neck of a patient with epidermodysplasia verruciformis.</div><div id=\"graphicVersion\">Graphic 102288 Version 1.0</div></div></div>"},"102289":{"type":"graphic_picture","displayName":"Epidermodysplasia verruciformis histo","title":"Histologic features of epidermodysplasia verruciformis","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Histologic features of epidermodysplasia verruciformis</div><div class=\"cntnt\"><img style=\"width:551px; height:432px;\" src=\"images/DERM/102289_Epdrmdyspls_vrrcfrms_hst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratosis, acanthosis, and pale vacuolated cells are visible in a H&amp;E staining of an epidermodysplasia verruciformis lesion.</div><div id=\"graphicVersion\">Graphic 102289 Version 2.0</div></div></div>"},"102290":{"type":"graphic_diagnosticimage","displayName":"CT of AFRS","title":"Computed tomography of allergic fungal rhinosinusitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of allergic fungal rhinosinusitis</div><div class=\"cntnt\"><img style=\"width:341px; height:798px;\" src=\"images/ALLRG/102290_CTAFRSbltrlpnsnsts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Coronal computed tomography (bone windows demonstrate bilateral panopacification of the sinuses with bony erosion and expansion into the left orbit).<br />(B) Soft tissue windows confirm differential densities, consistent with fungal sinusitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Rodney J Schlosser, MD, Department of Otolaryngology – Head and Neck Surgery, Medical University of South Carolina.</div><div id=\"graphicVersion\">Graphic 102290 Version 6.0</div></div></div>"},"102291":{"type":"graphic_diagnosticimage","displayName":"CT of AFRS with bone erosion","title":"Computed tomography of allergic fungal rhinosinusitis with bone erosion","html":"<div class=\"graphic\"><div style=\"width: 662px\" class=\"figure\"><div class=\"ttl\">Computed tomography of allergic fungal rhinosinusitis with bone erosion</div><div class=\"cntnt\"><img style=\"width:642px; height:540px;\" src=\"images/ALLRG/102291_CTAFRSboneersn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal computed tomography (soft tissue windows) demonstrates AFRS of both sphenoid sinuses with multiple areas of bone erosion (arrows). Note the differential densities consistent with fungal sinusitis.</div><div class=\"graphic_footnotes\">AFRS: allergic fungal rhinosinusitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Rodney J Schlosser, MD, Department of Otolaryngology – Head and Neck Surgery, Medical University of South Carolina.</div><div id=\"graphicVersion\">Graphic 102291 Version 4.0</div></div></div>"},"102292":{"type":"graphic_diagnosticimage","displayName":"CT of AFRS showing bone erosion and expansion of orbital walls","title":"Computed tomography of allergic fungal rhinosinusitis showing bone erosion and expansion of orbital walls","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Computed tomography of allergic fungal rhinosinusitis showing bone erosion and expansion of orbital walls</div><div class=\"cntnt\"><img style=\"width:476px; height:783px;\" src=\"images/ALLRG/102292_CTAFRSboneersnorbtdfrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Coronal computed tomography (soft tissue windows) demonstrates multiple areas of bony erosion and expansion along both medial orbital walls, the maxillary sinuses, and the ethmoid roof with extension intracranially. Note the differential densities on soft tissue windowing.<br />(B) Bone windows of the same patient after surgery and adjuvant medical therapy demonstrate complete evacuation of the fungal debris and polyps, essential for long-term treatment of allergic fungal rhinosinusitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Rodney J Schlosser, MD, Department of Otolaryngology &ndash; Head and Neck Surgery, Medical University of South Carolina.</div><div id=\"graphicVersion\">Graphic 102292 Version 6.0</div></div></div>"},"102293":{"type":"graphic_diagnosticimage","displayName":"CT versus MRI of AFRS","title":"Computed tomography versus magnetic resonance imaging of allergic fungal rhinosinusitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography versus magnetic resonance imaging of allergic fungal rhinosinusitis</div><div class=\"cntnt\"><img style=\"width:362px; height:723px;\" src=\"images/ALLRG/102293_CTversusMRIAFRS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Coronal computed tomography (bone windows) demonstrates bilateral skull base dehiscence.<br />(B) Coronal T2-weighted magnetic resonance image of the same patient demonstrates enhancement in areas of mucosal thickening in the maxillary and ethmoid sinuses. Note the decreased signal intensity in the area of skull base erosion in the left ethmoid sinus, which is classic for allergic fungal rhinosinusitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Rodney J Schlosser, MD, Department of Otolaryngology &ndash; Head and Neck Surgery, Medical University of South Carolina.</div><div id=\"graphicVersion\">Graphic 102293 Version 6.0</div></div></div>"},"102294":{"type":"graphic_diagnosticimage","displayName":"CT of sphenoid sinus fungal ball","title":"Computed tomography of sphenoid sinus fungal ball","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of sphenoid sinus fungal ball</div><div class=\"cntnt\"><img style=\"width:437px; height:438px;\" src=\"images/ALLRG/102294_CTfngsball.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fungus ball sphenoid: Coronal computed tomography (bone windows) demonstrate a classic fungus ball in the sphenoid sinus with ectopic calcifications and a small area of erosion of inner sinus septum.</div><div class=\"graphic_reference\">Reproduced with permission from: Rodney J Schlosser, MD, Department of Otolaryngology &ndash; Head and Neck Surgery, Medical University of South Carolina.</div><div id=\"graphicVersion\">Graphic 102294 Version 6.0</div></div></div>"},"102313":{"type":"graphic_table","displayName":"Tool for assessing pain in nonverbal persons","title":"Tool for assessing pain in nonverbal persons","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tool for assessing pain in nonverbal persons</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"45%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name</td> <td class=\"subtitle1\">Setting</td> <td class=\"subtitle1\">References</td> </tr> <tr> <td><strong>CNPI:</strong> Checklist of Nonverbal Pain Indicators</td> <td>Acute care setting, long-term care setting; acute/chronic pain</td> <td>1-4</td> </tr> <tr> <td><strong>PAINAD:</strong> The Pain Assessment in Advanced Dementia Scale</td> <td>Long-term care setting; chronic pain; preliminary reports of testing in acute pain not yet published</td> <td>5,6</td> </tr> <tr> <td><strong>Doloplus 2:</strong> The Doloplus 2</td> <td>Long-term care setting, geriatric centers, palliative care center; chronic pain</td> <td>7,8</td> </tr> <tr> <td><strong>ADD:</strong> The Assessment of Discomfort in Dementia Protocol</td> <td>Long-term care setting; acute/chronic pain</td> <td>9-11</td> </tr> <tr> <td><strong>NOPPAIN:</strong> Nursing Assistant-Administered Instrument to Assess Pain in Demented Individuals</td> <td>Long-term care setting; acute and chronic pain</td> <td>12</td> </tr> <tr> <td><strong>PACSLAC:</strong> The Pain Assessment Scale for Seniors with Severe Dementia</td> <td>Long-term care setting; chronic pain</td> <td>13</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Review of currently published tools for assessing pain in nonverbal persons. It is recommended to review each tool for appropriate use to the patient care setting.</div><div class=\"graphic_reference\">Source: Herr K, Coyne PJ, Key T, et al. Pain assessment in the nonverbal patient: Position statement with clinical practice recommendations. Pain Manag Nurs 2006; 7:44.<br />References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Feldt KS. The Checklist of Nonverbal Pain Indicators (CNPI). Pain Management Nursing 2000; 1:13.</LI>&#xD;&#xA;<LI>Feldt KS. Improving assessment and treatment of pain in cognitively impaired nursing home residents. Annals of Long Term Care 2000; 8:36.</LI>&#xD;&#xA;<LI>Feldt KS, Ryden MB, Miles S. Treatment of pain in cognitively impaired compared with cognitively intact older patients with hip-fracture. Journal of the American Geriatrics Society 1998; 46:1079.</LI>&#xD;&#xA;<LI>Jones KR, Fink R, Hutt E, et al. Measuring pain intensity in nursing home residents. Journal of Pain and Symptom Management 2005; 30:519.</LI>&#xD;&#xA;<LI>Lane P, Kuntupis M, MacDonald S, et al. A pain assessment tool for people with advanced Alzheimer's and other progressive dementias. Home Healthcare Nurse 2003; 21:32.</LI>&#xD;&#xA;<LI>Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the pain assessment in advanced dementia (PAINAD) scale. Journal of the American Medical Directors Association 2003; 4:9.</LI>&#xD;&#xA;<LI>Lefebre-Chapiro S. The Doloplus 2 scale—evaluating pain in the elderly. European Journal of Palliative Care 2001; 8:191.</LI>&#xD;&#xA;<LI><A spellcheck=true href=\"http://prc.coh.org/PainNOA/Doloplus%202_Tool.pdf\" target=_blank>http://prc.coh.org/PainNOA/Doloplus%202_Tool.pdf</A>.</LI>&#xD;&#xA;<LI>Kovach CR, Noonan PE, Griffie J, et al. Use of the assessment of discomfort in dementia protocol. Applied Nursing Research 2001; 14:193.</LI>&#xD;&#xA;<LI>Kovach CR, Noonan PE, Griffie J, et al. The assessment of discomfort in dementia protocol. Pain Management Nursing 2002; 3:16.</LI>&#xD;&#xA;<LI>Kovach CR, Weissman, DE, Griffie J, et al. Assessment and treatment of discomfort for people with late-stage dementia. Journal of Pain &amp; Symptom Management 1999; 18:412.</LI>&#xD;&#xA;<LI>Snow AL, Weber JB, O’Malley KJ, et al. NOPPAIN: a nursing assistant-administered pain assessment instrument for use in dementia. Dementia and Geriatric Cognitive Disorders 2003; 921:1.</LI>&#xD;&#xA;<LI>Fuchs-Lacelle S, Hadjistavropoulos T. Development and preliminary validation of the Pain Assessment Checklist for Seniors with Limited Ability to Communicate (PACSLAC). Pain Management Nursing 2004; 5:37.</LI></OL></div><div id=\"graphicVersion\">Graphic 102313 Version 2.0</div></div></div>"},"102314":{"type":"graphic_table","displayName":"Behavior pain indicators","title":"Six types of behavior pain indicators from the American Geriatric Society","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Six types of behavior pain indicators from the American Geriatric Society</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Behavior pain indicator</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td>Facial expressions</td> <td>Grimacing, closed or tightened eyes, rapid blinking</td> </tr> <tr> <td>Verbalizations/vocalizations</td> <td>Noisy breathing, moaning, calling out</td> </tr> <tr> <td>Body movement</td> <td>Guarding, restricted movement, mobility changes</td> </tr> <tr> <td>Changes in interpersonal interactions</td> <td>Withdrawn, resisting care, aggressive</td> </tr> <tr> <td>Changes in activity patterns or routines</td> <td>Refusing food, changes in rest pattern, increased wandering</td> </tr> <tr> <td>Mental status changes</td> <td>Increased confusion, distress, crying, or tears</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Herr K, Coyne PJ, Key T, et al. Pain assessment in the nonverbal patient: Position statement with clinical practice recommendations. Pain Manag Nurs 2006; 7:44.</div><div id=\"graphicVersion\">Graphic 102314 Version 1.0</div></div></div>"},"102316":{"type":"graphic_table","displayName":"ASK-TELL-ASK mnemonic","title":"ASK-TELL-ASK mnemonic: A process for delivering new information","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ASK-TELL-ASK mnemonic: A process for delivering new information</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>ASK (Are they ready to talk about results, prognosis, treatment options) <ul> <li>&nbsp;eg, \"Are you ready to hear about the biopsy?\" </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>TELL (Give information in small, clear amounts; build on what the patient knows) <ul> <li>eg, \"The biopsy showed cancer in your lungs.\" </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>ASK (Check to be sure they understand) <ul> <li>eg, \"Is that what you expected?\" </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Repeat cycle as many times as needed</p> <p class=\"indent1\">ASK: \"Would you like to hear about treatment options?\" (if \"Yes\", then TELL and re-ASK)</p> <p class=\"indent1\">ASK: \"Would you like to hear my recommendations?\" (if \"Yes\", then TELL and re-ASK)</p> </td> </tr> <tr> <td> <p>Tell me more (about areas or statements that you don't understand)</p> <p class=\"indent1\">\"Tell me more about what is concerning you most.\"</p> <p class=\"indent1\">\"Tell me more about your family's concerns.\"</p> <p>Be prepared to respond to emotion</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Back AL, Arnold RM, Baile WF, et al. Approaching difficult communication tasks in oncology. CA Cancer J Clin 2005; 55:164.</div><div id=\"graphicVersion\">Graphic 102316 Version 3.0</div></div></div>"},"102317":{"type":"graphic_picture","displayName":"Epidermodysplasia verruciformis hands","title":"Epidermodysplasia verruciformis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Epidermodysplasia verruciformis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/102317_Epdrmdyspls_vrrcfrm_hnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse verrucous hyperkeratotic papules on the hands of a patient with epidermodysplasia verruciformis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 102317 Version 1.0</div></div></div>"},"102332":{"type":"graphic_table","displayName":"HPV types in EV","title":"Types of human papillomavirus (HPV) detected in patients with epidermodysplasia verruciformis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of human papillomavirus (HPV) detected in patients with epidermodysplasia verruciformis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Genus and species</td> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td>&#945;2</td> <td>3, 10</td> <td>[1,2,3,4]</td> </tr> <tr> <td>&#945;5</td> <td>26</td> <td>[5]</td> </tr> <tr> <td>&#946;1</td> <td>5, 8, 12, 14, 19, 20, 21, 24, 25, 36, 93</td> <td>[2,4-9]</td> </tr> <tr> <td>&#946;2</td> <td>9, 15, 17, 22, 23, 38</td> <td>[2,4-7,9,10]</td> </tr> <tr> <td>&#946;5</td> <td>96</td> <td>[7]</td> </tr> <tr> <td>&#947;3</td> <td>50</td> <td>[11]</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Most patients with epidermodysplasia verruciformis carry multiple types of HPV.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Orth G, Jablonska S, Favre M, et al. Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis. Proc Natl Acad Sci U S A 1978; 75:1537.</LI>&#xD;&#xA;<LI>Majewski S, Jabłońska S. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol 1995; 131:1312.</LI>&#xD;&#xA;<LI>Gliński W, Obałek S, Jabłońska S, Orth G. T cell defect in patients with epidermodysplasia verruciformis due to human papillomavirus type 3 and 5. Dermatologica 1981; 162:141.</LI>&#xD;&#xA;<LI>Kamiński M, Pawińska M, Jablonska S, et alIncreased natural killer cell activity in patients with epidermodysplasia verruciformis. Arch Dermatol 1985; 121:84.</LI>&#xD;&#xA;<LI>de Oliveira WR, He Q, Rady PL et al. HPV typing in Brazilian patients with epidermodysplasia verruciformis: high prevalence of EV-HPV 25. J Cutan Med Surg 2004; 8:110.</LI>&#xD;&#xA;<LI>Berthelot C, Dickerson MC, Rady P, et al. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol 2007; 56:882.</LI>&#xD;&#xA;<LI>Dell'Oste V, Azzimonti B, De Andrea M, et al. High beta-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis. J Invest Dermatol 2009; 129:1026.</LI>&#xD;&#xA;<LI>Al Attia HM, Sherif AM. Buschke-Ollendorff syndrome in a grande multipara: a case report and short review of the literature. Clin Rheumatol 1998; 17:172.</LI>&#xD;&#xA;<LI>Kremsdorf D, Favre M, Jablonska S, et al. Molecular cloning and characterization of the genomes of nine newly recognized human papillomavirus types associated with epidermodysplasia verruciformis. J Virol 1984; 52:1013.</LI>&#xD;&#xA;<LI>Gober MD, Rady PL, He Q, et al. Novel homozygous frameshift mutation of EVER1 gene in an epidermodysplasia verruciformis patient. J Invest Dermatol 2007; 127:817.</LI>&#xD;&#xA;<LI>Favre M, Obalek S, Jablonska S, Orth G. Human papillomavirus (HPV) type 50, a type associated with epidermodysplasia verruciformis (EV) and only weakly related to other EV-specific HPVs. J Virol 1989; 63:4910.</LI></OL></div><div id=\"graphicVersion\">Graphic 102332 Version 1.0</div></div></div>"},"102334":{"type":"graphic_algorithm","displayName":"Nail psoriasis treatment algorithm","title":"Treatment algorithm for nail psoriasis","html":"<div class=\"graphic\"><div style=\"width: 794px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for nail psoriasis</div><div class=\"cntnt\"><img style=\"width:774px; height:308px;\" src=\"images/DERM/102334_Nail_psrs_trtmnt_algrthm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Nail psoriasis limited to one or two nails and without significant symptoms or functional impairment.<br />&para; Nail psoriasis associated with marked nail dystrophy involving more than two nails or nail psoriasis associated with significant symptoms or functional impairment.</div><div id=\"graphicVersion\">Graphic 102334 Version 2.0</div></div></div>"},"102335":{"type":"graphic_picture","displayName":"Flare on slit lamp examination","title":"Flare on slit lamp examination","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Flare on slit lamp examination</div><div class=\"cntnt\"><img style=\"width:754px; height:448px;\" src=\"images/EM/102335_Flare_slit_lamp_examination.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image shows flare in the anterior chamber. Note the fog-like beam (arrows). The beam is positioned over the pupil for optima viewing.</div><div class=\"graphic_reference\">Reproduced with permission from Tim Root, MD. <A href=\"http://www.ophthobook.com/\" target=_blank>www.ophthobook.com</A>.</div><div id=\"graphicVersion\">Graphic 102335 Version 2.0</div></div></div>"},"102336":{"type":"graphic_picture","displayName":"Cells on slit lamp examination","title":"Cells on slit lamp examination","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Cells on slit lamp examination</div><div class=\"cntnt\"><img style=\"width:506px; height:516px;\" src=\"images/EM/102336_Cells_slit_lamp_examination.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image shows cells in the anterior chamber. Note the small white flecks (arrows) seen in the slit beam under high power.</div><div class=\"graphic_reference\">Reproduced with permission from Tim Root, MD. <a href=\"http://www.ophthobook.com/\" spellcheck=\"true\" target=\"_blank\">www.ophthobook.com</a>.</div><div id=\"graphicVersion\">Graphic 102336 Version 1.0</div></div></div>"},"102338":{"type":"graphic_picture","displayName":"Single leg squat examination","title":"Single leg squat examination","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Single leg squat examination</div><div class=\"cntnt\"><img style=\"width:489px; height:874px;\" src=\"images/SM/102338_Single_leg_squat_examinatio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) In a correctly performed single leg squat examination maneuver, the patient's toe, knee, and hip should be aligned in a straight line or slightly varus position (solid line); the elbows and hips should be level (dashed lines); and the knees should remain slightly apart (arrow).<br />(B) Dipping of the pelvis&nbsp;toward the unsupported leg&nbsp;(Trendelenberg position) indicates weakness of the gluteus medius and minimus in the planted leg.<br />(C) Common signs of weakness include collapse of the knee of the supported leg inward (valgus collapse), which indicates gluteal and/or quadriceps weakness (solid line). Another common sign of weakness (and valgus collapse) is a squeezing together of the planted&nbsp;and unsupported legs&nbsp;(X). Normal strength enables the patient to&nbsp;maintain distance between the knees.<br />(D) Another sign of gluteal weakness is the compensated, or reverse Trendelenberg, position. The patient lifts the pelvis on the free side and/or leans their trunk towards the planted leg to compensate for gluteal weakness.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD.</div><div id=\"graphicVersion\">Graphic 102338 Version 1.0</div></div></div>"},"102339":{"type":"graphic_table","displayName":"Estimated energy requirements for adolescents","title":"Estimated energy requirements (EER) for boys and girls based on age and physical activity level","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated energy requirements (EER) for boys and girls based on age and physical activity level</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Age (years)</td> <td class=\"subtitle1\" colspan=\"8\">Estimated Energy Requirements (EER) in kcal/day*</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"4\">Boys</td> <td class=\"subtitle2\" colspan=\"4\">Girls</td> </tr> <tr> <td class=\"subtitle3\">Sedentary PAL</td> <td class=\"subtitle3\">Low Active PAL</td> <td class=\"subtitle3\">Active PAL</td> <td class=\"subtitle3\">Very Active PAL</td> <td class=\"subtitle3\">Sedentary PAL</td> <td class=\"subtitle3\">Low Active PAL</td> <td class=\"subtitle3\">Active PAL</td> <td class=\"subtitle3\">Very Active PAL</td> </tr> <tr> <td>9</td> <td>1530</td> <td>1787</td> <td>2043</td> <td>2359</td> <td>1415</td> <td>1660</td> <td>1890</td> <td>2273</td> </tr> <tr> <td>10</td> <td>1601</td> <td>1875</td> <td>2149</td> <td>2486</td> <td>1470</td> <td>1729</td> <td>1972</td> <td>2376</td> </tr> <tr> <td>11</td> <td>1691</td> <td>1985</td> <td>2279</td> <td>2640</td> <td>1538</td> <td>1813</td> <td>2071</td> <td>2500</td> </tr> <tr> <td>12</td> <td>1798</td> <td>2113</td> <td>2428</td> <td>2817</td> <td>1617</td> <td>1909</td> <td>2183</td> <td>2640</td> </tr> <tr> <td>13</td> <td>1935</td> <td>2276</td> <td>2618</td> <td>3038</td> <td>1684</td> <td>1992</td> <td>2281</td> <td>2762</td> </tr> <tr> <td>14</td> <td>2090</td> <td>2459</td> <td>2829</td> <td>3283</td> <td>1718</td> <td>2036</td> <td>2334</td> <td>2831</td> </tr> <tr> <td>15</td> <td>2223</td> <td>2618</td> <td>3013</td> <td>3499</td> <td>1731</td> <td>2057</td> <td>2362</td> <td>2870</td> </tr> <tr> <td>16</td> <td>2320</td> <td>2736</td> <td>3152</td> <td>3663</td> <td>1729</td> <td>2059</td> <td>2368</td> <td>2883</td> </tr> <tr> <td>17</td> <td>2366</td> <td>2796</td> <td>3226</td> <td>3754</td> <td>1710</td> <td>2042</td> <td>2353</td> <td>2871</td> </tr> <tr> <td>18</td> <td>2383</td> <td>2823</td> <td>3263</td> <td>3804</td> <td>1690</td> <td>2024</td> <td>2336</td> <td>2858</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EER: estimated energy requirements; PAL: physical activity levels; CDC: Centers for Disease Control and Prevention.<br />* Estimated energy requirements (EER) for boys and girls with reference height and weights equal to the median values of CDC growth charts<SUP>[1]</SUP> for four physical activity levels (PAL).</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>CDC Growth Charts: United States. Centers for Disease Control and Prevention; US Department of Health and Human Services. Available at: <A spellcheck=true href=\"http://www.cdc.gov/growthcharts/\" target=_blank>http://www.cdc.gov/growthcharts/</A>.</LI></OL>Data from: Institute of Medicine (IOM). Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids, National Academies Press, Washington, DC 2005.</div><div id=\"graphicVersion\">Graphic 102339 Version 1.0</div></div></div>"},"102345":{"type":"graphic_diagnosticimage","displayName":"TEE (ME LAX view) showing HCM with SAM","title":"TEE (ME LAX view) showing hypertrophic cardiomyopathy (HCM) with systolic anterior motion (SAM) of the anterior leaflet of the mitral valve","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">TEE (ME LAX view) showing hypertrophic cardiomyopathy (HCM) with systolic anterior motion (SAM) of the anterior leaflet of the mitral valve</div><div class=\"cntnt\"><img style=\"width:756px; height:501px;\" src=\"images/ANEST/102345_HCM_SAM_mtrl_sptl_cntct_Ed1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">TEE midesophageal long-axis view of a patient with hypertrophic cardiomyopathy and SAM with LVOT obstruction.&nbsp;The arrow shows the point of mitral-septal contact.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; ME: midesophageal; LAX: long-axis; HCM: hypertrophic cardiomyopathy; SAM: systolic anterior motion of the mitral valve; LVOT: left ventricular outflow tract.</div><div class=\"graphic_reference\">Reproduced with permission from Jonathan Mark, MD.</div><div id=\"graphicVersion\">Graphic 102345 Version 5.0</div></div></div>"},"102346":{"type":"graphic_table","displayName":"Bethesda 2014 classific cervix cytol","title":"Bethesda 2014 classification system for cervical cytology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bethesda 2014 classification system for cervical cytology</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Specimen type</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Indicate conventional smear (Pap smear), liquid-based preparation (Pap test) versus other</td> </tr> <tr> <td class=\"subtitle1_single\">Specimen adequacy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Satisfactory for evaluation (describe presence or absence of endocervical/transformation zone component and any other quality indicators, eg, partially obscuring blood, inflammation, etc) </li> <li>Unsatisfactory for evaluation (<em>specify reason</em>) <ul> <li>Specimen rejected/not processed (<em>specify reason</em>) </li> <li>Specimen processed and examined, but unsatisfactory for evaluation of epithelial abnormality because of (<em>specify reason</em>) </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">General categorization (<em>optional</em>)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Negative for intraepithelial lesion or malignancy </li> <li>Other: see \"Interpretation/results\" (eg, endometrial cells in a woman older than 45 years) </li> <li>Epithelial cell abnormality: see \"Interpretation/results\" (specify \"squamous\" <em>or</em> \"glandular,\" as <em>appropriate</em>) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Interpretation/results</td> </tr> <tr> <td class=\"indent1\"><strong>Negative for intraepithelial lesion or malignancy</strong></td> </tr> <tr> <td class=\"indent2\">(When there is no cellular evidence of neoplasia, state this in the \"General categorization\" above and/or in the \"Interpretation/results\" section of the report&#8212;whether there are organisms or other non-neoplastic findings)</td> </tr> <tr> <td class=\"indent1\"><strong>Non-neoplastic findings (<em>optional to report</em>)</strong></td> </tr> <tr> <td class=\"indent2\"> <ul> <li><strong>Non-neoplastic cellular variations:</strong> <ul> <li>Squamous metaplasia </li> <li>Keratotic changes </li> <li>Tubal metaplasia </li> <li>Atrophy </li> <li>Pregnancy-associated changes </li> </ul> </li> <li><strong>Reactive cellular changes associated with:</strong> <ul> <li>Inflammation (includes typical repair) <ul> <li>Lymphocytic (follicular) cervicitis </li> </ul> </li> <li>Radiation </li> <li>Intrauterine contraceptive device (IUD) </li> </ul> </li> <li><strong>Glandular cells status posthysterectomy</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Organisms</strong></td> </tr> <tr> <td class=\"indent2\"> <ul> <li><em>Trichomonas vaginalis</em> </li> <li>Fungal organisms morphologically consistent with <em>Candida</em> spp. </li> <li>Shift in flora suggestive of bacterial vaginosis </li> <li>Bacteria morphologically consistent with <em>Actinomyces</em> spp. </li> <li>Cellular changes consistent with herpes simplex virus </li> <li>Cellular changes consistent with cytomegalovirus </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Other</strong></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Endometrial cells (in a woman older than 45 years)<br /> (also specify if \"negative for squamous intraepithelial lesion\") </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Epithelial cell abnormalities</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li><strong>Squamous cell</strong> <ul> <li>Atypical squamous cells <ul> <li>Of undetermined significance (ASC-US) </li> <li>Cannot exclude HSIL (ASC-H) </li> </ul> </li> <li>Low-grade squamous intraepithelial lesion (LSIL)<br /> (encompassing: HPV/mild dysplasia/CIN-1) </li> <li>High-grade squamous intraepithelial lesion (HSIL)<br /> (encompassing: moderate and severe dysplasia, CIS; CIN-2 and CIN-3) <ul> <li>With features suspicious for invasion (<em>if invasion is suspected</em>) </li> </ul> </li> <li>Squamous cell carcinoma </li> </ul> </li> <li><strong>Glandular cell</strong> <ul> <li>Atypical <ul> <li>Endocervical cells (NOS <em>or specify in comments</em>) </li> <li>Endometrial cells (NOS <em>or specify in comments</em>) </li> <li>Glandular cells (NOS <em>or specify in comments</em>) </li> </ul> </li> <li>Atypical <ul> <li>Endocervical cells, favor neoplastic </li> <li>Glandular cells, favor neoplastic </li> </ul> </li> <li>Endocervical adenocarcinoma in situ </li> <li>Adenocarcinoma <ul> <li>Endocervical </li> <li>Endometrial </li> <li>Extrauterine </li> <li>Not otherwise specified (NOS) </li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Other malignant neoplasms (<em>specify</em>)</td> </tr> <tr> <td class=\"subtitle1_single\">Adjunctive testing</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Provide a brief description of the test method(s) and report the result so that it is easily understood by the clinician</td> </tr> <tr> <td class=\"subtitle1_single\">Computer-assisted interpretation of cervical cytology</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">If case examined by an automated device, specify the device and result</td> </tr> <tr> <td class=\"subtitle1_single\">Educational notes and comments appended to cytology reports (<em>optional</em>)</td> </tr> <tr> <td class=\"indent1\">Suggestions should be concise and consistent with clinical follow-up guidelines published by professional organizations (references to relevant publications may be included)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Nayar R, Wilbur DC. The Pap Test and Bethesda 2014: \"The reports of my demise have been greatly exaggerated. (after a quotation from Mark Twain)\". J Low Genit Tract Dis 2015; 19:175. DOI: <a href=\"http://journals.lww.com/jlgtd/Abstract/2015/07000/The_Pap_Test_and_Bethesda_2014___The_reports_of_my.1.aspx\" target=\"_blank\">10.1097/LGT.0000000000000115</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015 American Society for Colposcopy and Cervical Pathology, The International Society for the Study of Vulvovaginal Disease, and The International Federation of Cervical Pathology and Colposcopy. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 102346 Version 1.0</div></div></div>"},"102350":{"type":"graphic_table","displayName":"Intravenous anesthetic induction agents","title":"Intravenous anesthetic induction agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intravenous anesthetic induction agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"4\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Uses</td> <td class=\"subtitle1\">Suggested induction dose</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Potential adverse effects</td> </tr> <tr class=\"divider_bottom\"> <td>Propofol</td> <td>Induction agent of choice for most patients</td> <td> <ul> <li>1&nbsp;to 2.5 mg/kg </li> <li>Older age: 1 to 1.5 mg/kg </li> <li>Hypovolemia or hemodynamic compromise: &#8804;1 mg/kg </li> </ul> </td> <td> <ul> <li>Rapid onset and offset </li> <li>Antiemetic properties </li> <li>Antipruritic properties </li> <li>Bronchodilation </li> <li>Anticonvulsant properties </li> <li>Decreases CMRO<sub>2</sub>, CBF, and IC<span style=\"color: #ff0000;\"></span>P </li> </ul> </td> <td> <ul> <li>Dose-dependent hypotension </li> <li>Dose-dependent respiratory depression </li> <li>Pain during injection </li> <li>Microbial contamination&nbsp;risk </li> <li>Rare anaphylaxis in patients with allergy to <span style=\"font-size: 10pt; color: black;\">its soybean oil emulsion with egg phosphatide</span> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Etomidate</td> <td> <p><span style=\"color: black;\">May be</span><span style=\"color: black;\">&nbsp;selected</span> in patients with hemodynamic instability due to any cause</p> </td> <td> <ul> <li>0.15 to 0.3 mg/kg </li> <li>Presence of profound hypotension: 0.1 to 0.15 mg/kg </li> </ul> </td> <td> <ul> <li>Rapid onset and offset </li> <li>Hemodynamic stability with no changes in BP, HR, or CO </li> <li>Anticonvulsant properties </li> <li>Decreases CMRO<sub>2</sub>, CBF, and ICP </li> </ul> </td> <td> <ul> <li>High incidence of PONV </li> <li>Pain during injection </li> <li>Involuntary myoclonic movements </li> <li>Absence of analgesic effects </li> <li>Transient acute adrenocortical suppression </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Ketamine</td> <td> <p><span style=\"color: black;\">May be</span><span style=\"color: black;\">&nbsp;selected</span> in hypotensive patients or those likely to develop hypotension (eg, hypovolemia, hemorrhage, sepsis, severe cardiovascular compromise)</p> </td> <td> <ul> <li>1&nbsp;to 2 mg/kg </li> <li>Chronic use of tricyclic antidepressants: 1 mg/kg </li> <li>Presence of profound hypotension: 0.5 to 1 mg/kg </li> <li>Intramuscular dose:&nbsp;4 to&nbsp;6 mg/kg </li> </ul> </td> <td> <ul> <li>Rapid onset </li> <li>Increases BP, HR,&nbsp;and CO in most patients </li> <li>Profound analgesic properties </li> <li>Bronchodilation </li> <li>Maintains airway reflexes and respiratory drive </li> <li>Intramuscular route available if IV access lost </li> </ul> </td> <td> <p><strong>Cardiovascular&nbsp;effects</strong></p> <ul> <li>Increases myocardial oxygen demand due to increases in HR, BP, and CO </li> <li>Increases pulmonary arterial pressure (PAP) </li> <li>Potentiates cardiovascular toxicity of cocaine or tricyclic antidepressants </li> <li>Exacerbates hypertension, tachycardia, and arrhythmias&nbsp;in pheochromocytoma </li> <li>Direct mild myocardial depressant effects </li> </ul> <p><strong>Neurologic effects</strong></p> <ul> <li>Psychotomimetic effects (hallucinations, nightmares, vivid dreams) </li> <li>Increases CBF and ICP; may&nbsp;increase CMRO<sub>2</sub> </li> <li>Unique EEG effects may result in misinterpretation of BIS and other processed EEG values </li> </ul> <p><strong>Other effects</strong>&nbsp;</p> <ul> <li>Increases salivation </li> </ul> </td> </tr> <tr> <td>Methohexital</td> <td> <p>Induction for electroconvulsive therapy (ECT) because it activates seizure foci</p> </td> <td> <ul> <li>1.5 mg/kg </li> </ul> </td> <td> <ul> <li>Lowers seizure threshold, facilitating ECT </li> <li>Decreases CMRO<sub>2</sub>, CBF, and ICP </li> </ul> </td> <td> <ul> <li>Limited availability </li> <li>Dose-dependent&nbsp;hypotension </li> <li>Dose-dependent respiratory depression </li> <li>Involuntary myoclonic movements </li> <li>Pain during injection&nbsp; </li> <li>Contraindicated in patients with porphyria </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMRO<SUB>2</SUB>: cerebral metabolic oxygen requirement; CBF: cerebral blood flow; ICP: intracranial pressure; BP: blood pressure; HR: heart rate; CO: cardiac output; PONV: postoperative nausea and vomiting;&nbsp;EEG:electroencephalographic; ECT: electroconvulsive therapy.</div><div id=\"graphicVersion\">Graphic 102350 Version 11.0</div></div></div>"},"102355":{"type":"graphic_algorithm","displayName":"Algorithmic approach to management of locoregional paraganglioma","title":"Algorithmic approach to management of locoregional paragangliomas","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Algorithmic approach to management of locoregional paragangliomas</div><div class=\"cntnt\"><img style=\"width:602px; height:526px;\" src=\"images/ONC/102355_Algo_locoregnl_paraganglima.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 102355 Version 1.0</div></div></div>"},"102356":{"type":"graphic_algorithm","displayName":"Initiation and titration of PAP for OSA in adults","title":"Initiation and titration of positive airway pressure therapy for obstructive sleep apnea in adults","html":"<div class=\"graphic\"><div style=\"width: 766px\" class=\"figure\"><div class=\"ttl\">Initiation and titration of positive airway pressure therapy for obstructive sleep apnea in adults</div><div class=\"cntnt\"><img style=\"width:746px; height:636px;\" src=\"images/SLEEP/102356_Intn_trtn_PAP_thry_OSA_adlt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PSG: polysomnography; HSAT: home sleep apnea testing; CPAP: continuous positive airway pressure; BPAP: bilevel positive airway pressure; AHI: apnea-hypopnea index.<br />* Uncomplicated obstructive sleep apnea is that which is not complicated by other conditions associated with complex sleep-disordered breathing, including chronic obstructive pulmonary disease, heart failure, and obesity. Complicated obstructive sleep apnea is that complicated by other medical disorders including those associated with central sleep apnea or hypoventilation.<br />&para; In-laboratory titration is preferred in those in whom complex sleep-disordered breathing is suspected. In-home auto-titration may be preferred in those with anticipated or known variable pressure requirements (eg, obstructive sleep apnea exacerbated in supine or rapid eye movement [REM] sleep, variation in weight or use of alcohol, intermittent nasal obstruction) or if access to a sleep laboratory is delayed or inconvenient.<br />&Delta; Most patients undergo titration with CPAP. However, PAP titration with BPAP or other forms of positive pressure ventilation is sometimes indicated. Please refer to related UpToDate topics for details on choosing the method of PAP titration.<br /><span class=\"lozenge\">&loz;</span> CPAP titration may not be successful for many reasons, including intolerance of CPAP, air leaks, and identification of complex sleep disorders (eg, treatment-emergent central sleep apnea). Such issues need to be addressed individually and are best dealt with in a sleep laboratory setting during a PAP re-titration study.<br />&sect; Choosing among these options depends upon which method optimizes sleep quality.</div><div id=\"graphicVersion\">Graphic 102356 Version 6.0</div></div></div>"},"102357":{"type":"graphic_table","displayName":"Noninvasive risk factors with increased SCD risk in HCM","title":"Noninvasive risk factors associated with increased risk of sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Noninvasive risk factors associated with increased risk of sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk factor</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">Major risk factors</td> </tr> <tr> <td class=\"indent1\">Nonsustained ventricular tachycardia</td> <td>Defined as &#8805;3 consecutive ventricular&nbsp;beats at 120 beats per minute lasting less than 30 seconds. Multiple bursts identified on ambulatory monitoring are associated with increased risk, particularly in younger patients. Although there are no studies supporting a relationship between frequency, duration, and burden of NSVT and SCD risk, it would be reasonable to place greater weight on NSVT occurring at fast rates and/or with high burden.</td> </tr> <tr> <td class=\"indent1\">Maximal left ventricular wall thickness</td> <td>Greatest risk of SCD in patients with HCM is in patients with &#8805;30 mm wall thickness anywhere in the LV chamber. If maximal wall thickness is not clearly defined using echocardiography, consider additional evaluation with CMR to clarify the extent of LV wall thickening.</td> </tr> <tr> <td class=\"indent1\">Family history of sudden cardiac death</td> <td>SCD due to HCM in a close relative &#60;40 years of age should be considered evidence for potential increased risk in other related family members.</td> </tr> <tr> <td class=\"indent1\">Syncope</td> <td>Unexplained syncope which, based on clinical history, appears to be due to arrhythmia (and not neurally mediated) is associated with increased risk, particularly in young patients and when the event occurred close to the time of evaluation (&#60;6 months).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Abnormal blood pressure response to exercise</td> <td>An abnormal&nbsp;BP&nbsp;response to exercise is generally defined as a failure to increase systolic blood pressure by at least 20 mmHg from rest to peak exercise or a fall of &#62;20 mmHg from the peak exercise BP during ongoing exercise. Abnormal BP response to exercise is associated with a higher risk of SCD in patients ages 40 years or under, with an uncertain prognostic significance in patients &#62;40 years of age.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">Less common subgroups at increased SCD risk</td> </tr> <tr> <td class=\"indent1\">End-stage HCM (LVEF &#60;50 percent)</td> <td>Higher incidence of life-threatening VT associated with this uncommon phase of HCM. These patients often develop advanced heart failure at a young age and therefore are often considered for ICD as a bridge to definitive therapy with heart transplant.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">LV apical aneurysm</td> <td>Uncommon subgroup with thin-walled dyskinetic LV apex with regional scarring. Although data are limited, LV apical aneurysm appears associated with increased risk of adverse events including SCD and may warrant consideration for ICD.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">Potential arbiters of SCD risk</td> </tr> <tr> <td class=\"indent1\">Age</td> <td>Risk of SCD is greatest in young patients &#60;30 years old&nbsp;and lessens through mid-life. In patients who have achieved advanced age (&#8805;60 years), risk of SCD is low, even in the presence of other risk factors.</td> </tr> <tr> <td class=\"indent1\">Late gadolinium enhancement by CMR</td> <td>Extensive LGE (ie, myocardial fibrosis) occupying &#8805;15% of LV mass is associated with increased risk for SCD.</td> </tr> <tr> <td class=\"indent1\">Marked LV outflow tract obstruction</td> <td>Data on LVOT obstruction as a predictor for SCD are mixed, but a number of studies have demonstrated an association between high resting gradients and SCD. However, the use of LVOT obstruction as an independent risk factor is limited by the fact that LVOT obstruction is dynamic, can be mitigated by drug therapy, and can be abolished with invasive septal reduction therapies.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HCM: hypertrophic cardiomyopathy; SCD: sudden cardiac death; LVEF: left ventricular ejection fraction; CMR: cardiac magnetic resonance;&nbsp;NSVT: nonsustained ventricular tachycardia; BP: blood pressure; ICD: implantable cardioverter defibrillator; LGE: late gadolinium enhancement; LVOT: left ventricular outflow obstruction.</div><div id=\"graphicVersion\">Graphic 102357 Version 2.0</div></div></div>"},"102358":{"type":"graphic_table","displayName":"RA-associated interstitial pneumonia","title":"Rheumatoid arthritis-associated interstitial lung disease: Classification according to disease behavior","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rheumatoid arthritis-associated interstitial lung disease: Classification according to disease behavior</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical behavior</td> <td class=\"subtitle1\">Treatment and treatment goal</td> <td class=\"subtitle1\">Monitoring strategy</td> </tr> <tr> <td>Potentially reversible with risk of irreversible disease (eg, cases of drug-related lung disease in RA)</td> <td>Remove cause, treat to obtain a response to reverse changes</td> <td>Short-term (three to six months) observation to confirm disease regression, or occasionally need for palliation</td> </tr> <tr> <td>Reversible disease with risk of progression (eg, RA-cellular NSIP and some RA-fibrotic NSIP, RA-OP)</td> <td>Treat to initially achieve response and then rationalize longer term therapy</td> <td>Short-term observation to confirm treatment response. Long-term observation to ensure that gains are preserved</td> </tr> <tr> <td>Stable with residual disease (eg, some RA-fibrotic NSIP, some RA-UIP)</td> <td>No treatment if stable, aiming to maintain status</td> <td>Long-term observation to assess disease course</td> </tr> <tr> <td>Progressive, irreversible disease with potential for stabilization (eg, some RA-fibrotic NSIP, some RA-UIP)</td> <td>Consider treatment trial to stabilize</td> <td>Long-term observation to assess disease course</td> </tr> <tr> <td>Progressive, irreversible disease despite therapy (eg, RA-DAD, most RA-UIP, some RA-fibrotic NSIP)</td> <td>In absence of contraindications, consider treatment trial in selected patients to slow progression</td> <td>Short (DAD) or long-term observation to assess disease course, and need for transplant or effective palliation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RA: rheumatoid arthritis; NSIP: nonspecific interstitial pneumonia; UIP: usual interstitial pneumonitis; OP: organizing pneumonia; DAD: diffuse alveolar damage.</div><div class=\"graphic_reference\">Reproduced with permission from: Lake F, Proudman S. Rheumatoid arthritis and lung disease: from mechanisms to a practical approach. Semin Respir Crit Care Med 2014; 35:222. Copyright &copy; 2014 Thieme Publishers.</div><div id=\"graphicVersion\">Graphic 102358 Version 1.0</div></div></div>"},"102360":{"type":"graphic_table","displayName":"MAOIs and diet PI","title":"Diet during therapeutic use of monoamine oxidase inhibitors (MAOIs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diet during therapeutic use of monoamine oxidase inhibitors (MAOIs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food</td> <td class=\"subtitle1\">Allowed (not allowed if spoiled or improperly stored)*</td> <td class=\"subtitle1\">Minimize intake<sup>&#182;</sup></td> <td class=\"subtitle1\">Not allowed</td> </tr> <tr class=\"divider_bottom\"> <td>Beverages</td> <td>Decaffeinated beverages (eg, coffee, tea, soda); milk; most fruit juices</td> <td> <p>Caffeine-containing drinks</p> <p>Clear alcoholic spirits (eg, gin, vodka, rum)</p> <p>Red or white wine (no more than 2 4-ounce servings per day)</p> Bottled/canned beer, including nonalcoholic (no more than 2 12-ounce servings per day)</td> <td>Tap (draft) beer, Korean beer, vermouth</td> </tr> <tr class=\"divider_bottom\"> <td>Breads, cereals, crackers</td> <td>Commercial yeast breads, hot and cold cereals, most crackers (ie, containing no aged cheese)</td> <td>None</td> <td>Sourdough bread; crackers and breads that contain aged cheese</td> </tr> <tr class=\"divider_bottom\"> <td>Dairy, eggs, cheeses</td> <td>Butter, cottage cheese, eggs, farmer or pot cheese, cream cheese, ricotta cheese, pasteurized milk, pasteurized cream, ice cream, pudding, yogurt</td> <td>American processed cheese, mozzarella, parmesan, Romano, sour cream (limit these to 1 serving of &#189; cup)</td> <td><strong>All aged cheeses are absolutely not allowed</strong><sup>&#916;</sup>, including: blue/bleu, Camembert, cheddar, gorgonzola, gouda, gruyere, provolone, Roquefort, Stilton, Swiss</td> </tr> <tr class=\"divider_bottom\"> <td>Meat, fish, and poultry</td> <td>All fresh packaged, fresh frozen, or fresh processed (not aged or smoked) meats, fish, and poultry; fresh breakfast sausage</td> <td>Pepperoni, hot dogs, bologna</td> <td><strong>All aged, smoked, pickled, or cured meats/fish/poultry are absolutely not allowed</strong>, including: aged, smoked, pickled, or dried meats (eg, bacon, aged or dried sausage, all types of salami, Genoa, mortadella, corned beef, pastrami); aged chicken and beef liver; dried, pickled, or smoked fish (eg, pickled herring, lox, smoked salmon, smoked trout, shrimp paste); liverwurst; meat extracts (eg, flavoring cubes, bouillon); meat alternatives that contain soy product (eg, meatless hot dogs made from tofu)</td> </tr> <tr class=\"divider_bottom\"> <td>Starches&nbsp;&ndash; potatoes/rice</td> <td>Potatoes, rice, noodles, pasta, and most stuffings</td> <td>None</td> <td>Soy products (eg, tofu, tempeh)</td> </tr> <tr class=\"divider_bottom\"> <td>Vegetables and beans</td> <td>Most fresh, frozen, canned, or dried vegetables, leafy salad greens, lentils, and beans (except fava and soy beans); most veggie burgers (ie, containing no soy product)</td> <td>Chili peppers</td> <td>Fava or broad beans (Italian green beans) and their pods, kim chee (kimchi), sauerkraut, snow peas, soy beans, bean pastes, edamame beans</td> </tr> <tr class=\"divider_bottom\"> <td>Fruit and fruit juices</td> <td>Most fresh, frozen, or canned fruits and fruit juices</td> <td>Avocado (not over-ripened), canned figs, raspberries</td> <td>Avocado (over-ripened), banana (over-ripened), banana peel, dried fruit, any kind of fruit that is over-ripened</td> </tr> <tr class=\"divider_bottom\"> <td>Soups, gravies, casseroles, pizza</td> <td>Home prepared (not pre-packaged) soups, gravies, casseroles that contain <strong>no</strong> aged cheese, bouillons, flavoring cubes, or meat extracts</td> <td>Occasional consumption of 1-2 slices of pizza from large chain commercial outlets appears safe (ie, generally made with low tyramine cheese); avoid: larger quantities, extra cheese, or pizzas containing aged cheese</td> <td>Soups, gravies, casseroles, or pizzas that contain aged cheese; soups or casseroles with flavoring meat extracts (eg, flavoring cubes, bouillon); miso; broad or fava beans and their pods; tofu, tempeh, soy products (eg, soy sauce, teriyaki sauce); or yeast extracts</td> </tr> <tr class=\"divider_bottom\"> <td>Fats and oils</td> <td>Butter, cream cheese, margarine, mayonnaise, olive oil, vegetable oils</td> <td>Moderate amount (eg, 2-4 ounces) of peanut butter is considered safe</td> <td>Fats and oils included in fermented, aged, cured, smoked, pickled, or other foods that are not allowed</td> </tr> <tr class=\"divider_bottom\"> <td>Snacks</td> <td>Potato chips, popcorn, most nuts, most crackers (ie, containing no aged cheese)</td> <td>Moderate consumption of peanuts is considered safe</td> <td>Snack foods containing aged cheeses</td> </tr> <tr class=\"divider_bottom\"> <td>Sweets</td> <td>Sugar, hard candy, honey, molasses, syrups</td> <td>1 serving of chocolate is considered safe</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Desserts</td> <td>Cakes, cookies, gelatin, pastries, pies, sherbets, sorbets</td> <td>1 serving of chocolate-containing dessert is considered safe</td> <td>None</td> </tr> <tr> <td>Condiments and miscellaneous</td> <td>Ketchup, mustard, mayonnaise, non-cheese salad dressings, salt, spices, herbs, Worcestershire sauce</td> <td>None</td> <td>All aged or fermented soy and yeast products (eg, soy sauce, teriyaki sauce, soy paste, Thai or Vietnamese fish sauce, marmite/vegemite and other concentrated yeast extracts), sauerkraut</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Foods and beverages listed as \"not allowed\" often contain significant amounts of tyramine, which is a substance that can interact with some monoamine oxidase inhibitors (MAOIs). This can lead to problems like a dangerous increase in blood pressure.</LI>&#xD;&#xA;<LI>The ingredients of all foods and beverages (including those listed in this table as \"allowed\") should be reviewed prior to consumption to confirm they do not also include ingredients that are not allowed. If you stop taking your MAOI, continue to follow these dietary guidelines for 2 weeks afterwards.</LI>&#xD;&#xA;<LI>Ask your doctor or nurse what you should do if you accidentally eat or drink something from the \"not allowed\" column. If you have not had this discussion, call for advice or seek medical attention.</LI></UL></div><div class=\"graphic_footnotes\">* No leftover, improperly stored, handled, or spoiled foods of any type should be consumed. It is important to purchase and consume only fresh meats, poultry, and fish that are properly wrapped and stored under refrigeration and eaten the same day or frozen right away. Fresh produce should be consumed within 48 hours of purchase and not eaten if overripe. Use canned or frozen foods immediately upon opening or thawing.<br />¶ Eat these foods occasionally; generally, no more than 1 serving (eg, ½ cup) of 1-3 of these foods or beverages each day, unless otherwise noted.<br />Δ The majority of cases of food-related hypertensive crisis (a sudden spike in blood pressure that can cause serious problems such as stroke) during treatment with MAOIs are associated with consumption of aged cheeses.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hirsch M, Birnbaum RJ. An Approach to psychopharmacological treatment. In: The Ten-Minute guide to psychiatric diagnosis and treatment, Stern TA (Ed). New York: Professional Publishing Group, Ltd, 2005. p.355. Copyright © 2005 Castle Connolly Graduate Medical Publishing, Ltd.</LI>&#xD;&#xA;<LI>McCabe-Sellers BJ, Staggs CG, Bogle ML. Tyramine in foods and monoamine oxidase inhibitor drugs: A crossroad where medicine, nutrition, pharmacy and food industry converge; J Food Comp Anal 2006; 19:S58.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 102360 Version 5.0</div></div></div>"},"102362":{"type":"graphic_picture","displayName":"Vaginal adhesion in a girl","title":"Vaginal adhesion in a prepubescent girl","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Vaginal adhesion in a prepubescent girl</div><div class=\"cntnt\"><img style=\"width:555px; height:712px;\" src=\"images/PEDS/102362_Vaginal_adhesion_girl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vaginal adhesion (arrow) in a prepubescent girl.</div><div id=\"graphicVersion\">Graphic 102362 Version 1.0</div></div></div>"},"102364":{"type":"graphic_movie","displayName":"Urodynamic study: Intermittent voiding","title":"Urodynamic study demonstrating intermittent voiding in a child","html":"<div class=\"graphic normal\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Urodynamic study demonstrating intermittent voiding in a child</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/102364_Urodynamicintermtvoidvid.mp4\" style=\"width:560px;height:336px\"></div><img style=\"width:452px; height:317px;\" src=\"images/PEDS/102364_Urodynamicintermtvoidvid.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 102364 Version 1.0</div></div></div>"},"102368":{"type":"graphic_table","displayName":"RBC antibodies associated with HDFN","title":"Red blood cell antibodies associated with hemolytic disease of the fetus and newborn","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Red blood cell antibodies associated with hemolytic disease of the fetus and newborn</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antigen group</td> <td class=\"subtitle1\">Specific antigen</td> <td class=\"subtitle1\">Disease severity</td> </tr> <tr class=\"divider_bottom\"> <td>ABO</td> <td>A, B</td> <td>Mild</td> </tr> <tr class=\"divider_bottom\"> <td>Chido-Rodgers</td> <td>Ch1, Ch2, Ch3, Ch4, Ch5, Ch6, WH, Rg1, Rg2</td> <td>None</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Colton</td> <td>Co<sup>a</sup></td> <td>Moderate</td> </tr> <tr class=\"divider_bottom\"> <td>Co<sup>b</sup>, Co<sup>3</sup></td> <td>Mild</td> </tr> <tr class=\"divider_bottom\"> <td>Cromer</td> <td>Cr<sup>a</sup>, Tc<sup>a</sup>, Tc<sup>b</sup>, Tc<sup>c</sup>, Dr<sup>a</sup>, Es<sup>a</sup>, IFC, WES<sup>a</sup>, WES<sup>b</sup>, UMC, GUTI, SERF, ZENA, CROV, CRAM</td> <td>None</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Diego</td> <td>Di<sup>a</sup>, Di<sup>b</sup>, Wr<sup>a</sup>, ELO</td> <td>Moderate</td> </tr> <tr class=\"divider_bottom\"> <td>Wr<sup>b</sup>, Wd<sup>a</sup>, Rb<sup>a</sup>, WARR, Wu, Bp<sup>a</sup>, Mo<sup>a</sup>, Hg<sup>a</sup>, Vg<sup>a</sup>, Sw<sup>a</sup>, BOW, NFLD, Jn<sup>a</sup>, KREP, Tr<sup>a</sup>, Fr<sup>a</sup>, SW1</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Dombrock</td> <td>Do<sup>a</sup>, Do<sup>b</sup>, Gy<sup>a</sup>, Hy, Jo<sup>a</sup>, DOYA</td> <td>None</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Duffy</td> <td>Fy<sup>a</sup></td> <td>Moderate</td> </tr> <tr> <td>Fy<sup>b</sup></td> <td>Mild</td> </tr> <tr class=\"divider_bottom\"> <td>Fy<sup>3</sup>, Fy<sup>4</sup>, Fy<sup>5</sup>, Fy<sup>6</sup></td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Forssman</td> <td>FOR</td> <td>None</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Gerbich</td> <td>Ge3</td> <td>Moderate</td> </tr> <tr class=\"divider_bottom\"> <td>Ge2, Ge4, Wb, Ls<sup>a</sup>, An<sup>a</sup>, Dh<sup>a</sup>, GEIS</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Gill</td> <td>GIL</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Globoside</td> <td>PP<sub>1</sub>P<sub>k</sub></td> <td>Severe</td> </tr> <tr class=\"divider_bottom\"> <td>H</td> <td>H</td> <td>Moderate</td> </tr> <tr class=\"divider_bottom\"> <td>I</td> <td>I, i</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Indian</td> <td>In<sup>a</sup>, In<sup>b</sup>, INFI, INJA</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Junior</td> <td>Jr<sup>a</sup></td> <td>Mild (rare: severe)</td> </tr> <tr class=\"divider_bottom\"> <td>John Milton Hagen</td> <td>JMH, JMHK, JMHL, JMHG, JMHM</td> <td>None</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Kell</td> <td>K, k, Ku, Js<sup>b</sup></td> <td>Severe</td> </tr> <tr> <td>Kp<sup>b</sup></td> <td>Moderate</td> </tr> <tr> <td>Kp<sup>a</sup>, Js<sup>a</sup>, Ul<sup>a</sup></td> <td>Mild</td> </tr> <tr class=\"divider_bottom\"> <td>K11, K12, K13, K14, K15, K16, K17, K18, K19, K20, K21, K22, K23, K24, VLAN, TOU, RAZ, KUCI, KANT, KASH, VONG, KALT, KTIM, KYO</td> <td>None</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Kidd</td> <td>Jk<sup>a</sup>, Jk<sup>b</sup></td> <td>Mild (rare: severe)</td> </tr> <tr class=\"divider_bottom\"> <td>Jk3</td> <td>Mild</td> </tr> <tr class=\"divider_bottom\"> <td>Knops</td> <td>Kn<sup>a</sup>, Kn<sup>b</sup>, McC<sup>a</sup>, Sl1, Yka, Sl2, Sl3, KCAM</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Kx</td> <td>Kx</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Langereis</td> <td>Lan</td> <td>Mild (rare: moderate)</td> </tr> <tr class=\"divider_bottom\"> <td>Landsteiner-Weiner</td> <td>LW<sup>a</sup>, LW<sup>ab</sup>, LW<sup>b</sup></td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Lewis</td> <td>Le<sup>a</sup>, Le<sup>b</sup>, Le<sup>ab</sup>, Le<sup>bH</sup>, Ale<sup>b</sup>, Ble<sup>b</sup></td> <td>None</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Lutheran</td> <td>Lu<sup>a</sup></td> <td>Mild</td> </tr> <tr class=\"divider_bottom\"> <td>Lu<sup>b</sup>, Lu3, Lu4, Lu5, Lu6, Lu7, Lu8, Lu9, Lu10, Lu11, Lu12, Lu13, Lu14, Lu15, Lu16, Lu17, Au<sup>a</sup>, Au<sup>b</sup>, Lu20, Lu21</td> <td>None</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Mittenberger</td> <td>Mi<sup>a</sup></td> <td>Severe</td> </tr> <tr class=\"divider_bottom\"> <td>Mi<sup>b</sup></td> <td>None</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">MNSs</td> <td>Vw, Mur, MUT</td> <td>Severe</td> </tr> <tr> <td>U</td> <td>Moderate (rare: severe)</td> </tr> <tr> <td>S, s, Mt<sup>a</sup>, M<sup>v</sup></td> <td>Moderate&nbsp;</td> </tr> <tr> <td>M</td> <td>Mild (rare: severe)</td> </tr> <tr> <td>N, Hil, Or</td> <td>Mild</td> </tr> <tr class=\"divider_bottom\"> <td>He, Mi<sup>a</sup>, M<sup>c</sup>, M<sup>g</sup>, Vr, M<sup>e</sup>, St<sup>a</sup>, Ri<sup>a</sup>, Cl<sup>a</sup>, Ny<sup>a</sup>, Hut, Far, s<sup>D</sup>, Mit, Dantu, Hop, Nob, En<sup>a</sup>, En<sup>a</sup>KT, 'N', DANE, TSEN, MINY, SAT, ERIK, Os<sup>a</sup>, ENEP, ENEH, HAG, ENAV, MARS, ENDA, ENEV, MNTD</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Ok</td> <td>Ok<sup>a</sup></td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>P1Pk</td> <td>P, P1, P<sup>k</sup></td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Raph</td> <td>MER2</td> <td>None</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Rhesus (Rh)</td> <td>D, c, f, Ce, C<sup>w</sup>, cE</td> <td>Severe</td> </tr> <tr> <td>E, Hr<sub>o</sub></td> <td>Moderate (rare: severe)</td> </tr> <tr> <td>E<sup>W</sup>, hr<sup>s</sup>, Tar, Rh32, Hr<sup>B</sup></td> <td>Moderate</td> </tr> <tr> <td>G</td> <td>Mild (rare: severe)</td> </tr> <tr> <td>C</td> <td>Mild (rare: moderate)</td> </tr> <tr> <td>e, C<sup>x</sup>, VS, CE, Be<sup>a</sup>, JAL</td> <td>Mild</td> </tr> <tr class=\"divider_bottom\"> <td>V, Hr, C<sup>G</sup>, D<sup>W</sup>, c-like, hr<sup>H</sup>, Rh29, Go<sup>a</sup>, Rh33, hr<sup>B</sup>, Rh35, Evans, Rh39, Rh41, Rh42, Crawford, Nou, Riv, Sec, CELO, Dav, STEM, FPTT, MAR, BARC, JAHK, DAK, LOCR, CENR, CEST</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>RHAG</td> <td>Duclos, Ol<sup>a</sup>, Duclos-like</td> <td>None</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Scianna</td> <td>Rd</td> <td>Mild (rare: moderate)</td> </tr> <tr> <td>SC2</td> <td>Mild </td> </tr> <tr class=\"divider_bottom\"> <td>SC1, SC3, STAR, SCER, SCAN</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Vel</td> <td>Vel</td> <td>Mild (rare: severe)</td> </tr> <tr class=\"divider_bottom\"> <td>Yt (Cartwright)</td> <td>Yt<sup>a</sup>, Yt<sup>b</sup></td> <td>None</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Xg</td> <td>Xg<sup>a</sup></td> <td>Mild</td> </tr> <tr class=\"divider_bottom\"> <td>CD99</td> <td>None</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antigens that do not belong to a blood group system</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cost</td> <td>Cs<sup>a</sup>, Cs<sup>b</sup></td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Er</td> <td>Er<sup>a</sup>, Er<sup>b</sup></td> <td>None</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"2\">High-prevalence antigens</td> <td>At<sup>a</sup></td> <td>Mild</td> </tr> <tr class=\"divider_bottom\"> <td>AnWj, ABTI, Emm, MAM, PEL, Sd<sup>a</sup></td> <td>None</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Low-prevalence antigens</td> <td>HJK</td> <td>Severe</td> </tr> <tr> <td>Kg, Sara</td> <td>Moderate</td> </tr> <tr> <td>Chr<sup>a</sup>, Bi, Bx<sup>a</sup>, To<sup>a</sup>, Pt<sup>a</sup>, Re<sup>a</sup>, Je<sup>a</sup>, Li<sup>a</sup>, Milne, RASM, JFV, JONES, HOFM, REIT</td> <td>None</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Mild disease: published reports of need for bililight therapy or simple transfusion in neonatal life.<br />Moderate disease: published reports of need for exchange transfusion in neonatal life.<br />Severe disease: published reports of hydrops fetalis or need for intrauterine transfusions.<br />Disease severity indicated in parentheses indicates a case report of a more severely affected fetus or neonate has been published, in contrast to the majority of reports.<br />Refer to UpToDate topics on HDFN for further details.</div><div class=\"graphic_footnotes\">HDFN: hemolytic disease of the fetus and newborn.</div><div id=\"graphicVersion\">Graphic 102368 Version 6.0</div></div></div>"},"102369":{"type":"graphic_algorithm","displayName":"Approach to the male patient with suspected urethritis","title":"Approach to the male patient with suspected urethritis","html":"<div class=\"graphic\"><div style=\"width: 743px\" class=\"figure\"><div class=\"ttl\">Approach to the male patient with suspected urethritis</div><div class=\"cntnt\"><img style=\"width:723px; height:669px;\" src=\"images/ID/102369_Dgnstcapprmnsympurthrts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NAAT: nucleic acid amplification test; STI: sexually transmitted infection; WBC/hpf: white blood cells per high powered field.<br />* First-void urine refers to the initial portion of the first urine stream upon wakening. The more practical first-catch urine refers to the initial portion of the urine stream at least one hour after the most recent micturition. Both are collected without precleaning the urethral meatus, and the volume collected is limited to approximately 10 mL.<br />¶ Although urethritis is often treated empirically prior to the results of NAAT for specific organisms, this testing remains important for documentation of specific infections and facilitation of sex partner management. However, NAAT for <EM>N. gonorrhoeae</EM> is not necessary to document <EM>N. gonorrhoeae</EM> infection if intracellular diplococci are identified on a point-of-care stain of the urethral specimen.<br />Δ A methylene blue/gentian violet stain is an alternative to the Gram stain and can be performed more rapidly.</div><div id=\"graphicVersion\">Graphic 102369 Version 5.0</div></div></div>"},"102375":{"type":"graphic_figure","displayName":"Trends in % of deaths due to HIV by age group, US, 1987 to 2010","title":"Trends in age at death due to HIV infection, United States, 1987 to 2010","html":"<div class=\"graphic\"><div style=\"width: 698px\" class=\"figure\"><div class=\"ttl\">Trends in age at death due to HIV infection, United States, 1987 to 2010</div><div class=\"cntnt\"><img style=\"width:678px; height:354px;\" src=\"images/ID/102375_Trnd_dth_due_HIV_ag_US_7_10.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Mortality Slide Series. Centers for Disease Control and Prevention. Available at: <A href=\"http://www.cdc.gov/hiv/pdf/statistics_surveillance_HIV_mortality.pdf\" target=_blank>http://www.cdc.gov/hiv/pdf/statistics_surveillance_HIV_mortality.pdf</A> (Accessed July 2, 2015).</div><div id=\"graphicVersion\">Graphic 102375 Version 2.0</div></div></div>"},"102376":{"type":"graphic_figure","displayName":"Median age at death due to HIV, United States, 1987 to 2010","title":"Median age at death due to HIV infection, United States, 1987 to 2010","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Median age at death due to HIV infection, United States, 1987 to 2010</div><div class=\"cntnt\"><img style=\"width:628px; height:368px;\" src=\"images/ID/102376_Md_age_dth_due_HIV_US_87_10.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Mortality Slide Series. Centers for Disease Control and Prevention. Available at: <a href=\"http://www.cdc.gov/hiv/pdf/statistics_surveillance_HIV_mortality.pdf\" spellcheck=\"true\" target=\"_blank\">http://www.cdc.gov/hiv/pdf/statistics_surveillance_HIV_mortality.pdf</a> (Accessed July 2, 2015).</div><div id=\"graphicVersion\">Graphic 102376 Version 2.0</div></div></div>"},"102377":{"type":"graphic_figure","displayName":"CKD treatment management guidance based on prognosis","title":"Treatment management guidance based on prognosis and chance of achieving acceptable post-treatment quality of life","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">Treatment management guidance based on prognosis and chance of achieving acceptable post-treatment quality of life</div><div class=\"cntnt\"><img style=\"width:784px; height:516px;\" src=\"images/NEPH/102377_CKD_tx_manag_guid_prognosis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Left of the curve (prognosis predictable and quality of life acceptable)&nbsp;- Patients tend to be healthier with fewer comorbidities. The prognosis is predictable and quality of life preserved. Treatments that focus on longevity (such as minimization of renal progression and management of secondary complications of kidney disease) are provided concurrently with treatments that address symptoms. The patient determines whether potentially longer survival outweighs the burdens as associated with additional medications, blood work, and clinic visits.&nbsp;</LI>&#xD;&#xA;<LI>Top of the curve (prognosis unpredictable/quality of life unclear)&nbsp;- Prognosis is less predictable. The treatment plan may include medical management of kidney disease and/or symptom management and should align with the patient's goals. Treatments that focus on longevity and symptom management should be elected for patients whose goals focus on living as long as possible. Symptom management without treatments that focus on longevity may be elected for those patients whose goals focus on the quality of life. These patients warrant close reassessment of prognosis and goals of care, with modification of the treatment plan as necessary.&nbsp;</LI>&#xD;&#xA;<LI>Right of the curve (predictable prognosis/quality of life poor)&nbsp;- Patients have a predictable poor prognosis and/or poor quality of life. Treatments focused on medical management of kidney disease are not likely to provide meaningful benefit. The treatment plan focuses on symptom control, comfort, and preparation for end of life, and medical therapies that do not address symptoms are often omitted.</LI></UL></div><div class=\"graphic_footnotes\">CKD: chronic kidney disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Goldstein NE, Black AL, Morrison RS. Titrating guidance: A model to guide physicians in assisting patients and family members who are facing complex decisions. Arch Intern Med 2008; 168:1733. Copyright &copy; 2008 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 102377 Version 2.0</div></div></div>"},"102378":{"type":"graphic_form","displayName":"Voiding and fluid intake","title":"Voiding and fluid intake diary","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Voiding and fluid intake diary</div><div class=\"cntnt\"><img style=\"width:598px; height:786px;\" src=\"images/PEDS/102378_Voiding_fluid_intake.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Instructions to parents or primary care provider on completing the voiding/drinking diary: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Fill out this chart on a day without school or kindergarten (weekend or holiday). This should start on one morning and continue through to the next morning. If possible, fill out the diary two days in a row, as this is even more reliable.</LI>&#xD;&#xA;<LI>Talk to your child beforehand. He/she should tell you when he/she wants to go to the toilet and should empty the urine into a measuring cup. Please measure the amount of urine and record it with the time of day. You do not have to collect the urine, but can discard it afterwards.</LI>&#xD;&#xA;<LI>If your child needs to strain to start getting the voiding going or if the stream is interrupted, note this in the \"Straining/interrupted stream\" column.</LI>&#xD;&#xA;<LI>If your child feels a sudden urge to go to the toilet, please note this in the \"Urge\" column.</LI>&#xD;&#xA;<LI>If your child wets his/her clothes, note the time and if they were wet or damp.</LI>&#xD;&#xA;<LI>If you observe that your child crosses his/her legs, squats, or tries to hold back the urine in any other way, note the time and observation in the \"Comments/observations\" column.</LI>&#xD;&#xA;<LI>The time of each bowel moment, and any episode of fecal soiling should be noted in the \"Comments/observations\" column.</LI>&#xD;&#xA;<LI>Measure and note the amount of fluids and the time your child drinks during the day.</LI></OL></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2016 International Children's Continence Society (ICCS). All rights reserved.</div><div id=\"graphicVersion\">Graphic 102378 Version 1.0</div></div></div>"},"102382":{"type":"graphic_figure","displayName":"Increasing incidence of Vibrio alginolyticus in the US 1996-2010","title":"Increasing incidence of Vibrio alginolyticus in the United States, 1996-2010","html":"<div class=\"graphic\"><div style=\"width: 655px\" class=\"figure\"><div class=\"ttl\">Increasing incidence of Vibrio alginolyticus in the United States, 1996-2010</div><div class=\"cntnt\"><img style=\"width:635px; height:392px;\" src=\"images/ID/102382_Incr_inc_vbr_algnl_US_96_10.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Newton A, Kendall M, Vugia DJ, et al. Increasing rates of vibriosis in the United States, 1996-2010: review of surveillance data from 2 systems. Clin Infect Dis; 2012 Jun;54 Suppl 5:S391-5, by permission of Oxford University Press on behalf of the Infectious Diseases Society of America. Copyright &copy; 2012.</div><div id=\"graphicVersion\">Graphic 102382 Version 6.0</div></div></div>"},"102385":{"type":"graphic_algorithm","displayName":"Evaluation of suspected polycythemia vera","title":"Evaluation of suspected polycythemia vera","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Evaluation of suspected polycythemia vera</div><div class=\"cntnt\"><img style=\"width:506px; height:660px;\" src=\"images/HEME/102385_Eval_susp_polycythemia_vera.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PV: polycythemia vera; EPO: erythropoietin.</div><div id=\"graphicVersion\">Graphic 102385 Version 3.0</div></div></div>"},"102395":{"type":"graphic_picture","displayName":"Atopic dermatitis neck","title":"Atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/102395_Atopicdrmttsnck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atopic dermatitis involving the sides of the neck. Note the scaling and characteristic reticular pigmentation.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 102395 Version 2.0</div></div></div>"},"102398":{"type":"graphic_picture","displayName":"Hemorrhages on cervix in trichomoniasis infection","title":"Hemorrhages on cervix in trichomoniasis infection","html":"<div class=\"graphic\"><div style=\"width: 867px\" class=\"figure\"><div class=\"ttl\">Hemorrhages on cervix in trichomoniasis infection</div><div class=\"cntnt\"><img style=\"width:847px; height:562px;\" src=\"images/OBGYN/102398_Trichomoniasis_infct_cervix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Punctate hemorrhages on cervix.</div><div id=\"graphicVersion\">Graphic 102398 Version 2.0</div></div></div>"},"102404":{"type":"graphic_table","displayName":"Characteristics of cryofibrinogenemia","title":"Characteristics of cryofibrinogenemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of cryofibrinogenemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Primary</td> <td class=\"subtitle1\">Secondary</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Age, mean, years</strong></td> <td class=\"centered\">42 to 63</td> <td class=\"centered\">48 to 63</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Gender ratio, male:female</strong></td> <td class=\"centered\">1:1 to 1:2.7</td> <td class=\"centered\">1:1.6 to 1:4.5</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Clinical manifestations</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Cold sensitivity </li> </ul> </td> <td class=\"centered\">53 to 88%</td> <td class=\"centered\">21 to 25%</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Purpura </li> </ul> </td> <td class=\"centered\">4 to 78%</td> <td class=\"centered\">0 to 65%</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Skin necrosis or ulceration </li> </ul> </td> <td class=\"centered\">6 to 56%</td> <td class=\"centered\">6 to 25%</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Raynaud phenomenon </li> </ul> </td> <td class=\"centered\">17 to 54%</td> <td class=\"centered\">0 to 24%</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Arthralgia </li> </ul> </td> <td class=\"centered\">6 to 34%</td> <td class=\"centered\">14 to 58%</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Mononeuritis </li> </ul> </td> <td class=\"centered\">6 to 22%</td> <td class=\"centered\">4 to 19%</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Livedo </li> </ul> </td> <td class=\"centered\">3 to 25%</td> <td class=\"centered\">0 to 19%</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Ecchymosis </li> </ul> </td> <td class=\"centered\">0 to 36%</td> <td class=\"centered\">7 to 16%</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Renal involvement </li> </ul> </td> <td class=\"centered\">0 to 22%</td> <td class=\"centered\">2 to 25%</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Urticaria </li> </ul> </td> <td class=\"centered\">0 to 11%</td> <td class=\"centered\">2 to 14%</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Myalgias </li> </ul> </td> <td class=\"centered\">0 to 13%</td> <td class=\"centered\">0 to 14%</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Fever </li> </ul> </td> <td class=\"centered\">0 to 11%</td> <td class=\"centered\">7%</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Complications</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Gangrene </li> </ul> </td> <td class=\"centered\">0 to 4%</td> <td class=\"centered\">1 to 8%</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Thrombotic event </li> </ul> </td> <td class=\"centered\">0 to 56%</td> <td class=\"centered\">3 to 25%</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Characteristics of primary (essential) and secondary cryofibrinogenemia using data from published studies.</div><div class=\"graphic_reference\">Data from: Michaud M, Pourrat J. Cryofibrinogenemia. J Clin Rheum 2013; 19:142.</div><div id=\"graphicVersion\">Graphic 102404 Version 1.0</div></div></div>"},"102411":{"type":"graphic_table","displayName":"MERS countries","title":"Countries with reported cases of Middle East respiratory syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Countries with reported cases of Middle East respiratory syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td>Algeria</td> <td>Netherlands</td> </tr> <tr> <td>Austria</td> <td>Oman</td> </tr> <tr> <td>Bahrain</td> <td>Philippines</td> </tr> <tr> <td>China</td> <td>Qatar</td> </tr> <tr> <td>Egypt</td> <td>Saudi Arabia</td> </tr> <tr> <td>France</td> <td>South Korea</td> </tr> <tr> <td>Germany</td> <td>Thailand</td> </tr> <tr> <td>Greece</td> <td>Tunisia</td> </tr> <tr> <td>Iran</td> <td>Turkey</td> </tr> <tr> <td>Italy</td> <td>United Arab Emirates</td> </tr> <tr> <td>Jordan</td> <td>United Kingdom</td> </tr> <tr> <td>Kuwait</td> <td>United States</td> </tr> <tr> <td>Lebanon</td> <td>Yemen</td> </tr> <tr> <td>Malaysia</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 102411 Version 3.0</div></div></div>"},"102412":{"type":"graphic_figure","displayName":"Trigger areas for nausea and vomiting","title":"Trigger areas for nausea and vomiting","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Trigger areas for nausea and vomiting</div><div class=\"cntnt\"><img style=\"width:544px; height:538px;\" src=\"images/GAST/102412_Trigger_areas_nausea_vomit.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Malagelada J-R, Malagelada C. Nausea and vomiting. In: Sleisenger and Fordtran's Gastrointestinal Disease, 10th ed, Feldman M, Freidman LS, Brandt LJ (Eds). WB Saunders, Philadelphia 2015. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 102412 Version 1.0</div></div></div>"},"102437":{"type":"graphic_figure","displayName":"Diagnosing CAD in renal transplant candidates","title":"Diagnosing coronary artery disease in renal transplant candidates","html":"<div class=\"graphic\"><div style=\"width: 690px\" class=\"figure\"><div class=\"ttl\">Diagnosing coronary artery disease in renal transplant candidates</div><div class=\"cntnt\"><img style=\"width:670px; height:770px;\" src=\"images/NEPH/102437_Diag_CAD_renal_transplant.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Receiver-operating characteristic (ROC) curves for diagnosing coronary artery disease (CAD) in renal transplant candidates.</div><div class=\"graphic_footnotes\">MPS: myocardial perfusion scintigraphy; DSE: dobutamine stress echocardiography.</div><div class=\"graphic_reference\">From: Wang LW, Fahim MA, Hayen A, et al. Cardiac testing for coronary artery disease in potential kidney transplant recipients. Cochrane Database Syst Rev 2011; (12):CD008691. <a href=\"http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008691.pub2/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008691.pub2/abstract</a>. Copyright &copy; 2011 The Cochrane Collaboration. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 102437 Version 1.0</div></div></div>"},"102455":{"type":"graphic_table","displayName":"Low-protein diet for children with PKU","title":"Low-protein diet for children with phenylketonuria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Low-protein diet for children with phenylketonuria</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Formula</td> <td class=\"subtitle1\">Food</td> </tr> <tr> <td> <ul> <li>Formula provides protein (with no phenylalanine), which is safe for children with PKU </li> <li>Formula takes the place of high-protein foods such as meat and dairy products </li> </ul> </td> <td> <ul> <li>In addition to formula, the diet includes foods that are low in protein (low in phenylalanine) </li> <li>Count protein from food using guidelines below </li> <li>The amount of grams is determined individually for each patient </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Low-protein foods - No limit</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fruits</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Almost protein free &ndash; No limit </li> <li>All fruits &ndash; Fresh or canned </li> <li>Offer three to four times/day </li> <li>Examples: Apple, orange, pear, peach, melon, banana, pineapple, nectarine, berries, plum, kiwi, mango, grapefruit, clementine, plantain, fruit cocktail, applesauce, grapes </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Vegetables</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Most are low in protein &ndash; No limit </li> <li>Examples: Carrot, celery, cucumber, lettuce, onion, beet, cabbage, green pepper, red pepper, zucchini, asparagus, cauliflower, squash, mushrooms, broccoli, green beans, wax beans, artichokes, eggplant, spinach, tomato </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Special low-protein foods</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Very low protein &ndash; No limit </li> <li>Order from Cambrooke Foods, Dietary Specialties, Loprofin, PKU Perspectives </li> <li>Examples: Pasta, rice, bread, bagel, cereal, broth, cookies, snacks, peanut butter, cheese, prepared foods such as pizza, burgers, nuggets </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other foods</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Contain sugar and fat, but no protein &ndash; Add extra calories </li> <li>Examples: <ul> <li>Beverages &ndash; Soda, Tang, lemonade, Kool-Aid, Hi C, Gatorade, Sunny Delight, apple juice, cranberry juice </li> <li>Fats &ndash; Butter, margarine, vegetable oil, mayonnaise, salad dressing </li> <li>Other &ndash; Nondairy creamer, jelly, jam, sugar, maple syrup, popsicle, Italian ice, sorbet, Hunts lemon pudding, marshmallow, candy such as Starbursts, Skittles </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Medium-protein foods &ndash; Need to count protein</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Bread and cereal products</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>When reading food labels, look for foods that have 2 grams of protein or less (in a serving) </li> <li>Examples: <ul> <li>Breakfast foods: Toast, bagel, English muffin, waffle, pancake, cereal, small muffin, donut </li> <li>Lunch and dinner foods: Bread, pita, roll, tortilla, rice, pasta </li> <li>Snack foods: Potato chips, corn chips, rice cakes, Goldfish, crackers, popcorn, cookies </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Starchy vegetables</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <li>These vegetables have more protein than other vegetables (approximately 2 grams of protein in a small serving) </li> <li>Examples: Corn, peas, potato, sweet potato, French fries, onion rings </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">High-protein foods &ndash; Do not eat</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <li>These foods have too much protein: <ul> <li>Meat, chicken, fish </li> <li>Dairy products including milk, cheese, yogurt, ice cream </li> <li>Eggs </li> <li>Nuts including peanut butter </li> <li>Seeds </li> <li>Vegetarian sources of protein including soy, tofu, legumes (beans), split peas, hummus </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Olaf A Bodamer, MD, PhD, FAAP, FACMG.</div><div id=\"graphicVersion\">Graphic 102455 Version 1.0</div></div></div>"},"102473":{"type":"graphic_figure","displayName":"Cobalamin pathway","title":"Cobalamin pathway","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Cobalamin pathway</div><div class=\"cntnt\"><img style=\"width:606px; height:422px;\" src=\"images/ALLRG/102473_Cobalamin_pathway.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TC: transcobalamin; CBL: cobalamin complementation group A-H; MMA: methylmalonic aciduria.</div><div class=\"graphic_reference\">Courtesy of Olaf A Bodamer, MD, PhD, FAAP, FACMG.</div><div id=\"graphicVersion\">Graphic 102473 Version 1.0</div></div></div>"},"102479":{"type":"graphic_figure","displayName":"Cervix transformation zone","title":"Cervical squamocolumnar junction and transformation zone","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Cervical squamocolumnar junction and transformation zone</div><div class=\"cntnt\"><img style=\"width:523px; height:449px;\" src=\"images/OBGYN/102479_Cervix_transformation_zone.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SCJ: squamocolumnar junction.</div><div id=\"graphicVersion\">Graphic 102479 Version 2.0</div></div></div>"},"102499":{"type":"graphic_figure","displayName":"Gastric eversion","title":"Gastric eversion","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Gastric eversion</div><div class=\"cntnt\"><img style=\"width:466px; height:697px;\" src=\"images/SURG/102499_Gastric_eversion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When treating a patient who is bleeding from stress ulcers, the initial gastrotomy needs to be made high enough to allow for eversion and close inspection of the flattened rugal folds of the upper stomach.</div><div class=\"graphic_reference\">Original figure modified for this publication. Starzl TE, Sanders RJ. A maneuver for detection of the site of gastric hemorrhage. Surg Gynecol Obstet 1963; 116:121. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 102499 Version 1.0</div></div></div>"},"102509":{"type":"graphic_table","displayName":"Seattle criteria athlete ECG findings","title":"Seattle criteria classifying the normal and abnormal electrocardiogram findings in athletes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Seattle criteria classifying the normal and abnormal electrocardiogram findings in athletes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Normal ECG findings in athletes</td> </tr> <tr> <td colspan=\"2\">1. Sinus bradycardia (&#8805;30 bpm)</td> </tr> <tr> <td colspan=\"2\">2. Sinus arrhythmia</td> </tr> <tr> <td colspan=\"2\">3. Ectopic atrial rhythm</td> </tr> <tr> <td colspan=\"2\">4. Junctional escape rhythm</td> </tr> <tr> <td colspan=\"2\">5. 1&#176; AV block (PR interval &#62;200 ms)</td> </tr> <tr> <td colspan=\"2\">6. Mobitz Type I (Wenckebach) 2&#176; AV block</td> </tr> <tr> <td colspan=\"2\">7. Incomplete RBBB</td> </tr> <tr> <td colspan=\"2\">8. Isolated QRS voltage criteria for LVH <ul class=\"decimal_heading\"> <li><strong>Except:</strong> QRS voltage criteria for LVH occurring with any non-voltage criteria for LVH such as left atrial enlargement, left axis deviation, ST segment depression, T-wave inversion, or pathological Q waves </li> </ul> </td> </tr> <tr> <td colspan=\"2\">9. Early repolarization (ST elevation, J-point elevation, J-waves, or terminal QRS slurring)</td> </tr> <tr> <td colspan=\"2\">10. Convex (\"domed\") ST segment elevation combined with T-wave inversion in leads V1&ndash;V4 in black/African athletes</td> </tr> <tr> <td colspan=\"2\"><strong>These common training-related ECG alterations are physiological adaptations to regular exercise, considered normal variants in athletes and do not require further evaluation in asymptomatic athletes</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">AV, atrioventricular; bpm, beats per minute; LVH, left ventricular hypertrophy; ms, milliseconds; RBBB, right bundle branch block</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Abnormal ECG findings in athletes</td> </tr> <tr> <td class=\"subtitle2\">Abnormal ECG finding</td> <td class=\"subtitle2\">Definition</td> </tr> <tr> <td>T-wave inversion</td> <td>&#62;1 mm in depth in two or more leads V2&ndash;V6, II and aVF, or I and aVL (excludes III, aVR and V1)</td> </tr> <tr> <td>ST segment depression</td> <td>&#8805;0.5 mm in depth in two or more leads</td> </tr> <tr> <td>Pathologic Q waves</td> <td>&#62;3 mm in depth or &#62;40 ms in duration in two or more leads (except for III and aVR)</td> </tr> <tr> <td>Complete left bundle branch block</td> <td>QRS &#8805;120 ms, predominantly negative QRS complex in lead V1 (QS or rS), and upright monophasic R wave in leads I and V6</td> </tr> <tr> <td>Intraventricular conduction delay</td> <td>Any QRS duration &#8805;140 ms</td> </tr> <tr> <td>Left axis deviation</td> <td>&ndash;30&#176; to &ndash;90&#176;</td> </tr> <tr> <td>Left atrial enlargement</td> <td>Prolonged P wave duration of &#62;120 ms in leads I or II with negative portion of the P wave &#8805;1 mm in depth and &#8805;40 ms in duration in lead V1</td> </tr> <tr> <td>Right ventricular hypertrophy pattern</td> <td>R&ndash;V1+S&ndash;V5 &#62;10.5 mm AND right axis deviation &#62;120&#176;</td> </tr> <tr> <td>Ventricular pre-excitation</td> <td>PR interval &#60;120 ms with a delta wave (slurred upstroke in the QRS complex) and wide QRS (&#62;120 ms)</td> </tr> <tr> <td>Long QT interval*</td> <td> <p>QTc &#8805;470 ms (male)</p> <p>QTc &#8805;480 ms (female)</p> QTc &#8805;500 ms (marked QT prolongation)</td> </tr> <tr> <td>Short QT interval*</td> <td>QTc &#8804;320 ms</td> </tr> <tr> <td>Brugada-like ECG pattern</td> <td>High take-off and downsloping ST segment elevation followed by a negative T wave in &#8805;2 leads in V1&ndash;V3</td> </tr> <tr> <td>Profound sinus bradycardia</td> <td>&#60;30 bpm or sinus pauses &#8805;3 s</td> </tr> <tr> <td>Atrial tachyarrhythmias</td> <td>Supraventricular tachycardia, atrial fibrillation, atrial flutter</td> </tr> <tr> <td>Premature ventricular contractions</td> <td>&#8805;2 PVCs per 10 s tracing</td> </tr> <tr> <td>Ventricular arrhythmias</td> <td>Couplets, triplets, and non-sustained ventricular tachycardia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; bpm: beats per minute; AV: atrioventricular; RBBB: right bundle branch block; LVH: left ventricular hypertrophy; PVC: premature ventricular contraction.<br />* The QT interval corrected for heart rate is ideally measured with heart rates of 60 to 90 bpm. Consider repeating the ECG after mild aerobic activity for borderline or abnormal QTc values with a heart rate &lt;50 bpm.</div><div class=\"graphic_reference\">From: Drezner JA, Ackerman MJ, Anderson J, et al. Electrocardiographic interpretation in athletes: The \"Seattle Criteria\". Br J Sports Med 2013; 47:123. Reproduced with permission from BMJ Publishing Group Ltd. Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 102509 Version 2.0</div></div></div>"},"102519":{"type":"graphic_algorithm","displayName":"Initial DMT for relapsing-remitting MS","title":"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Initial disease-modifying therapy for relapsing-remitting multiple sclerosis</div><div class=\"cntnt\"><img style=\"width:594px; height:170px;\" src=\"images/NEURO/102519_Initial_DMT_relaps_remit_MS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CIS: clinically isolated syndromes.</div><div id=\"graphicVersion\">Graphic 102519 Version 1.0</div></div></div>"},"102521":{"type":"graphic_algorithm","displayName":"Failure of initial DMT for relapsing-remitting MS","title":"Treatment algorithm for relapsing-remitting MS that is refractory to initial disease-modifying therapy","html":"<div class=\"graphic\"><div style=\"width: 790px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for relapsing-remitting MS that is refractory to initial disease-modifying therapy</div><div class=\"cntnt\"><img style=\"width:770px; height:612px;\" src=\"images/NEURO/102521_Failure_DMT_relaps_remit_MS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DMT: disease-modifying therapy; IVIG: intravenous immunoglobulin.</div><div id=\"graphicVersion\">Graphic 102521 Version 2.0</div></div></div>"},"102532":{"type":"graphic_algorithm","displayName":"Algorithm for management of CPAM","title":"Algorithm for management of congenital pulmonary airway malformations (CPAM) in infants and children","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of congenital pulmonary airway malformations (CPAM) in infants and children</div><div class=\"cntnt\"><img style=\"width:764px; height:470px;\" src=\"images/PEDS/102532_Algo_management_CPAM.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CPAM: congenital pulmonary airway malformation; PPB: pleuropulmonary blastoma; CT: computerized tomography; MRI: magnetic resonance imaging.<br />* Symptoms may consist of respiratory distress, tachypnea, and/or failure to thrive.<br />&para; Either CT or MRI may be used for advanced thoracic imaging.<br />&Delta; Pleuropulmonary blastoma risk factors include family history, bilateral or multifocal cysts, and pneumothorax.<br /><span class=\"lozenge\">&loz;</span> There is no consensus among experts in this field regarding observation versus elective surgical resection for asymptomatic infants with low-risk characteristics. Experts generally agree that observation entails a measureable risk for complications of CPAM, which occasionally are catastrophic. Moreover, outcomes are worse for patients undergoing surgery after symptoms develop compared with those undergoing elective surgery. Most experts also agree that some patients can be observed if the lesion is small and the patient remains <strong>completely</strong> asymptomatic.<br />&sect; Both simple chest radiographs and CT imaging have been recommended for monitoring of patients managed with observation alone. There is no consensus on the optimal strategy for imaging.</div><div class=\"graphic_reference\">Courtesy of Christopher M Oermann, MD.</div><div id=\"graphicVersion\">Graphic 102532 Version 1.0</div></div></div>"},"102552":{"type":"graphic_table","displayName":"Nonvascular conditions that mimic vertebrobasilar insufficiency","title":"Nonvascular conditions that mimic vertebrobasilar insufficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonvascular conditions that mimic vertebrobasilar insufficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Benign positional vertigo</td> </tr> <tr> <td>Labyrinthine dysfunction (alcohol, aminoglycosides)</td> </tr> <tr> <td>Vestibular neuronitis</td> </tr> <tr> <td>Cerebellar degeneration</td> </tr> <tr> <td>CPA tumors</td> </tr> <tr> <td>Myxedema</td> </tr> <tr> <td>Electrolyte imbalance</td> </tr> <tr> <td>Hypoglycemia</td> </tr> <tr> <td>Migraine</td> </tr> <tr> <td>Seizure</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CPA: cerebellopontine angle.</div><div id=\"graphicVersion\">Graphic 102552 Version 2.0</div></div></div>"},"102555":{"type":"graphic_table","displayName":"Medications that can cause bradycardia in children","title":"Medications that can cause bradycardia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications that can cause bradycardia in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_single\">Acetylcholinesterase inhibitors (indirect-acting parasympathomimetic)</td> </tr> <tr> <td class=\"indent1\">Donepezil</td> </tr> <tr> <td class=\"indent1\">Echothiophate*</td> </tr> <tr> <td class=\"indent1\">Edrophonium</td> </tr> <tr> <td class=\"indent1\">Galantamine</td> </tr> <tr> <td class=\"indent1\">Neostigmine</td> </tr> <tr> <td class=\"indent1\">Physostigmine</td> </tr> <tr> <td class=\"indent1\">Pyridostigmine</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rivastigmine</td> </tr> <tr> <td class=\"subtitle2_single\">Analgesic, anesthetic, sedative-hypnotic</td> </tr> <tr> <td class=\"indent1\">Barbiturates (eg, phenobarbital, pentobarbital)</td> </tr> <tr> <td class=\"indent1\">Benzodiazepines (eg, lorazepam, diazepam)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Dexmedetomidine</td> </tr> <tr> <td class=\"indent1\">Local anesthetics (eg, lidocaine, mepivacaine, prilocaine)</td> </tr> <tr> <td class=\"indent1\">Opioids (morphine &#62; fentanyl)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Propofol</td> </tr> <tr> <td class=\"subtitle2_single\">Antimigraine</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ergots (eg, ergotamine)</td> </tr> <tr> <td class=\"subtitle2_single\">Cholinergic (direct-acting parasympathomimetic)</td> </tr> <tr> <td class=\"indent1\">Acetylcholine*</td> </tr> <tr> <td class=\"indent1\">Carbachol*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cevimeline*</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiovascular</td> </tr> <tr> <td class=\"indent1\">Alpha<sub>2</sub>-adrenergic agonists (eg, clonidine, guanfacine, methyldopa)</td> </tr> <tr> <td class=\"indent1\">Antiarrhythmics (eg, amiodarone, adenosine, lidocaine)</td> </tr> <tr> <td class=\"indent1\">Beta-blockers</td> </tr> <tr> <td class=\"indent1\">Calcium channel blockers (dihydropyridine &#62; nondihydropyridine)</td> </tr> <tr> <td class=\"indent1\">Digoxin</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nitrates (eg, nitroglycerin, nitroprusside)</td> </tr> <tr> <td class=\"subtitle2_single\">Corticosteroids</td> </tr> <tr> <td class=\"indent1\">Glucocorticoids (eg, methylprednisolone, prednisone)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mineralocorticoids (eg, fludrocortisone)</td> </tr> <tr> <td class=\"subtitle2_single\">Psychotropic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lithium</td> </tr> <tr> <td class=\"subtitle2_single\">Vasoactive (including topical decongestants and vasoconstrictors)*</td> </tr> <tr> <td class=\"indent1\">Alpha-adrenergic agonists (phenylephrine*, midodrine, naphazoline*, oxymetazoline*, tetrahydrozoline*)</td> </tr> <tr> <td class=\"indent1\">Octreotide</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Medications associated with bradycardia in children. Effect may be related to dose, method, and rate of administration or exposure.</div><div class=\"graphic_footnotes\">* Includes decongestant nasal sprays (imidazoline derivatives), eye drops (miotics, vasoconstrictors), and other topical vasoactive agents that may cause severe bradycardia upon oral ingestion of relatively small amounts. <br />¶ Bradycardia may be seen with rapid intravenous administration or&nbsp;overdose, or in combined use with opioid analgesics.</div><div id=\"graphicVersion\">Graphic 102555 Version 2.0</div></div></div>"},"102557":{"type":"graphic_algorithm","displayName":"Treatment of superficial thrombophlebitis","title":"Treatment of superficial thrombophlebitis","html":"<div class=\"graphic\"><div style=\"width: 718px\" class=\"figure\"><div class=\"ttl\">Treatment of superficial thrombophlebitis</div><div class=\"cntnt\"><img style=\"width:698px; height:560px;\" src=\"images/SURG/102557_Trtmnt_sprfcl_thrombophlebi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At 45 days, if the clinical issue has resolved, the anticoagulation stops.<br />There are two other scenarios: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Patient still has ongoing clinical signs and symptoms (redness, tenderness). In this case, the anticoagulation should be continued and the patient worked up for underlying etiologies of superficial thrombophlebitis, like malignant and hypercoagulable state.</LI>&#xD;&#xA;<LI>The clinical redness and tenderness is gone, but on follow-up duplex examination there is still significant thrombus. Many would recommend checking and following d-dimers at that point and also work up for malignancy and hypercoagulable state with consideration to continue the anticoagulation.</LI></OL></div><div class=\"graphic_footnotes\">GSV: great saphenous vein; SSV: small saphenous vein; DVT: deep vein thrombosis; SFJ: saphenofemoral junction; SPJ: saphenopopliteal junction.<br />* Symptomatic care consists of anti-inflammatory agents, compression therapy, and topical agents.<br />¶ Phlebitis causes pain, erythema, and palpable cord along the course of a superficial vein. The GSV is located along the medial leg and thigh. The SSV is located posteriorly in the calf from the knee to the ankle. Significant extremity swelling should raise suspicion for deep vein involvement.<br />Δ Some favor ultrasound for all patients with suspected phlebitis of a superficial vein because the correlation between the physical exam and the location of the thrombus is often poor.<br /><FONT class=lozenge>◊</FONT> For patients with thrombosis of the GSV or SSV approaching the SFJ or SPJ, respectively, following vein ablation procedures, continued conservative treatment is advocated.<br />§ In a tributary or axial vein.<br />¥ Anticoagulation may be continued (or initiated, if not already started) for ongoing symptoms or for ultrasound evidence of significant residual thrombus. Evaluation for hypercoagulability or malignancy may be indicated.<br />‡ Follow-up in 2 to 3 days for GSV or SSV and 7 to 10 days for tributary veins; sooner if symptoms progress.</div><div id=\"graphicVersion\">Graphic 102557 Version 1.0</div></div></div>"},"102574":{"type":"graphic_table","displayName":"Antibiotic regimens for neonatal sepsis","title":"Suggested antimicrobial regimens in the management of neonatal sepsis in term and late preterm infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested antimicrobial regimens in the management of neonatal sepsis in term and late preterm infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Antibiotic regimen</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Empiric therapy</td> </tr> <tr> <td class=\"indent1\">Early onset (&#60;7 days)</td> <td>Ampicillin AND gentamicin</td> </tr> <tr> <td class=\"indent1\">Late onset (&#8805;7 days): Admitted from the community</td> <td>Ampicillin AND gentamicin</td> </tr> <tr> <td class=\"indent1\">Late onset (&#8805;7 days): Hospitalized since birth</td> <td>Gentamicin AND vancomycin</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Special circumstances:</td> </tr> <tr> <td class=\"indent2\">Suspected meningitis - early onset</td> <td>Ampicillin AND gentamicin*</td> </tr> <tr> <td class=\"indent2\">Suspected meningitis -&nbsp;late onset, admitted from the community</td> <td>Ampicillin, gentamicin, AND cefotaxime<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent2\">Suspected meningitis -&nbsp;late onset, hospitalized since birth</td> <td>Gentamicin, vancomycin, AND cefotaxime<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent2\">Suspected pneumonia</td> <td> <p>Ampicillin AND gentamicin</p> Alternatives: <ul class=\"decimal_heading\"> <li>Ampicillin AND cefotaxime<sup>&#182;</sup>, OR </li> <li>Vancomycin AND cefotaxime<sup>&#182;</sup>, OR </li> <li>Vancomycin AND gentamicin </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Suspected infection of soft tissues, skin, joints, or bones (<em>S. aureus</em> is a likely pathogen)</td> <td>Vancomycin or vancomycin AND nafcillin</td> </tr> <tr> <td class=\"indent2\">Suspected intravascular catheter-related infection</td> <td>Vancomycin AND gentamicin</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Suspected infection due to organisms found in the gastrointestinal tract (eg, anaerobic bacteria)</td> <td> <p>Ampicillin, gentamicin, AND clindamycin</p> Alternatives: <ul class=\"decimal_heading\"> <li>Ampicillin, gentamicin, AND metronidazole OR </li> <li>Piperacillin-tazobactam AND gentamicin </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pathogen-specific therapy</td> </tr> <tr> <td class=\"indent1\">Group B <em>Streptococcus</em></td> <td>Penicillin G</td> </tr> <tr> <td class=\"indent1\"><em>Escherichia coli</em>: Ampicillin-sensitive</td> <td>Ampicillin</td> </tr> <tr> <td class=\"indent1\"><em>Escherichia coli</em>: Ampicillin-resistant</td> <td> <p>Cefotaxime<sup>&#182;</sup></p> Alternative: <ul class=\"decimal_heading\"> <li>Meropenem </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Multidrug-resistant gram-negative bacilli (including ESBL-producing organisms)</td> <td>Meropenem</td> </tr> <tr> <td class=\"indent1\"><em>Listeria monocytogenes</em></td> <td>Ampicillin AND gentamicin</td> </tr> <tr> <td class=\"indent1\">Methicillin-susceptible <em>S. aureus</em> (MSSA)</td> <td>Nafcillin OR cefazolin</td> </tr> <tr> <td class=\"indent1\">Methicillin-resistant <em>S. aureus</em> (MRSA)</td> <td>Vancomycin</td> </tr> <tr> <td class=\"indent1\">Coagulase-negative staphylococci</td> <td>Vancomycin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ESBL: extended-spectrum beta-lactamase.<br />* Cefotaxime should be added to the empiric regimen for suspected&nbsp;early-onset meningitis if the CSF Gram stain reveals gram-negative bacilli.<br />¶ If cefotaxime is not available, alternative agents include ceftazidime, ceftriaxone (not to be used in infants with clinically significant hyperbilirubinemia or those receiving concurrent IV calcium [including parenteral nutrition]),&nbsp;or meropenem. Meropenem is preferred if there is concern for infection due to a multidrug-resistant gram-negative organism.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Edwards MS, Baker CJ. Bacterial infections in the neonate. In: Principles and Practice of Pediatric Infectious Diseases, 4th ed, Long SS, Pickering LK, Prober CG (Eds), Elsevier Saunders, Philadelphia 2012. p.538.</li>&#xD;&#xA;    <li>Nizet V, Klein JO. Bacterial sepsis and meningitis. In: Infectious diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, et al (Eds), Elsevier Saunders, Philadelphia 2010. p.222.</li>&#xD;&#xA;    <li>American Academy of Pediatrics. Group B streptococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, 2015. p.745.</li>&#xD;&#xA;    <li>American Academy of Pediatrics. Escherichia coli and other Gram-negative bacilli (septicemia and meningitis in neonates). In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.340.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 102574 Version 5.0</div></div></div>"},"102588":{"type":"graphic_figure","displayName":"Diaphragm strength and supine position","title":"Relationship between diaphragm strength and supine position","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">Relationship between diaphragm strength and supine position</div><div class=\"cntnt\"><img style=\"width:617px; height:266px;\" src=\"images/PULM/102588_Diaphragm_strength_spn_pstn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship between percentage fall in vital capacity on adopting the supine posture and diaphragm strength (assessed by measuring transdiaphragmatic pressure during maximum sniffs). Fall in vital capacity is seldom substantial until strength is reduced to 30% of normal.</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright &copy; 2015 American Thoracic Society. Cite: Mier-Jedrzejowicz A, Brophy C, Moxham J, Green M. Assessment of diaphragm weakness. Am Rev Respir Dis 1988; 137:877. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 102588 Version 1.0</div></div></div>"},"102589":{"type":"graphic_picture","displayName":"Lumbosacral hairy patch","title":"Lumbosacral hairy patch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lumbosacral hairy patch</div><div class=\"cntnt\"><img style=\"width:320px; height:496px;\" src=\"images/PEDS/102589_Lumbosacral_hairy_patch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patch of hair overlying the lumbosacral spine, which may be associated with spinal dysraphism.</div><div class=\"graphic_reference\">Reproduced with permission from: Lovell and Winter's Pediatric Orthopaedics, 7th ed, Weinstein SL, Flynn JM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2014. Copyright &copy; 2014 Lippincott Williams &amp; Wilkins (<a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>). Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 102589 Version 1.0</div></div></div>"},"102591":{"type":"graphic_table","displayName":"Normal PImax and PEmax","title":"Reference normal range for maximal expiratory (PEmax) and inspiratory (PImax) pressure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reference normal range for maximal expiratory (PEmax) and inspiratory (PImax) pressure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Number of subjects</td> <td class=\"subtitle1\">PEmax</td> <td class=\"subtitle1\">PImax</td> <td class=\"subtitle1\">Source (reference)</td> <td class=\"subtitle1\">Mouthpiece design</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Male</td> </tr> <tr> <td class=\"indent1\">106</td> <td>23.4&#177;4.5</td> <td>12.7&#177;3.1</td> <td>1</td> <td>Tube</td> </tr> <tr> <td class=\"indent1\">60</td> <td>22.8&#177;4.1</td> <td>12.1&#177;2.1</td> <td>2</td> <td>Tube</td> </tr> <tr> <td class=\"indent1\">80</td> <td>21.2&#177;4.4</td> <td>12.4&#177;2.7</td> <td>3</td> <td>Tube</td> </tr> <tr> <td class=\"indent1\">325</td> <td>15.1&#177;8.0</td> <td>11.1&#177;3.5</td> <td>4</td> <td>Flanged</td> </tr> <tr> <td class=\"indent1\">80</td> <td>14.4&#177;3.3</td> <td>10.4&#177;3.0</td> <td>5</td> <td>Flanged</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">46</td> <td>13.7&#177;3.7</td> <td>10.3&#177;2.5</td> <td>6</td> <td>Flanged</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Female</td> </tr> <tr> <td class=\"indent1\">94</td> <td>16.1&#177;2.9</td> <td>9.6&#177;2.4</td> <td>1</td> <td>Tube</td> </tr> <tr> <td class=\"indent1\">60</td> <td>14.9&#177;2.6</td> <td>8.5&#177;1.5</td> <td>2</td> <td>Tube</td> </tr> <tr> <td class=\"indent1\">121</td> <td>13.5&#177;6.7</td> <td>8.9&#177;2.4</td> <td>3</td> <td>Tube</td> </tr> <tr> <td class=\"indent1\">480</td> <td>9.2&#177;3.2</td> <td>7.0&#177;2.6</td> <td>4</td> <td>Flanged</td> </tr> <tr> <td class=\"indent1\">87</td> <td>9.1&#177;1.6</td> <td>7.2&#177;2.1</td> <td>5</td> <td>Flanged</td> </tr> <tr> <td class=\"indent1\">60</td> <td>8.7&#177;3.2</td> <td>6.9&#177;2.3</td> <td>6</td> <td>Flanged</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Table representing normal ranges (mean &plusmn; standard deviation) in adults for maximal inspiratory and expiratory pressures in kilopascals (1 kPa = 10.19 cm H<sub>2</sub>O).</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Hughes PD, Polkey MI, Harrus ML, et al. Diaphragm strength in chronic heart failure. Am J Respir Crit Care Med 1999; 160:529.</li>&#xD;&#xA;    <li>Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307.</li>&#xD;&#xA;    <li>Ker JA, Schultz CM, Ker J. Respiratory muscle endurance in heart failure--the effect of clinical severity. S Afr Med J 1998; 88 Suppl 1:C20.</li>&#xD;&#xA;    <li>Polkey MI, Kyroussis D, Hamnegard CH, et al. Diaphragm strength in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154:1310.</li>&#xD;&#xA;    <li>Lemos A, de Souza AI, Figueiroa JN, et al. Respiratory muscle strength in pregnancy. Respir Med 2010; 104:1638.</li>&#xD;&#xA;    <li>Chetta A, Harris ML, Lyall RA, et al. Whistle mouth pressure as test of expiratory muscle strength. Eur Respir J 2001; 17:688.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reprinted with permission of the American Thoracic Society. Copyright &copy; 2015 American Thoracic Society. American Thoracic Society/European Respiratory Society. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med 2002; 166:518. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 102591 Version 1.0</div></div></div>"},"102592":{"type":"graphic_table","displayName":"Normal SNIP and PImax","title":"Normal sniff nasal inspiratory pressure (SNIP) and maximal inspiratory pressure (PImax)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal sniff nasal inspiratory pressure (SNIP) and maximal inspiratory pressure (PImax)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age groups (years)</td> <td class=\"subtitle1\">N (number of subjects)</td> <td class=\"subtitle1\">SNIP cm H<sub>2</sub>O (standard deviation)</td> <td class=\"subtitle1\">PImax (FRC) cm H<sub>2</sub>O (standard deviation)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Men</td> </tr> <tr> <td class=\"indent1\">20 to 35</td> <td>20</td> <td>117 (29.5)</td> <td>109.5 (27)</td> </tr> <tr> <td class=\"indent1\">36 to 50</td> <td>20</td> <td>105 (24.5)</td> <td>105 (20.5)</td> </tr> <tr> <td class=\"indent1\">51 to 65</td> <td>20</td> <td>111.5 (15.5)</td> <td>103.5 (21.5)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">66 to 80</td> <td>20</td> <td>91 (21.5)</td> <td>82.5 (22.5)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Women</td> </tr> <tr> <td class=\"indent1\">20 to 35</td> <td>20</td> <td>84 (14.5)</td> <td>77.5 (18)</td> </tr> <tr> <td class=\"indent1\">36 to 50</td> <td>20</td> <td>94 (21)</td> <td>86.5 (21)</td> </tr> <tr> <td class=\"indent1\">51 to 65</td> <td>20</td> <td>83.5 (18)</td> <td>79.5 (17)</td> </tr> <tr> <td class=\"indent1\">66 to 80</td> <td>20</td> <td>75.5 (11)</td> <td>58 (16)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Table representing maximum values of SNIP and PImax at functional residual capacity (FRC) in healthy adults.</div><div class=\"graphic_reference\">Data from: Uldrey C, Fitting JW. Maximal values of sniff nasal inspiratory pressure in healthy subjects. Thorax 1995; 50:371.</div><div id=\"graphicVersion\">Graphic 102592 Version 1.0</div></div></div>"},"102595":{"type":"graphic_picture","displayName":"Merkel cell carcinoma dermoscopy","title":"Clinical and dermoscopic images of Merkel cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 817px\" class=\"figure\"><div class=\"ttl\">Clinical and dermoscopic images of Merkel cell carcinoma</div><div class=\"cntnt\"><img style=\"width:797px; height:353px;\" src=\"images/DERM/102595_Merkel_cell_crcnm_drmscpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Merkel cell carcinoma presenting as a red nodule with scaling on the cheek of this patient. Note the background sun-damaged skin.<br />(B) Dermoscopy shows a polymorphous vascular pattern composed of linear vessels over a pink background. White scales are also present.</div><div id=\"graphicVersion\">Graphic 102595 Version 1.0</div></div></div>"},"102596":{"type":"graphic_table","displayName":"Specific issues in screening for transwomen and transmen","title":"Specific issues in screening for transwomen and transmen with past or current hormone use","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Specific issues in screening for transwomen and transmen with past or current hormone use</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Transwomen (MTF)</td> <td class=\"subtitle1\">Transmen (FTM)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Breast cancer</strong></td> <td class=\"divider_bottom\" rowspan=\"2\">Discuss screening in patients &#62;50 years with additional risk factors for breast cancer*</td> <td>Intact breasts: Routine screening as for natal females</td> </tr> <tr class=\"divider_bottom\"> <td>Postmastectomy: Yearly chest wall and axillary exams<sup>&#182;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Cervical cancer</strong></td> <td class=\"divider_bottom\" rowspan=\"2\">Vaginoplasty: No screening</td> <td>Cervix intact: Routine screening as for natal females</td> </tr> <tr class=\"divider_bottom\"> <td>No cervix: No screening</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Prostate cancer</strong></td> <td>Routine screening as for natal males</td> <td>N/A</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Cardiovascular disease</strong></td> <td>Screen for risk factors</td> <td>Screen for risk factors</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Diabetes mellitus</strong></td> <td>On estrogen: Increased risk</td> <td>Routine screening<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hyperlipidemia</strong></td> <td>On estrogen: Annual lipid screening</td> <td>On testosterone: Annual lipid screening</td> </tr> <tr> <td rowspan=\"2\"><strong>Osteoporosis</strong></td> <td>Testes intact: Routine screening as for natal males</td> <td rowspan=\"2\"> <p>Screen all patients &#62;65 years</p> Screen patients age 50 to 65 if off hormones for &#62;5 years</td> </tr> <tr> <td> <p>Postorchiectomy: Screen all patients &#62;65 years</p> Screen patients age 50 to 65 years if off hormones for &#62;5 years</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Estrogen/progestin therapy for &gt;5 years, family history, body mass index (BMI)&nbsp;&gt;35.<br />¶ While there is no evidence to support clinical breast examinations in this population, we perform yearly chest wall and axillary exams and use this as an opportunity to examine scar tissue, examine any changes, and educate the patient about the small but possible risk of breast cancer.<br />Δ Transmen with polycystic ovary syndrome (PCOS) should be screened for diabetes as for natal females with PCOS. Refer to the UpToDate material on further evaluation after diagnosis of PCOS in adults.</div><div id=\"graphicVersion\">Graphic 102596 Version 2.0</div></div></div>"},"102597":{"type":"graphic_figure","displayName":"Pressure-flow loops","title":"Pressure-flow dissociation under inspiratory flow limitation conditions","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Pressure-flow dissociation under inspiratory&nbsp;flow limitation conditions</div><div class=\"cntnt\"><img style=\"width:506px; height:386px;\" src=\"images/SLEEP/102597_Pressure_flow_loops.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure-flow loops depicting two breaths under inspiratory flow limitation (IFL) and non-flow limitation (NIFL). Note the pressure-flow dissociation under IFL conditions, with flow reaching a plateau despite increasing driving pressure.</div><div id=\"graphicVersion\">Graphic 102597 Version 1.0</div></div></div>"},"102598":{"type":"graphic_picture","displayName":"Giant platelet on peripheral blood smear","title":"Giant platelet on a peripheral blood smear","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Giant platelet on a peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:444px; height:375px;\" src=\"images/PEDS/102598_Gnt_pltlt_periph_bld_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear from a child showing giant platelet (arrow).</div><div id=\"graphicVersion\">Graphic 102598 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"102601":{"type":"graphic_algorithm","displayName":"Latent TB screening SOT","title":"Screening solid organ transplant candidates for latent tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 896px\" class=\"figure\"><div class=\"ttl\">Screening solid organ transplant candidates for latent tuberculosis</div><div class=\"cntnt\"><img style=\"width:876px; height:516px;\" src=\"images/ID/102601_Latent_TB_screening_SOT.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BCG: Bacille Calmette-Gu&eacute;rin; TST: tuberculin skin test; IGRA: interferon-gamma release assay; LTBI: latent tuberculosis infection; TB: tuberculosis.<br />* Either test is acceptable, depending on availability and cost.<br />&para; For those with two indeterminate IGRAs, the decision regarding the need for treatment of latent TB will need to be made on a case-by-case basis according to the individual's risk-benefit ratio, with consideration of signs of prior infection (eg, granulomas on chest imaging), prior contact with people with known disease, other history of probable exposure, and risk of drug toxicities.<br />&Delta; Factors that make an individual at high risk for TB exposure include but are not limited to:<br /><ul>&#xD;&#xA;    <li>​A previous positive TST without history of BCG vaccine after infancy.</li>&#xD;&#xA;    <li>Close contact with a person with active tuberculosis.</li>&#xD;&#xA;    <li>Radiographic changes consistent with prior granulomatous disease in a person from a country with a high prevalence of TB.</li>&#xD;&#xA;</ul></div><div id=\"graphicVersion\">Graphic 102601 Version 1.0</div></div></div>"},"102602":{"type":"graphic_table","displayName":"Diseases familial PPB","title":"Diseases associated with familial pleuropulmonary blastoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diseases associated with familial pleuropulmonary blastoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Lungs</strong></td> <td>Pleuropulmonary blastoma (PPB)</td> </tr> <tr class=\"divider_bottom\"> <td>Lung cysts</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Urinary tract</strong></td> <td>Cystic nephroma</td> </tr> <tr> <td>Renal cysts</td> </tr> <tr> <td>Wilms tumor</td> </tr> <tr class=\"divider_bottom\"> <td>Bladder cancer (rhabdomyosarcoma, transition-cell carcinoma, papilloma)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Intestine</strong></td> <td>Polyps</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Thyroid</strong></td> <td>Nodular hyperplasias</td> </tr> <tr class=\"divider_bottom\"> <td>Follicular and papillary carcinomas</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Blood</strong></td> <td>Leukemia/lymphoma</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Gonadal tumors</strong></td> <td>Stromal sex cord tumors (Sertoli Leydig)</td> </tr> <tr class=\"divider_bottom\"> <td>Germ cell tumors (seminoma, dysgerminoma)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Brain tumors</strong></td> <td>Medulloblastoma</td> </tr> <tr> <td>Glioblastoma multiforme</td> </tr> <tr> <td>Ependymoma</td> </tr> <tr class=\"divider_bottom\"> <td>Sarcoma</td> </tr> <tr> <td rowspan=\"7\"><strong>Other</strong></td> <td>Nasal chondromesenchymal hamartoma</td> </tr> <tr> <td>Hepatic cystic mesenchymal hamartoma</td> </tr> <tr> <td>Synovial sarcoma</td> </tr> <tr> <td>Globe melanosarcoma or medulloepithelioma</td> </tr> <tr> <td>Neuroblastoma</td> </tr> <tr> <td>Anaplastic carcinoma of the pharynx</td> </tr> <tr> <td>Neurofibromatosis type 1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These diseases were associated with pleuropulmonary blastoma (PPB) in the index case or family members, as reported from the International Pleuropulmonary Blastoma Registry.</div><div class=\"graphic_reference\">Data from: Priest JR, Williams GM, Hill DA, et al. Pulmonary cysts in early childhood and the risk of malignancy. Pediatr Pulmonol 2009; 44:14.</div><div id=\"graphicVersion\">Graphic 102602 Version 1.0</div></div></div>"},"102603":{"type":"graphic_figure","displayName":"Creatine synthesis and metabolism","title":"Creatine synthesis and metabolism","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Creatine synthesis and metabolism</div><div class=\"cntnt\"><img style=\"width:644px; height:461px;\" src=\"images/ALLRG/102603_Creatn_synthesis_metabolism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>The formation of GAA is the rate-limiting reaction facilitated by inhibition of AGAT activity via negative feedback through creatine and competitive inhibition through ornithine.</li>&#xD;&#xA;    <li>The major proportion of creatine is taken up from the blood via the creatine transporter.</li>&#xD;&#xA;    <li>The brain is capable of producing minor amounts of creatine.</li>&#xD;&#xA;    <li>Intracellular creatine is reversibly converted into creatine-phosphate through the action of creatine kinase.</li>&#xD;&#xA;    <li>Creatine/creatine phosphate (CK) and ADP/ATP together with CK represent a high-energy phosphate shuttle exiting mainly in brain and muscle.</li>&#xD;&#xA;    <li>Creatinine results from the nonenzymatic conversion of creatine and is excreted in the urine with a constant daily turnover of 1.5% of body creatine.</li>&#xD;&#xA;    <li>An individual's daily creatinine excretion is directly proportional to total body creatine and in particular to muscle mass (ie, 20 to 25 mg/kg/24 hours in children and adults).</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">AGAT: arginine:glycine amidinotransferase; GAMT: guanidinoacetate methyltransferase; CRTR: creatine transporter; ATP: adenosine triophosphate; CK: creatine kinase; ADP: adenosine diphosphate.</div><div class=\"graphic_reference\">Reproduced from: Dunbar M, Jaggumantri S, Sargent M, et al. Treatment of X-linked creatine transporter (SLC6A8) deficiency: Systematic review of the literature and three new cases. Mol Genet Metab 2014; 112:259. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 102603 Version 1.0</div></div></div>"},"102604":{"type":"graphic_table","displayName":"Congenital disorders of creatine metabolism","title":"Congenital disorders of creatine metabolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Congenital disorders of creatine metabolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Deficiency</td> <td class=\"subtitle1\">AGAT</td> <td class=\"subtitle1\">GAMT</td> <td class=\"subtitle1\">CT</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Clinical Features</td> </tr> <tr> <td class=\"indent1\">Developmental delay/intellectual disability</td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Speech delay</td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Autism</td> <td>+/&ndash;</td> <td>+</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Epilepsy</td> <td>+/&ndash;</td> <td>+</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Movement disorder</td> <td>&nbsp;</td> <td>+</td> <td>+/&ndash;</td> </tr> <tr> <td class=\"indent1\">Basal ganglia changes</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Myopathy</td> <td>+</td> <td>&nbsp;</td> <td>+</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Behavioral problems</td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Biochemical features</td> </tr> <tr> <td class=\"indent1\">Brain creatine deficiency</td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Guanidinoacetate (U, P, CSF*)</td> <td>Low to low normal</td> <td>High</td> <td>Normal</td> </tr> <tr> <td class=\"indent1\">Creatine</td> <td>Low (U), normal (CSF)</td> <td>Low (U, P, CSF)</td> <td> <p>Males: High normal to high (U, P), normal (CSF)</p> Females: Normal to mildly elevated (U)</td> </tr> <tr> <td class=\"indent1\">Creatinine</td> <td>Low (U), low to normal (P)</td> <td>Low to normal (U,P)</td> <td> <p>Males: Low (U, CSF), low to normal (P)</p> Females: Low to normal (P)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Creatine/creatinine ratio (U)</td> <td>Normal</td> <td>Normal</td> <td> <p>Males: High</p> Females: Normal to mildly elevated</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Treatment</td> </tr> <tr> <td class=\"indent1\">Creatine supplementation</td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Ornithine supplementation</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Arginine restricted diet</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Arginine supplementation</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Glycine-supplementation</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Other </td> <td>&nbsp;</td> <td>Sodium-benzoate</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AGAT: arginine:glycine amidinotransferase; GAMT: guanidinoacetate methyltransferase; CT: creatine transporter; U: urine; P: plasma; CSF: cerebrospinal fluid.<br />* CSF level of guanidinoacetate known for GAMT deficiency only.</div><div class=\"graphic_reference\">Adapted from: Stockler-Ipsiroglu S, van Karnebeek CDM. Cerebral creatine deficiencies: A group of treatable intellectual developmental disorders. Semin Neurol 2014; 34:350.</div><div id=\"graphicVersion\">Graphic 102604 Version 1.0</div></div></div>"},"102607":{"type":"graphic_algorithm","displayName":"Approach to gram-negative organisms","title":"Classification of gram-negative organisms by laboratory features","html":"<div class=\"graphic\"><div style=\"width: 972px\" class=\"figure\"><div class=\"ttl\">Classification of gram-negative organisms by laboratory features</div><div class=\"cntnt\"><img style=\"width:952px; height:254px;\" src=\"images/ID/102607_Appr_gram_negative_organism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Other gram-negative organisms that occasionally appear in clinical specimens are described in the text. Examples of Gram stains may be found in the text.</div><div id=\"graphicVersion\">Graphic 102607 Version 2.0</div></div></div>"},"102608":{"type":"graphic_algorithm","displayName":"Approach to gram-positive cocci","title":"Classification of gram-positive cocci by laboratory features","html":"<div class=\"graphic\"><div style=\"width: 1146px\" class=\"figure\"><div class=\"ttl\">Classification of gram-positive cocci by laboratory features</div><div class=\"cntnt\"><img style=\"width:1126px; height:300px;\" src=\"images/ID/102608_Apprch_gram-positive_cocci.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Other gram-positive organisms that occasionally appear in clinical specimens are described in the text. Examples of Gram stains may be found in the text.</div><div id=\"graphicVersion\">Graphic 102608 Version 3.0</div></div></div>"},"102609":{"type":"graphic_table","displayName":"Ocular toxo vs retinoblastoma","title":"Distinguishing between ocular toxocariasis and retinoblastoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing between ocular toxocariasis and retinoblastoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Parameter</td> <td class=\"subtitle1\" colspan=\"2\">Description</td> </tr> <tr> <td class=\"subtitle2\">Ocular toxocariasis</td> <td class=\"subtitle2\">Retinoblastoma</td> </tr> <tr> <td>Morphology</td> <td>Centrally located mass with moderate enhancement revealed by MRI</td> <td>Nodular in contour and lies along the posterior pole of the globe</td> </tr> <tr> <td>Enhancement</td> <td>Moderate uveoscleral enhancement or enhancement of a granuloma</td> <td>Usually characterized by moderate or avid enhancement</td> </tr> <tr> <td>Calcification</td> <td>Rare</td> <td>Punctate or speckled calcification in more than 90 percent of cases</td> </tr> <tr> <td>Demographics</td> <td>Patients usually 5 to 10 years of age</td> <td>Observed before 5 years of age in more than 90 percent of cases, average age at diagnosis is approximately 18 months</td> </tr> <tr> <td>Signs and complications</td> <td>Usually presents with unilateral visual loss, and pain and redness are common presenting symptoms</td> <td>Leukocoria in more than half of cases; strabismus is the second most common presentation, occurring in approximately 20 percent of cases</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">From: Fan CK, Holland CV, Loxton K, Barghouth U. Cerebral toxocariasis: Silent progression to neurodegenerative disorders? Clin Microbiol Rev 2015; 28(3):663-86. DOI: 10.1128/CMR.00106-14. Reproduced with permission from American Society for Microbiology. Copyright &copy; 2015.</div><div id=\"graphicVersion\">Graphic 102609 Version 2.0</div></div></div>"},"102612":{"type":"graphic_table","displayName":"BRCA testing SGO criteria","title":"Society of Gynecology Oncology criteria for <em>BRCA</em> mutation testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Society of Gynecology Oncology criteria for <em>BRCA</em> mutation testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Patients with an increased likelihood of having an inherited predisposition to breast* and ​​​​​ovarian/tubal/peritoneal cancer who should receive genetic counseling and be offered genetic testing:</td> </tr> <tr> <td class=\"subtitle1_single\">Women <strong>affected</strong> with:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>High-grade epithelial ovarian/tubal/peritoneal cancer </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Breast cancer &#8804;45 years </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Breast cancer with close relative<sup>&#182;</sup> with breast cancer &#8804;50 years or close relative<sup>&#182;</sup> with epithelial ovarian/tubal/peritoneal cancer at any age </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Breast cancer &#8804;50 years with a limited family history<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Breast cancer with &#8805;2 close relatives<sup>&#182;</sup> with breast cancer at any age </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Breast cancer with &#8805;2 close relatives<sup>&#182;</sup> with pancreatic cancer, aggressive prostate cancer (Gleason score &#8805;7) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Two breast primaries, with the first diagnosed prior to age 50 </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Triple negative breast cancer &#8804;60 years </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>With breast cancer and Ashkenazi Jewish ancestry </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Pancreatic cancer with &#8805;2 close relatives<sup>&#182;</sup> with breast, ovarian/tubal/peritoneal, pancreatic, or aggressive prostate cancer (Gleason score &#8805;7) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Women <strong>unaffected</strong> with cancer, but with:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>A first degree or several close relatives that meet one of the above criteria </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>A close relative<sup>&#182;</sup> carrying a known <em>BRCA1</em> or <em>BRCA2</em> mutation </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>A close relative with male breast cancer </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Patients with an increased likelihood of having an inherited predisposition to breast* and ovarian/tubal/peritoneal cancer who should receive genetic counseling and be offered genetic testing.</div><div class=\"graphic_footnotes\">* Invasive and ductal carcinoma in situ breast cancers.<br />&para; Close relative is defined as a first degree (parent, sibling, offspring), second degree (grandparent, grandchild, uncle, aunt, nephew, niece, half-sibling) or third degree (first cousin, great-grandparent or great-grandchild) relative.<br />&Delta; Limited family history includes fewer than 2 first- or second-degree female relatives of female relatives surviving beyond 45 years.</div><div class=\"graphic_reference\">Reproduced from: Lancaster JM, Powell CB, Chen LM, et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2015; 136:3. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 102612 Version 2.0</div></div></div>"},"102613":{"type":"graphic_table","displayName":"Cutaneous T and B pseudolymphomas","title":"Cutaneous T and B cell pseudolymphomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cutaneous T and B cell pseudolymphomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cutaneous pseudo-T-cell lymphomas</td> </tr> <tr> <td class=\"indent1\">Actinic reticuloid</td> </tr> <tr> <td class=\"indent1\">Lymphomatoid contact dermatitis</td> </tr> <tr> <td class=\"indent1\">Lymphomatoid drug reactions</td> </tr> <tr> <td class=\"indent1\">Idiopathic cutaneous pseudo-T-cell lymphoma</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Superficial type</li> <li>Nodular/diffuse type</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Persistent arthropod bite reactions</td> </tr> <tr> <td class=\"indent1\">Nodular scabies</td> </tr> <tr> <td class=\"indent1\">CD8<sup>+</sup> pseudolymphoma in human immunodeficiency virus (HIV) and other immunodeficiencies</td> </tr> <tr> <td class=\"subtitle1_single\">Cutaneous pseudo-B-cell lymphoma (lymphocytoma cutis)</td> </tr> <tr> <td class=\"indent1\">Idiopathic lymphocytoma cutis</td> </tr> <tr> <td class=\"indent1\">Borrelia lymphocytoma</td> </tr> <tr> <td class=\"indent1\">Lymphocytoma cutis in tattoos</td> </tr> <tr> <td class=\"indent1\">Lymphocytoma cutis after vaccination of acupuncture</td> </tr> <tr> <td class=\"indent1\">Lymphomatoid drug eruption (rare cases)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 102613 Version 1.0</div></div></div>"},"102614":{"type":"graphic_table","displayName":"Modified seasonal pattern assessment questionnaire","title":"Modified seasonal pattern assessment questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified seasonal pattern assessment questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"5\" width=\"10%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Name:</strong></td> <td colspan=\"2\"><strong>Age:</strong></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Date of birth:</strong><br /> (dd/mm/yyyy)</td> <td colspan=\"2\"> <p><strong>Sex:</strong></p> <p class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Male</p> <p class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Female</p> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"6\"><strong>Date form completed:</strong><br /> (dd/mm/yyyy)<br /> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text sublist1\" colspan=\"6\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">1. To what degree do each of the following change <em>with the seasons</em>? (Mark one square only per question.)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\">&nbsp;</td> <td class=\"subtitle2_left\"> <p>0</p> No change</td> <td class=\"subtitle2_left\"> <p>1</p> Slight change</td> <td class=\"subtitle2_left\"> <p>2</p> Moderate change</td> <td class=\"subtitle2_left\"> <p>3</p> Marked change</td> <td class=\"subtitle2_left\"> <p>4</p> Extremely marked change</td> </tr> <tr> <td class=\"indent2\">A. Sleep length</td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent2\">B. Social activity (including family, friends, and coworkers)</td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent2\">C. Mood (overall feeling of well being)</td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent2\">D. Weight</td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent2\">E. Appetite</td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">F. Energy level</td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\">&nbsp;</td> <td colspan=\"5\"><strong>Total score:</strong>__________</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">2. If you experience changes with the seasons, do you feel that these are a problem for you?</td> </tr> <tr> <td colspan=\"6\"> <p class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span>No</p> <p class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span>Yes</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">If yes, is the problem...</td> <td>Mild<br /> <span class=\"primarybox_left\">&nbsp;</span></td> <td>Moderate<br /> <span class=\"primarybox_left\">&nbsp;</span></td> <td>Marked<br /> <span class=\"primarybox_left\">&nbsp;</span></td> <td>Severe<br /> <span class=\"primarybox_left\">&nbsp;</span></td> <td>Disabling<br /> <span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">3. Do you typically feel worst in Winter?</td> </tr> <tr> <td colspan=\"6\"> <p class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span>No</p> <p class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span>Yes</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A positive screen requires each of the following:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Global seasonality score &ge;11</li>&#xD;&#xA;    <li>Seasonal changes are a problem to at least a moderate degree in mood and behavior (eg, sleep, social activity, and weight)</li>&#xD;&#xA;    <li>Patient feels worst in winter</li>&#xD;&#xA;</ol>&#xD;&#xA;Patients who screen positive for seasonal affective disorder should be interviewed to establish the diagnosis.</div><div class=\"graphic_reference\">Modified from: Rosenthal NE, Bradt GH, Wehr TA. Seasonal pattern assessment questionnaire. Bethesda, MD, National Institute of Mental Health, 1984.</div><div id=\"graphicVersion\">Graphic 102614 Version 2.0</div></div></div>"},"102651":{"type":"graphic_picture","displayName":"Sphincterotomy using electrocautery PI","title":"Sphincterotomy: Papilla widened by application of electrocautery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sphincterotomy: Papilla widened by application of electrocautery</div><div class=\"cntnt\"><img style=\"width:410px; height:428px;\" src=\"images/GAST/102651_Sphnctrtmy_elctrctry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A cut has been made in the papilla using an electrical current (electrocautery). This is done using a special cannula that includes a wire through which the electrical current is applied.</div><div id=\"graphicVersion\">Graphic 102651 Version 1.0</div></div></div>"},"102660":{"type":"graphic_picture","displayName":"Gallstone extraction from CBD PI","title":"Gallstone extraction from the common bile duct","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gallstone extraction from the common bile duct</div><div class=\"cntnt\"><img style=\"width:428px; height:441px;\" src=\"images/GAST/102660_Gallstone_extraction_CBD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After making a cut in the papilla to widen it, a gallstone is removed from the common bile duct using a metal basket.</div><div id=\"graphicVersion\">Graphic 102660 Version 1.0</div></div></div>"},"102665":{"type":"graphic_table","displayName":"Reducing postoperative pulmonary complications","title":"Strategies to reduce postoperative pulmonary complications in patients at increased risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strategies to reduce postoperative pulmonary complications in patients at increased risk</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Preoperative strategies</td> </tr> <tr> <td class=\"indent1\">Smoking cessation: preferably more than eight weeks prior to surgery (however, briefer periods of cessation are not harmful)</td> </tr> <tr> <td class=\"indent1\">For patients with COPD or asthma, optimize control with inhaled bronchodilators and possibly inhaled glucocorticoids, and possibly systemic glucocorticoids as per guidelines in the nonoperative setting</td> </tr> <tr> <td class=\"indent1\">For patients with a flare of COPD or asthma, administer systemic glucocorticoids (eg, prednisone 40 mg/day for five days) and delay elective surgery until COPD/asthma is under good control and has returned to baseline</td> </tr> <tr> <td class=\"indent1\">Reserve preoperative antibiotics for patients with symptoms and signs of lower respiratory infection*</td> </tr> <tr> <td class=\"indent1\">Delay elective surgery in patients with COPD or asthma, if respiratory infection present</td> </tr> <tr> <td class=\"indent1\">Provide preoperative education regarding lung expansion maneuvers</td> </tr> <tr> <td class=\"indent1\">Initiate chest physical therapy (eg, aerobic exercises, breathing exercises, inspiratory muscle training)</td> </tr> <tr> <td class=\"subtitle1_single\">Intraoperative strategies</td> </tr> <tr> <td class=\"indent1\">Choose shorter procedure (less than three hours) when possible</td> </tr> <tr> <td class=\"indent1\">Choose less invasive procedure when possible (eg, laparoscopic), as long as operative time not prolonged</td> </tr> <tr> <td class=\"indent1\">Consider neuraxial anesthesia rather than general anesthesia</td> </tr> <tr> <td class=\"indent1\">Regional anesthesia (nerve block) when this is an option</td> </tr> <tr> <td class=\"indent1\">For patients with COPD or asthma, administer inhaled short-acting beta-adrenergic (eg, albuterol) 2 to 4 puffs within 30 minutes before intubation</td> </tr> <tr> <td class=\"indent1\">Avoid long-acting neuromuscular blocking agents for induction or during procedure</td> </tr> <tr> <td class=\"indent1\">Avoid pulmonary artery catheterization, unless clearly indicated for procedure (eg, patient with congenital heart disease and pulmonary hypertension)</td> </tr> <tr> <td class=\"subtitle1_single\">Postoperative strategies</td> </tr> <tr> <td class=\"indent1\">Initiate deep breathing exercises or incentive spirometry in high risk patients</td> </tr> <tr> <td class=\"indent1\">Use epidural analgesia in place of parenteral opioids, as appropriate</td> </tr> <tr> <td class=\"indent1\">For patients with asthma and AERD, avoid using NSAIDS for pain control (eg, ketorolac, ibuprofen)</td> </tr> <tr> <td class=\"indent1\">CPAP (eg, 10 cm H<sub>2</sub>O via nasal or face mask for four to six hours) may reduce the incidence of hypoxemia, pneumonia, reintubation, and ICU admission in high risk patients</td> </tr> <tr> <td class=\"indent1\">Avoiding use of nasogastric tubes after abdominal surgery (unless needed for symptom control) may reduce pulmonary complications</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; AERD: aspirin exacerbated respiratory disease; NSAIDS: nonsteroidal anti-inflammatory drugs; CPAP: continuous positive airway pressure; ICU: intensive care unit.<br />* Does not refer to perioperative antibiotic prophylaxis for wound infection.</div><div id=\"graphicVersion\">Graphic 102665 Version 1.0</div></div></div>"},"102674":{"type":"graphic_picture","displayName":"Radiofrequency treatment for GERD","title":"Radiofrequency treatment for gastroesophageal reflux disease","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">Radiofrequency treatment for gastroesophageal reflux disease</div><div class=\"cntnt\"><img style=\"width:617px; height:505px;\" src=\"images/GAST/102674_Rdfrqncy_trtmnt_GERD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance of the EGJ and cardia immediately before and immediately after radiofrequency treatment in a patient with gastroesophageal reflux disease. Tightening of the EGJ is noted after treatment.</div><div class=\"graphic_footnotes\">EGJ: esophagogastric junction.</div><div id=\"graphicVersion\">Graphic 102674 Version 1.0</div></div></div>"},"102676":{"type":"graphic_table","displayName":"Survival of trauma patients following emergency thoracotomy","title":"Analysis of trauma patient survival following emergency department thoracotomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Analysis of trauma patient survival following emergency department thoracotomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"55%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Number of studies</td> <td class=\"subtitle1\">Hospital survival</td> <td class=\"subtitle1\">% (95% CI)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Injury mechanism</td> </tr> <tr> <td class=\"indent1\">Penetrating injury</td> <td class=\"centered\">64</td> <td class=\"centered\">674/6390</td> <td class=\"centered\">10.6 (9.8-11.3)</td> </tr> <tr> <td class=\"indent2\">Percentage of surviving penetrating trauma patients neurologically intact post-EDT</td> <td class=\"centered\">35</td> <td class=\"centered\">282/312</td> <td class=\"centered\">90.4 (86.7-93.3)</td> </tr> <tr> <td class=\"indent2\">Gun shot wounds</td> <td class=\"centered\">44</td> <td class=\"centered\">213/2966</td> <td class=\"centered\">7.2 (6.3-8.2)</td> </tr> <tr> <td class=\"indent2\">Stab wounds</td> <td class=\"centered\">44</td> <td class=\"centered\">302/1907</td> <td class=\"centered\">15.8 (14.3-17.5)</td> </tr> <tr> <td class=\"indent1\">Blunt injury</td> <td class=\"centered\">42</td> <td class=\"centered\">50/2172</td> <td class=\"centered\">2.3 (1.7-3.0)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Percentage of surviving blunt&nbsp;trauma patients neurologically&nbsp;intact post-EDT</td> <td class=\"centered\">8</td> <td class=\"centered\">19/32</td> <td class=\"centered\">59.4 (41.9-75.2)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Primary injury location</td> </tr> <tr> <td class=\"indent1\">Cardiac</td> <td class=\"centered\">24</td> <td class=\"centered\">250/1449</td> <td class=\"centered\">17.3 (15.4-19.3)</td> </tr> <tr> <td class=\"indent1\">Thoracic</td> <td class=\"centered\">27</td> <td class=\"centered\">222/2117</td> <td class=\"centered\">10.5 (9.2-11.9)</td> </tr> <tr> <td class=\"indent1\">Abdominal</td> <td class=\"centered\">22</td> <td class=\"centered\">60/856</td> <td class=\"centered\">7.0 (5.4-8.9)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Neck or extremity</td> <td class=\"centered\">8</td> <td class=\"centered\">9/128</td> <td class=\"centered\">7.0 (3.5-12.5)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Physiologic predictors</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Prehospital CPR</td> </tr> <tr> <td class=\"indent2\">Yes</td> <td class=\"centered\">9</td> <td class=\"centered\">22/425</td> <td class=\"centered\">5.2 (3.4-7.6)</td> </tr> <tr> <td class=\"indent2\">No</td> <td class=\"centered\">8</td> <td class=\"centered\">41/301</td> <td class=\"centered\">13.6 (10.1-17.9)</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">ED signs of life</td> </tr> <tr> <td class=\"indent2\">Yes</td> <td class=\"centered\">35</td> <td class=\"centered\">290/1523</td> <td class=\"centered\">19.0 (17.1-21.1)</td> </tr> <tr> <td class=\"indent2\">No</td> <td class=\"centered\">33</td> <td class=\"centered\">62/2166</td> <td class=\"centered\">2.9 (2.2-3.6)</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">ED cardiac rhythm</td> </tr> <tr> <td class=\"indent2\">Asystole</td> <td class=\"centered\">8</td> <td class=\"centered\">10/382</td> <td class=\"centered\">2.6 (1.4-4.6)</td> </tr> <tr> <td class=\"indent2\">Pulseless electrical activity</td> <td class=\"centered\">3</td> <td class=\"centered\">17/152</td> <td class=\"centered\">11.2 (6.9-17.0)</td> </tr> <tr> <td class=\"indent2\">Sinus</td> <td class=\"centered\">3</td> <td class=\"centered\">21/63</td> <td class=\"centered\">33.3 (22.6-45.6)</td> </tr> <tr> <td class=\"indent2\">Other</td> <td class=\"centered\">5</td> <td class=\"centered\">4/83</td> <td class=\"centered\">4.8 (1.6-11.2)</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">ED vital signs</td> </tr> <tr> <td class=\"indent2\">Yes</td> <td class=\"centered\">25</td> <td class=\"centered\">241/1382</td> <td class=\"centered\">17.4 (15.5-19.5)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">No</td> <td class=\"centered\">35</td> <td class=\"centered\">135/3516</td> <td class=\"centered\">3.8 (3.2-4.5)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Overall</td> </tr> <tr> <td class=\"indent1\">EDT hospital survival</td> <td class=\"centered\">71</td> <td class=\"centered\">871/10,238</td> <td class=\"centered\">8.5 (8.0-9.1)</td> </tr> <tr> <td class=\"indent1\">EDT neuro intact hospital survival</td> <td class=\"centered\">47</td> <td class=\"centered\">408/6746</td> <td class=\"centered\">6.1 (5.5-6.6)</td> </tr> <tr> <td class=\"indent1\">Percentage&nbsp;EDT survivors neurologically intact</td> <td class=\"centered\">45</td> <td class=\"centered\">466/544</td> <td class=\"centered\">85.7 (82.5-88.4)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">All described predictors of EDT were&nbsp;analyzed individually across all studies.</div><div class=\"graphic_footnotes\">CPR: Cardiopulmonary resuscitation; ED: Emergency department; EDT: Emergency department thoracotomy</div><div class=\"graphic_reference\">From: Seamon MJ, Haut ER, Van Arendonk K, et al. An evidence-based approach to patient selection for emergency department thoracotomy: A practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg 2015; 79:159. DOI: <a href=\"http://journals.lww.com/jtrauma/Fulltext/2015/07000/An_evidence_based_approach_to_patient_selection.24.aspx\" target=\"_blank\">10.1097/TA.0000000000000648</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015 American Association for the Surgery of Trauma. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 102676 Version 1.0</div></div></div>"},"102679":{"type":"graphic_algorithm","displayName":"Adolescent idiopathic scoliosis diagnostic algorithm","title":"Suggested approach to the evaluation and diagnosis of adolescent idiopathic scoliosis (AIS)","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Suggested approach to the evaluation and diagnosis of adolescent idiopathic scoliosis (AIS)</div><div class=\"cntnt\"><img style=\"width:555px; height:841px;\" src=\"images/PEDS/102679_AdlsidpthcsclsDXalged1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BMI: body mass index.<br />* Scoliometer readings in children with BMI ≥85<SUP>th</SUP> percentile for age and sex are typically lower than in children with BMI &lt;85<SUP>th</SUP> percentile for age and sex.<br />¶ Standing, full-length (C7 to the sacrum and iliac crest), posteroanterior (PA), and lateral views of the spine.<br />Δ Neurologic findings include (but are not limited to) headache, neck pain, intrinsic wasting of the hands, absent abdominal reflex, asymmetric lower extremity atrophy, pes cavus, and midline skin lesions.<br /><FONT class=lozenge>◊</FONT> Radiographic findings of congenital scoliosis or intraspinal pathology include (but are not limited to) wedged vertebrae, hemivertebrae, vertebral body lucency, erosion of the pedicles, and increased kyphosis. Refer to UpToDate topic on clinical features and diagnosis of adolescent idiopathic scoliosis for details.<br />§ Other indications for MRI of the spine include left-sided thoracic curve, male sex, and increase in Cobb angle of ≥10° per year, but these indications are controversial.</div><div id=\"graphicVersion\">Graphic 102679 Version 6.0</div></div></div>"},"102680":{"type":"graphic_diagnosticimage","displayName":"Wedge vertebrae","title":"Wedge vertebrae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wedge vertebrae</div><div class=\"cntnt\"><img style=\"width:307px; height:617px;\" src=\"images/PEDS/102680_Wedge_vertebrae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wedge vertebrae (arrows) in patient with congenital scoliosis. Congenital scoliosis often is associated with anomalies in other organ systems, as indicated by the tracheostomy and feeding tubes.</div><div class=\"graphic_reference\">Courtesy of Susan A Scherl, MD.</div><div id=\"graphicVersion\">Graphic 102680 Version 1.0</div></div></div>"},"102681":{"type":"graphic_diagnosticimage","displayName":"Hemivertebra","title":"Hemivertebra","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemivertebra</div><div class=\"cntnt\"><img style=\"width:264px; height:364px;\" src=\"images/PEDS/102681_Hemivertebra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemivertebra (arrow) in patient with congenital scoliosis.</div><div class=\"graphic_reference\">Courtesy of Susan A Scherl, MD.</div><div id=\"graphicVersion\">Graphic 102681 Version 1.0</div></div></div>"},"102688":{"type":"graphic_figure","displayName":"Products for treating bleeding in the setting of liver disease","title":"Products for treating bleeding in the setting of liver disease","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Products for treating bleeding in the setting of liver disease</div><div class=\"cntnt\"><img style=\"width:609px; height:614px;\" src=\"images/HEME/102688_Prdct_trt_bld_st_dss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vitamin K is a cofactor in the post-translational modification of coagulation factors in the liver. FFP and PCC provide coagulation factors (refer to UpToDate content for specific constituents in PCC). rFVIIa is a procoagulant. Cryoprecipitate provides fibrinogen. DDAVP can stimulate release of von Willebrand factor to counteract platelet dysfunction. Antifibrinolytics promote clot stability. Refer to UpToDate topics on hemostatic abnormalities in patients with liver disease for further details and indications for these interventions.</div><div class=\"graphic_footnotes\">FFP: Fresh Frozen Plasma; PCC: prothrombin complex concentrate; rFVIIa: recombinant activated factor VII; TF: tissue factor; FXa: activated factor X; DDVAP: desmopressin.</div><div class=\"graphic_reference\">Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Gastroenterology and Hepatology. Shah NL, Intagliata NM, Northup PG, et al. Procoagulant therapeutics in liver disease: a critique and clinical rationale. Nat Rev Gastroenterol Hepatol 2014; 11:678. Copyright &copy; 2014. <a href=\"http://www.nature.com/nrgastro\" target=\"_blank\">www.nature.com/nrgastro</a>.</div><div id=\"graphicVersion\">Graphic 102688 Version 2.0</div></div></div>"},"102695":{"type":"graphic_table","displayName":"FFP versus Cryoprecipitate","title":"Comparison of Fresh Frozen Plasma and Cryoprecipitate","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of Fresh Frozen Plasma and Cryoprecipitate</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">FFP</td> <td class=\"subtitle1\">Cryoprecipitate</td> </tr> <tr> <td><strong>Volume</strong></td> <td>250 to 300 mL</td> <td>10 to 20 mL</td> </tr> <tr> <td><strong>Time to prepare</strong></td> <td>30 minutes</td> <td>30 minutes</td> </tr> <tr> <td><strong>Fibrinogen</strong></td> <td>700 to 800 mg</td> <td>150 to 250 mg</td> </tr> <tr> <td><strong>Other coagulation factors</strong></td> <td>All, including factors II, VII, VIII, IX, X, XI, and vWF</td> <td>Factors VIII, XIII, and vWF</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Values for fibrinogen are approximate, per one unit of each component. FFP contains coagulation factors at the same concentration present in plasma. Cryoprecipitate is a highly concentrated source of fibrinogen. Cryoprecipitate also contains factor XIII, von Willebrand factor (vWF), and factor VIII; however, it is not used to replace these factors because factor concentrates and recombinant products with better safety profiles are available. The cost per unit of fibrinogen is similar in FFP and Cryoprecipiate. In severe liver disease, pools of 8 to 10 units of Cryoprecipitate may be used so the total cost (and amount of fibrinogen given) may be greater. Refer to UpToDate topics on plasma components and specific uses of these products for indications and further details.</div><div class=\"graphic_footnotes\">FFP: Fresh Frozen Plasma; Cryo: Cryoprecipitate.</div><div id=\"graphicVersion\">Graphic 102695 Version 1.0</div></div></div>"},"102722":{"type":"graphic_algorithm","displayName":"Osteoclast inhibitors, patients with bone mets from solid tumors","title":"Osteoclast inhibitors for patients with bone metastases from solid tumors","html":"<div class=\"graphic\"><div style=\"width: 871px\" class=\"figure\"><div class=\"ttl\">Osteoclast inhibitors for patients with bone metastases from solid tumors</div><div class=\"cntnt\"><img style=\"width:851px; height:487px;\" src=\"images/ONC/102722_Ostclstinhbptntbnmtsldtmr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CRPC: castration-resistant prostate cancer.<br />* Intravenous pamidronate, and oral clodronate and ibandronate (where available) are acceptable alternatives to zoledronic acid for selected patients, but they are not preferred for most patients.<br />¶ There are no prospective data from randomized trials to support extrapolation of the extended dosing interval (ie, every 12 weeks) to non-breast, non-prostate solid tumors. However, there may be circumstances (eg, no rapid bone resorption, limited bone disease) where an alternate dosing interval fits the goals of care. Continue treatment indefinitely.<br />Δ Modification to the dosing intervals of long-term bisphosphonate therapy should be directed by the risk of skeletal-related events, the potential for treatment-related toxicities, and the goals of care. The available data supporting this strategy are in breast cancer only. There are no data on switching dosing from every 4 weeks to every 12 weeks in CRPC.</div><div id=\"graphicVersion\">Graphic 102722 Version 3.0</div></div></div>"},"102732":{"type":"graphic_table","displayName":"Kayser-Jones Brief Oral Health Status Examination tool","title":"Kayser-Jones Brief Oral Health Status Examination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Kayser-Jones Brief Oral Health Status Examination</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Resident's name</td> <td>Date</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">Examiner's name</td> <td><strong>TOTAL SCORE</strong></td> </tr> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Measurement</td> <td class=\"subtitle1\">0</td> <td class=\"subtitle1\">1</td> <td class=\"subtitle1\">2</td> </tr> <tr class=\"centered\"> <td>Lymph nodes</td> <td>Observe and feel nodes</td> <td>No enlargement</td> <td>Enlarged, not tender</td> <td>Enlarged and tender*</td> </tr> <tr class=\"centered\"> <td>Lips</td> <td>Observe, feel tissue and ask resident, family or staff (eg, primary caregiver)</td> <td>Smooth, pink, moist</td> <td>Dry, chapped, or red at corners*</td> <td>White or red patch, bleeding or ulcer for two weeks*</td> </tr> <tr class=\"centered\"> <td>Tongue</td> <td>Observe, feel tissue and ask resident, family or staff (eg, primary caregiver)</td> <td>Normal roughness, pink, and moist</td> <td>Coated, smooth, patchy, severely fissured or some redness</td> <td>Red, smooth, white, or red patch; ulcer for two weeks*</td> </tr> <tr class=\"centered\"> <td>Tissue inside cheek, floor and roof of mouth</td> <td>Observe, feel tissue and ask resident, family or staff (eg, primary caregiver)</td> <td>Pink and moist</td> <td>Dry, shiny, rough, red, or swollen*</td> <td>White or red patch, bleeding, hardness; ulcer for two weeks*</td> </tr> <tr class=\"centered\"> <td>Gums between teeth and/or under artificial teeth</td> <td>Gently press gums with tip of tongue blade</td> <td>Pink, small indentations; firm, smooth, and pink under artificial teeth</td> <td>Redness at border around one to six teeth; one red area or sore spot under artificial teeth*</td> <td>Swollen or bleeding gums, redness at border around seven or more teeth, loose teeth; generalized redness or sores under artificial teeth*</td> </tr> <tr class=\"centered\"> <td>Saliva<br /> (effect on tissue)</td> <td>Touch tongue blade to center of tongue and floor of mouth</td> <td>Tissues moist, saliva free flowing and watery</td> <td>Tissues dry and sticky</td> <td>Tissues parched and red, no saliva*</td> </tr> <tr class=\"centered\"> <td>Condition of natural teeth</td> <td>Observe and count number of decayed or broken teeth</td> <td>No decayed or broken teeth/roots</td> <td>One to three decayed or broken teeth/roots*</td> <td>Four or more decayed or broken teeth/roots; fewer than four teeth in either jaw*</td> </tr> <tr class=\"centered\"> <td>Condition of artificial teeth</td> <td>Observe and ask patient, family or staff (eg, primary caregiver)</td> <td>Unbroken teeth, worn most of the time</td> <td>One broken/missing tooth, or worn for eating or cosmetics only</td> <td>More than one broken or missing tooth, or either denture missing or never worn*</td> </tr> <tr class=\"centered\"> <td>Pairs of teeth in chewing position<br /> (natural or artificial)</td> <td>Observe and count pairs of teeth in chewing position</td> <td>Twelve or more pairs of teeth in chewing position</td> <td>Eight to 11 pairs of teeth in chewing position</td> <td>Zero to seven pairs of teeth in chewing position*</td> </tr> <tr class=\"divider_bottom centered\"> <td>Oral cleanliness</td> <td>Observe appearance of teeth or dentures</td> <td>Clean, no food particles/tartar in the mouth or on artificial teeth</td> <td>Food particles/tartar in one or two places in the mouth or on artificial teeth</td> <td>Food particles/tartar in most places in the mouth or on artificial teeth</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\">Upper dentures labeled: Yes _____ No _____ None _____</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\">Lower dentures labeled: Yes _____ No _____ None _____</td> </tr> <tr> <td colspan=\"5\">Is your mouth comfortable? Yes _____ No _____ If no, please explain:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"5\"> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> <tr> <td colspan=\"5\"> <p>Additional comments:</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Refer to dentist immediately.</div><div class=\"graphic_reference\">Originally published in: Kayser-Jones J, Bird WF, Paul SM, et al. An instrument to assess the oral health status of nursing home residents. Gerontologist 1995; 35:814. Reproduced with permission from Jeanie Kayser-Jones, RN, PhD, FAAN. Copyright &copy; 1995.</div><div id=\"graphicVersion\">Graphic 102732 Version 1.0</div></div></div>"},"102733":{"type":"graphic_diagnosticimage","displayName":"Ultrasound footling breech","title":"Ultrasound examination of footling breech presentation at 36 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Ultrasound examination of footling breech presentation at 36 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:555px; height:468px;\" src=\"images/OBGYN/102733_Ultrsnd_footl_brch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Footling breech presentation at 36 weeks of gestation. The fetal foot is just above the cervix. The fetal head (not shown) is in the fundus.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 102733 Version 1.0</div></div></div>"},"102746":{"type":"graphic_algorithm","displayName":"Management of patients following thyroidectomy for MTC","title":"Management of patients following thyroidectomy for medullary thyroid cancer","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Management of patients following thyroidectomy for medullary thyroid cancer</div><div class=\"cntnt\"><img style=\"width:710px; height:452px;\" src=\"images/ENDO/102746_Mngmnt_thyroidectomy_MTC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CEA: carcinoembryonic antigen; CT: computed tomography; Ctn: calcitonin; EBRT: external beam radiotherapy; MRI: magnetic resonance imaging; MTC: medullary thyroid cancer; TFT: thyroid function test; TKI: tyrosine kinase inhibitor; TSH: thyroid-stimulating hormone; TTX: total thyroidectomy; US: ultrasound.<br />* Additional imaging includes CT or MRI of neck, chest, and abdomen; bone scan or bone MRI in patients suspected of having skeletal metastases.</div><div class=\"graphic_reference\">Reproduced with permission from: Wells Jr SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25:567. Copyright &copy; 2015 Mary Ann Liebert, Inc. Publishers. All rights reserved.</div><div id=\"graphicVersion\">Graphic 102746 Version 3.0</div></div></div>"},"102747":{"type":"graphic_algorithm","displayName":"Evaluation of patients with MTC diagnosed by thyroid nodule FNA","title":"Evaluation and management of patients with medullary thyroid cancer diagnosed on the basis of fine needle aspiration biopsy of a thyroid nodule","html":"<div class=\"graphic\"><div style=\"width: 704px\" class=\"figure\"><div class=\"ttl\">Evaluation and management of patients with medullary thyroid cancer diagnosed on the basis of fine needle aspiration biopsy of a thyroid nodule</div><div class=\"cntnt\"><img style=\"width:684px; height:640px;\" src=\"images/ENDO/102747_Eval_MTC_dgn_thyrd_ndl_FNA.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ADX: adrenalectomy; Ctn: calcitonin; CEA: carcinoembryonic antigen; EBRT: external beam radiotherapy; FNA: fine needle aspiration; HPTH: hyperparathyroidism; LND: lymph node dissection; MTC: medullary thyroid cancer; M: metastatic MTC; PHEO: pheochromocytoma; TKI: tyrosine kinase inhibitor; TTX: total thyroidectomy; US: ultrasound.<br />* Ctn and CEA are measured to determine whether they are produced by the tumor, and if so, as a baseline for comparison with the results obtained after surgery. In addition, patients with preoperative Ctn &gt;500 pg/mL require additional preoperative imaging.</div><div class=\"graphic_reference\">Modified with permission from: Wells Jr SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25:567. Copyright &copy; 2015 Mary Ann Liebert, Inc. Publishers. All rights reserved.</div><div id=\"graphicVersion\">Graphic 102747 Version 4.0</div></div></div>"},"102750":{"type":"graphic_figure","displayName":"Effect of sleep on ventilation and upper mechanics","title":"Effect of sleep on ventilation and upper mechanics","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Effect of sleep on ventilation and upper mechanics</div><div class=\"cntnt\"><img style=\"width:553px; height:395px;\" src=\"images/SLEEP/102750_Effct_slp_vnt_up_mch.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During sleep, compared with wakefulness, important changes include decreased flow and volume (dotted line), augmented supraglottic pressure, and increased end-tidal PCO<SUB>2</SUB> (dashed line).</div><div class=\"graphic_footnotes\">EEG: electroencephalogram.</div><div id=\"graphicVersion\">Graphic 102750 Version 1.0</div></div></div>"},"102761":{"type":"graphic_algorithm","displayName":"Longitudinal melanonychia differential diagnosis","title":"Approach to the differential diagnosis and management of longitudinal melanonychia","html":"<div class=\"graphic\"><div style=\"width: 1005px\" class=\"figure\"><div class=\"ttl\">Approach to the differential diagnosis and management of longitudinal melanonychia</div><div class=\"cntnt\"><img style=\"width:985px; height:726px;\" src=\"images/DERM/102761_Lngtdnl_mlnnych_dffrnt_dgn.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 102761 Version 2.0</div></div></div>"},"102766":{"type":"graphic_algorithm","displayName":"Algorithm for management of HDGC","title":"Suggested algorithm for management of hereditary diffuse gastric cancer (HDGC) with an emphasis on germline <em>CDH1</em> mutation carriers, International Gastric Cancer Linkage Consortium, 2015","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Suggested algorithm for management of hereditary diffuse gastric cancer (HDGC) with an emphasis on germline <em>CDH1</em> mutation carriers, International Gastric Cancer Linkage Consortium, 2015</div><div class=\"cntnt\"><img style=\"width:600px; height:676px;\" src=\"images/ONC/102766_Algorithm_management_HDGC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GC: gastric cancer; DGC: diffuse gastric cancer; LBC: lobular breast cancer; MLPA: multiplex-ligation probe amplification.<br />* Including first and second degree relatives.</div><div class=\"graphic_reference\">From: van der Post RS, Vogelaar IP, Camiero F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 2015; 52:361. Reproduced with permission from BMJ Publishing Group Ltd. Copyright &copy; 2015.</div><div id=\"graphicVersion\">Graphic 102766 Version 1.0</div></div></div>"},"102779":{"type":"graphic_picture","displayName":"Plane xanthoma","title":"Plane xanthomas","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Plane xanthomas</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/102779_Plane_xanthoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow plaques beneath the mandible.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 102779 Version 1.0</div></div></div>"},"102780":{"type":"graphic_picture","displayName":"Xanthelasma on eyelid","title":"Xanthelasma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Xanthelasma</div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/DERM/102780_Xanthelasma_eyelid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow plaques on the eyelids.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 102780 Version 1.0</div></div></div>"},"102781":{"type":"graphic_picture","displayName":"Periorbital necrobiotic xanthogranuloma","title":"Necrobiotic xanthogranuloma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Necrobiotic xanthogranuloma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/102781_Prrbtl_ncrbtc_xnthgrnlm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow-brown, infiltrated plaques with telangiectasias on the periorbital skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 102781 Version 1.0</div></div></div>"},"102782":{"type":"graphic_picture","displayName":"Necrobiotic xanthogranuloma","title":"Necrobiotic xanthogranuloma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Necrobiotic xanthogranuloma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/102782_Necrobiotic_xnthgrnlm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow-orange plaques with erythematous borders, central atrophy, and telangiectasias on the neck and trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 102782 Version 1.0</div></div></div>"},"102783":{"type":"graphic_picture","displayName":"Ulcerated necrobiotic xanthogranuloma","title":"Necrobiotic xanthogranuloma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Necrobiotic xanthogranuloma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/102783_Ulcrt_ncrbtc_xnthgrnlm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow plaques with erythema and ulceration.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 102783 Version 1.0</div></div></div>"},"102798":{"type":"graphic_diagnosticimage","displayName":"Early stress fracture of fibula on ultrasound","title":"Early stress fracture of fibula on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 662px\" class=\"figure\"><div class=\"ttl\">Early stress fracture of fibula on ultrasound</div><div class=\"cntnt\"><img style=\"width:642px; height:678px;\" src=\"images/SM/102798_Erly_tbl_strss_frctr_ultrsnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The two ultrasound images above were taken at the initial office visit of a young athlete complaining of pain at the&nbsp;distal fibula. Plain radiographs were normal, but the ultrasound images clearly show cortical disruption and callus formation consistent with a stress fracture.&nbsp;The disruption of the&nbsp;fibular cortex (which appears as a dense white line) is apparent below the arrow and callus in the top image. Callus formation can also be seen within the box in the lower image.</div><div class=\"graphic_reference\">Courtesy of Dave Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 102798 Version 2.0</div></div></div>"},"102799":{"type":"graphic_diagnosticimage","displayName":"Stress fracture distal fibular shaft","title":"Stress fracture of distal shaft of fibula","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Stress fracture of distal shaft of fibula</div><div class=\"cntnt\"><img style=\"width:581px; height:854px;\" src=\"images/SM/102799_Strss_frctr_dstl_tbl_shft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain radiograph above was taken six weeks after the patient's initial evaluation, when the&nbsp;first radiograph images were normal but ultrasound revealed signs of a stress fracture. This later radiograph clearly shows a fracture in the distal fibula with callus formation.</div><div class=\"graphic_reference\">Courtesy of David J. Berkoff, MD.</div><div id=\"graphicVersion\">Graphic 102799 Version 2.0</div></div></div>"},"102800":{"type":"graphic_diagnosticimage","displayName":"Tibial stress fracture MRI","title":"Tibial stress fracture MRI","html":"<div class=\"graphic\"><div style=\"width: 860px\" class=\"figure\"><div class=\"ttl\">Tibial stress fracture MRI</div><div class=\"cntnt\"><img style=\"width:840px; height:361px;\" src=\"images/SM/102800_Tbl_strss_frctr_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In image A,&nbsp;a fracture line can be seen that extends across approximately 80 percent of cortex. A lateral view of the same stress fracture (B) shows the fracture line crossing the entire antero-posterior&nbsp;width of the tibia. In image C,&nbsp;a stress fracture of the proximal anterior tibia has a stellate appearance and is surrounded by edema.</div><div class=\"graphic_reference\">Courtesy of Stephen M Simons, MD.</div><div id=\"graphicVersion\">Graphic 102800 Version 1.0</div></div></div>"},"102803":{"type":"graphic_diagnosticimage","displayName":"Fibrous tumor of the pleura CT","title":"Fibrous tumor of pleura","html":"<div class=\"graphic\"><div style=\"width: 753px\" class=\"figure\"><div class=\"ttl\">Fibrous tumor of pleura</div><div class=\"cntnt\"><img style=\"width:733px; height:237px;\" src=\"images/PULM/102803_Fbrs_tmr_plr_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: CT scan shows a large left posterior chest mass (arrow). Panels B and C: Decubitus views, from the same patient, show the extreme mobility and pliability of this tumor. The left lateral decubitus view (panel B) and right lateral decubitus view (panel C) show that the tumor is now abutting the mediastinal contour and has moved to abut the anterior chest wall. These features are nearly diagnostic of a fibrous tumor of the pleura.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 102803 Version 3.0</div></div></div>"},"102804":{"type":"graphic_algorithm","displayName":"Algorithm for the diagnosis of PAVM","title":"Algorithm for the diagnosis of pulmonary arteriovenous malformations in adults","html":"<div class=\"graphic\"><div style=\"width: 896px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis of pulmonary arteriovenous malformations in adults</div><div class=\"cntnt\"><img style=\"width:876px; height:482px;\" src=\"images/PULM/102804_Algorithm_diagnosis_PAVM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm assumes that most patients have had a chest radiograph and that the suspicion for PAVM remains regardless of whether it is normal or a typical nodule is present. Patients considered as having a high clinical suspicion for PAVM is patient-specific but may include those with a typical chest radiograph and/or multiple clinical features suggestive of PAVM or HHT.</div><div class=\"graphic_footnotes\">PAVM: pulmonary arteriovenous malformation; CT: computed tomography; TTCE: transthoracic contrast echocardiography; TEE: transesophageal echocardiogram; HHT: hereditary hemorrhagic telangiectasia, assuming no CT is done.<br />* Indications for diagnostic investigations include patients with one or more of the following: a suspicious nodule on chest radiography, stigmata of right-to-left shunt (eg, cyanosis, clubbing, history of cerebral stroke or abscess), unexplained hemoptysis, hemothorax, hypoxemia or dyspnea, patients with platypnea, orthodeoxia, and adults with a personal or family history of hereditary hemorrhagic telangiectasia.<br />¶ 100 percent oxygen method or radionuclide scanning for shunt assessment may be supplementary or an alternative to TTCE but are not as sensitive or as specific as TTCE. However, we prefer to proceed directly to CT scanning when TTCE is unavailable.<br />Δ Some patients may warrant follow up with CT chest (eg, patients with a high clinical suspicion for PAVM: typical nodule on chest radiograph or history of stroke. Please refer to the UpToDate topic on pulmonary arteriovenous malformations: clinical features and diagnostic evaluation in adults).<br /><FONT class=lozenge>◊</FONT> The evaluation in this population depends upon the reason for an indeterminate scan. Please refer to the UpToDate topic on pulmonary arteriovenous malformations: clinical features and diagnostic evaluation in adults.<br />§ Observation in this population involves yearly evaluation clinically and a repeat TTCE within three to five years. Please refer to the UpToDate topic on pulmonary arteriovenous malformations: clinical features and diagnostic evaluation in adults.<br />¥ For patients that present incidentally with a CT scan diagnostic of PAVM, transthoracic echocardiography is not necessary. However, when incidental CT scans are non diagnostic, some experts perform TTCE and/or&nbsp;repeat the CT scan with contrast.<br />‡ Inclusive in this group are patients with non diagnostic CT scans including those with atypical nodules that do not have the classic features of an AVM (see text for details). The evaluation should be individualized in this population. Some experts occasionally perform contrast pulmonary angiography in patients with high grade shunt and indeterminate CT scans in whom the clinical suspicion is high. However, observation with follow up TTCE and/or CT is also appropriate (eg, those with minimal symptoms and/or a low grade shunt).<br />† This population may have small PAVMs that are missed on CT and may require yearly clinical evaluation and repeat CT within three to five years. Alternative causes of shunt should also be sought (eg, great vessel shunt, hepatopulmonary syndrome). Rarely, is a pulmonary angiogram done for patients with symptoms suggestive of a treatable PAVM (eg, idiopathic stroke). Please refer to the UpToDate topic on pulmonary arteriovenous malformations: clinical features and diagnostic evaluation in adults.</div><div id=\"graphicVersion\">Graphic 102804 Version 3.0</div></div></div>"},"102805":{"type":"graphic_algorithm","displayName":"Algorithm for treating PAVM","title":"Algorithm for treating pulmonary arteriovenous malformations","html":"<div class=\"graphic\"><div style=\"width: 760px\" class=\"figure\"><div class=\"ttl\">Algorithm for treating pulmonary arteriovenous malformations</div><div class=\"cntnt\"><img style=\"width:740px; height:966px;\" src=\"images/PULM/102805_Algo_treating_PAVM_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; PAVM: pulmonary arteriovenous malformation; PH: pulmonary hypertension.<br />* A cutoff for feeding artery size ≥3 mm is a universally agreed upon diameter as most interventional radiologists can readily access pulmonary arteries of this size. However, it is generally accepted that PAVMS ≥2 mm should also be targeted angiographically, when feasible.<br />¶ In our experience patients can tolerate contrast safely with appropriate pre-medication (please refer to the UpToDate topic for the treatment of patients with contrast allergies).<br />Δ Some PAVMS may be previously identified on CT while others may not have been identified on CT.<br /><FONT class=lozenge>◊</FONT> Surgery may be an option for PAVMS not amenable to embolotherapy or for patients with life-threatening hemorrhage in a facility without access to embolotherapy.<br />§ Reasons for lack of response to embolotherapy include failed embolotherapy (eg, coil migration), the development of new symptomatic PAVMS and/or the development of PH. This population may present with worsening symptoms or persistent or new PAVMS on CT. For those in whom PH is suspected, right heart catheterization may be appropriate. Please refer to the UpToDate topic on the therapeutic approach to adult patients with PAVMS.<br />¥ Surgery is rarely needed since embolization is typically successful. Surgery may also be indicated in patients with life-threatening acute hemorrhage from a ruptured PAVM in a facility <STRONG>without</STRONG> access to embolotherapy.<br />‡ Lung transplantation is a last resort therapy especially for those with diffuse bilateral disease and/or those who are at considerable risk of dying from their underlying PAVM. Please refer to the UpToDate topic on the therapeutic approach to adult patients with PAVMS.</div><div id=\"graphicVersion\">Graphic 102805 Version 3.0</div></div></div>"},"102806":{"type":"graphic_diagnosticimage","displayName":"Atypical PAVM","title":"Suspicious nodule with features atypical for PAVM","html":"<div class=\"graphic\"><div style=\"width: 701px\" class=\"figure\"><div class=\"ttl\">Suspicious nodule with features atypical for PAVM</div><div class=\"cntnt\"><img style=\"width:681px; height:223px;\" src=\"images/PULM/102806_Atypical_PAVM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced computed tomography of the chest (serial consecutive cuts shown) showing a 1 cm moderately-enhancing nodule (rings) with a small feeding artery (arrow) and no draining vein. Subsequent pulmonary angiography revealed no PAVM. This CT displays some of the atypical features associated with PAVM including only one tubular structure leading into the sac and irregular sac borders. Other potential atypical features include irregular or no contrast enhancement and tubular structures that don't blend with the sac but continue past the nodule/sac (not shown).</div><div class=\"graphic_footnotes\">PAVM: pulmonary arteriovenous malformation.</div><div id=\"graphicVersion\">Graphic 102806 Version 2.0</div></div></div>"},"102807":{"type":"graphic_table","displayName":"Causes of pulmonary artery venous malformations","title":"Causes of pulmonary artery venous malformations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of pulmonary artery venous malformations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Hereditary hemorrhagic telangiectasia</td> </tr> <tr> <td>Hepatic cirrhosis</td> </tr> <tr> <td>Penetrating chest trauma or congenital heart surgery</td> </tr> <tr> <td>Mitral stenosis</td> </tr> <tr> <td>Schistosomiasis</td> </tr> <tr> <td>Actinomycosis</td> </tr> <tr> <td>Fanconi's syndrome</td> </tr> <tr> <td>Metastatic thyroid carcinoma</td> </tr> <tr> <td>Status post surgery for congenital heart disease</td> </tr> <tr> <td>Idiopathic</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 102807 Version 1.0</div></div></div>"},"102808":{"type":"graphic_diagnosticimage","displayName":"Large typical PAVM","title":"Large typical pulmonary arteriovenous malformation (PAVM)","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Large typical pulmonary arteriovenous malformation (PAVM)</div><div class=\"cntnt\"><img style=\"width:493px; height:374px;\" src=\"images/PULM/102808_Lrg_typcl_PAVM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced computed tomography of the chest revealed a large pulmonary arteriovenous malformation (arrow) with a large feeding artery (6 mm) and draining vein seen as parallel structures (arrowhead). This image displays many of the typical features diagnostic of PAVM including a smooth or slightly lobulated sac with well delineated borders, at least two tubular structures (ie, vessels) that seamlessly blend into the sac, the tubular structures are&nbsp;often parallel and larger than other vessels in the vicinity (especially for peripheral lesions), and good contrast enhancement.</div><div id=\"graphicVersion\">Graphic 102808 Version 1.0</div></div></div>"},"102809":{"type":"graphic_diagnosticimage","displayName":"Multiple pulmonary arteriovenous malformations I","title":"Computed tomography of multiple pulmonary arteriovenous malformations I","html":"<div class=\"graphic\"><div style=\"width: 711px\" class=\"figure\"><div class=\"ttl\">Computed tomography of multiple pulmonary arteriovenous malformations I</div><div class=\"cntnt\"><img style=\"width:691px; height:502px;\" src=\"images/PULM/102809_Mltpl_plm_artrvn_mlfrm_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Non-enhanced computed tomography of the chest showing two large and one small pulmonary arteriovenous malformations (arrows).</div><div id=\"graphicVersion\">Graphic 102809 Version 1.0</div></div></div>"},"102810":{"type":"graphic_diagnosticimage","displayName":"Multiple pulmonary arteriovenous malformations II","title":"Computed tomography of multiple pulmonary arteriovenous malformations II","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Computed tomography of multiple pulmonary arteriovenous malformations II</div><div class=\"cntnt\"><img style=\"width:526px; height:375px;\" src=\"images/PULM/102810_Mltpl_plm_artrvn_mlfrm_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Non-enhanced computed tomography of the chest showing two small pulmonary arteriovenous malformations (arrows).</div><div id=\"graphicVersion\">Graphic 102810 Version 1.0</div></div></div>"},"102812":{"type":"graphic_diagnosticimage","displayName":"Normal pulmonary angiography","title":"Normal pulmonary angiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal pulmonary angiography</div><div class=\"cntnt\"><img style=\"width:315px; height:351px;\" src=\"images/PULM/102812_Nrml_plmnry_anggrphy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary angiography of the left main pulmonary artery reveals normal branching of the pulmonary vessels.</div><div id=\"graphicVersion\">Graphic 102812 Version 1.0</div></div></div>"},"102813":{"type":"graphic_diagnosticimage","displayName":"PAVM pulmonary angiography","title":"Pulmonary arteriovenous malformation pulmonary angiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary arteriovenous malformation pulmonary angiography</div><div class=\"cntnt\"><img style=\"width:253px; height:412px;\" src=\"images/PULM/102813_PAVM_plmnry_anggrphy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary angiography of the left main pulmonary artery revealed seven pulmonary arteriovenous malformations (rings), six of which were eligible for embolization. Only one of these was visualized on plain chest radiograph.</div><div id=\"graphicVersion\">Graphic 102813 Version 1.0</div></div></div>"},"102814":{"type":"graphic_diagnosticimage","displayName":"Diffuse PAVM I","title":"Pulmonary angiogram of diffuse pulmonary arteriovenous malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary angiogram of diffuse pulmonary arteriovenous malformation</div><div class=\"cntnt\"><img style=\"width:401px; height:792px;\" src=\"images/PULM/102814_Diffuse_PAVM_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left anterior oblique selective right pulmonary angiogram early and late arterial images.<br />(A) Diffuse involvement of the posterior and medial segment arteries is easily seen while the anterior and lateral segments are uninvolved.<br />(B) In late arterial phase, early venous drainage into the left atrium is seen from the diffusely involved posterior medial segments.</div><div class=\"graphic_reference\">From: Pierucci P, Murphy J, Henderson KJ et al. New definition and natural history of patients with diffuse pulmonary arteriovenous malformations: Twenty-seven year experience. Chest 2008; 133:653. Reproduced with permission from the American College of Chest Physicians. Copyright &copy; 2008.</div><div id=\"graphicVersion\">Graphic 102814 Version 2.0</div></div></div>"},"102815":{"type":"graphic_diagnosticimage","displayName":"Diffuse PAVM II","title":"Pulmonary angiogram of diffuse pulmonary arteriovenous malformation with coils","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary angiogram of diffuse pulmonary arteriovenous malformation with coils</div><div class=\"cntnt\"><img style=\"width:386px; height:792px;\" src=\"images/PULM/102815_Diffuse_PAVM_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shallow left anterior oblique views of super selective right pulmonary angiograms in late arterial phases. In both the anterior segment (A) and the lateral segment (B), diffuse involvement from each subsegmental branch is noted. At the end of each subsegmental branch is tiny almost \"telangiectasia-type\" abnormalities. The pulmonary veins from each of these segments are already opacified.</div><div class=\"graphic_reference\">From: Pierucci P, Murphy J, Henderson KJ et al. New definition and natural history of patients with diffuse pulmonary arteriovenous malformations: Twenty-seven year experience. Chest 2008; 133:653. Reproduced with permission from the American College of Chest Physicians. Copyright &copy; 2008.</div><div id=\"graphicVersion\">Graphic 102815 Version 2.0</div></div></div>"},"102817":{"type":"graphic_picture","displayName":"Intermittent pneumatic compression device","title":"Intermittent pneumatic compression device","html":"<div class=\"graphic\"><div style=\"width: 875px\" class=\"figure\"><div class=\"ttl\">Intermittent pneumatic compression device</div><div class=\"cntnt\"><img style=\"width:855px; height:784px;\" src=\"images/PULM/102817_Intrmt_pnmtc_cmprs_dvc.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Image courtesy of ArjoHuntleigh, Inc.</div><div id=\"graphicVersion\">Graphic 102817 Version 1.0</div></div></div>"},"102819":{"type":"graphic_picture","displayName":"Venous foot pump","title":"Venous foot pump","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Venous foot pump</div><div class=\"cntnt\"><img style=\"width:763px; height:652px;\" src=\"images/PULM/102819_Venous_ft_pmp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative image of a venous foot pump device that includes the pump, tubing, and two foot wraps.</div><div class=\"graphic_reference\">Courtesy of Medtronic. A-V Impulse is a trademark of a Medtronic company. &copy; 2014 Covidien.</div><div id=\"graphicVersion\">Graphic 102819 Version 1.0</div></div></div>"},"102820":{"type":"graphic_picture","displayName":"Mixed hemangioma-lymphangioma of the tongue","title":"A child with mixed hemangioma-lymphangioma of the tongue","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">A child with mixed hemangioma-lymphangioma of the tongue</div><div class=\"cntnt\"><img style=\"width:648px; height:486px;\" src=\"images/PEDS/102820_Mixed_hemang_lymphang_tongu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These tongue lesions are a combination of lymphangioma and hemangioma. There are widely scattered clear vesicular lesions interspersed with blood-filled bleb-like papules.</div><div class=\"graphic_reference\">Courtesy of Patrick O'Donnell, MD.</div><div id=\"graphicVersion\">Graphic 102820 Version 1.0</div></div></div>"},"102821":{"type":"graphic_picture","displayName":"Buccal choristoma","title":"Oral cavity of an infant showing a buccal choristoma","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Oral cavity of an infant showing a buccal choristoma</div><div class=\"cntnt\"><img style=\"width:505px; height:514px;\" src=\"images/PEDS/102821_Buccal_choristoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A choristoma is a mass of normal cells in an abnormal location (ie, heterotopia). Heterotopic gastric mucosa, enteric duplication cysts, heterotopic neural tissue, and ectopic cartilage and bone all have been reported in the oral cavity.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 102821 Version 1.0</div></div></div>"},"102822":{"type":"graphic_picture","displayName":"Natal tooth","title":"Newborn infant with a natal tooth","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Newborn infant with a natal tooth</div><div class=\"cntnt\"><img style=\"width:648px; height:486px;\" src=\"images/PEDS/102822_Natal_tooth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Teeth that are present in the oral cavity at the time of birth are natal teeth; those that erupt during the neonatal period are neonatal teeth. Although this newborn has an upper incisor, the majority of natal teeth are the primary mandibular incisors.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 102822 Version 1.0</div></div></div>"},"102824":{"type":"graphic_table","displayName":"Types of autosomal dominant tubulointerstitial kidney disease","title":"Types of autosomal dominant tubulointerstitial kidney disease (medullary cystic kidney disease)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of autosomal dominant tubulointerstitial kidney disease (medullary cystic kidney disease)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Characteristic</td> <td class=\"subtitle1\">Uromodulin kidney disease</td> <td class=\"subtitle1\">ADTKD due to <em>REN </em>mutations</td> <td class=\"subtitle1\">Mucin-1 kidney disease</td> </tr> <tr class=\"divider_bottom\"> <td>Inheritance</td> <td>Autosomal dominant</td> <td>Autosomal dominant</td> <td>Autosomal dominant</td> </tr> <tr class=\"divider_bottom\"> <td>Urinalysis results</td> <td>Bland without protein</td> <td>Bland without protein</td> <td>Bland without protein</td> </tr> <tr class=\"divider_bottom\"> <td>Renal ultrasound</td> <td>Normal or small kidneys, occasional cysts</td> <td>Normal or small kidneys, occasional cysts</td> <td>Normal or small kidneys, occasional cysts</td> </tr> <tr class=\"divider_bottom\"> <td>Age of ESRD (years)</td> <td>20 to 70</td> <td>40 to 80</td> <td>20 to 80</td> </tr> <tr class=\"divider_bottom\"> <td>Kidney biopsy</td> <td>Interstitial fibrosis, nondiagnostic</td> <td>Interstitial fibrosis, nondiagnostic</td> <td>Interstitial fibrosis, nondiagnostic</td> </tr> <tr class=\"divider_bottom\"> <td>Definitive diagnosis</td> <td>Genetic analysis</td> <td>Genetic analysis</td> <td>Genetic analysis</td> </tr> <tr class=\"divider_bottom\"> <td>Associated findings</td> <td>Many family members with gout, some in the teenage years</td> <td>Low or low-normal blood pressure, hyperuricemia, anemia in childhood, mild hyperkalemia</td> <td>No associated findings</td> </tr> <tr class=\"divider_bottom\"> <td>Treatment</td> <td>No specific treatment; allopurinol for gout</td> <td>High-sodium diet or fludrocortisone</td> <td>No specific treatment</td> </tr> <tr class=\"divider_bottom\"> <td>Frequency</td> <td>Rare</td> <td>Very rare</td> <td>Rare</td> </tr> <tr> <td>Other names</td> <td>Medullary cystic kidney disease type 2 (MCKD2), familial juvenile hyperuricemic nephropathy (FJHN)</td> <td>Familial juvenile hyperuricemic nephropathy&nbsp;type 2 (FJHN2)</td> <td>Medullary cystic kidney disease type 1 (MCKD1)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADTKD: autosomal dominant tubulointerstitial kidney disease; ESRD: end-stage renal disease.</div><div id=\"graphicVersion\">Graphic 102824 Version 2.0</div></div></div>"},"102826":{"type":"graphic_picture","displayName":"Miliaria crystallina close view","title":"Miliaria crystallina","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Miliaria crystallina</div><div class=\"cntnt\"><img style=\"width:766px; height:521px;\" src=\"images/DERM/102826_Miliar_crystlln_close_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small vesicles on non-inflamed bases.</div><div class=\"graphic_reference\">Courtesy of Kenneth Greer, MD.</div><div id=\"graphicVersion\">Graphic 102826 Version 1.0</div></div></div>"},"102828":{"type":"graphic_table","displayName":"NMOSD diagnostic criteria for adults","title":"Neuromyelitis optica spectrum disorders diagnostic criteria for adult patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuromyelitis optica spectrum disorders diagnostic criteria for adult patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diagnostic criteria for NMOSD with AQP4-IgG</td> </tr> <tr> <td class=\"indent1\">1. At least one core clinical characteristic</td> </tr> <tr> <td class=\"indent1\">2. Positive test for AQP4-IgG using best available detection method (cell-based assay strongly recommended)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">3. Exclusion of alternative diagnoses</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic criteria for NMOSD without AQP4-IgG or NMOSD with unknown AQP4-IgG status</td> </tr> <tr> <td class=\"indent1\">1. At least two core clinical characteristics occurring as a result of one or more clinical attacks and meeting all of the following requirements:</td> </tr> <tr> <td class=\"indent2\">a. At least one core clinical characteristic must be optic neuritis, acute myelitis with LETM, or area postrema syndrome</td> </tr> <tr> <td class=\"indent2\">b. Dissemination in space (two or more different core clinical characteristics)</td> </tr> <tr> <td class=\"indent2\">c. Fulfillment of additional MRI requirements, as applicable</td> </tr> <tr> <td class=\"indent1\">2. Negative tests for AQP4-IgG using best available detection method, or testing unavailable</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">3. Exclusion of alternative diagnoses</td> </tr> <tr> <td class=\"subtitle1_single\">Core clinical characteristics</td> </tr> <tr> <td class=\"indent1\">1. Optic neuritis</td> </tr> <tr> <td class=\"indent1\">2. Acute myelitis</td> </tr> <tr> <td class=\"indent1\">3. Area postrema syndrome: Episode of otherwise unexplained hiccups or nausea and vomiting</td> </tr> <tr> <td class=\"indent1\">4. Acute brainstem syndrome</td> </tr> <tr> <td class=\"indent1\">5. Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions</td> </tr> <tr> <td class=\"subtitle1_single\">Additional MRI requirements for NMOSD without AQP4-IgG and NMOSD with unknown AQP4-IgG status</td> </tr> <tr> <td class=\"indent1\">1. Acute optic neuritis: Requires brain MRI showing (a) normal findings or only nonspecific white matter lesions, <strong>or</strong> (b) optic nerve MRI with T2-hyperintense lesion or T1-weighted gadolinium enhancing lesion extending over more than one-half the optic nerve length or involving optic chiasm</td> </tr> <tr> <td class=\"indent1\">2. Acute myelitis: Requires associated intramedullary MRI lesion extending over &#8805;3 contiguous segments (LETM) <strong>or</strong> &#8805;3 contiguous segments of focal spinal cord atrophy in patients with history compatible with acute myelitis</td> </tr> <tr> <td class=\"indent1\">3. Area postrema syndrome: Requires associated dorsal medulla/area postrema lesions</td> </tr> <tr> <td class=\"indent1\">4. Acute brainstem syndrome: Requires associated periependymal brainstem lesions</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AQP4: aquaporin-4; IgG: immunoglobulin G; LETM: longitudinally extensive transverse myelitis lesions; NMOSD: neuromyelitis optica spectrum disorders.</div><div class=\"graphic_reference\">From: Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85:177. DOI: <a href=\"http://www.neurology.org/content/85/2/177.long\" target=\"_blank\">10.1212/WNL.0000000000001729</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 102828 Version 1.0</div></div></div>"},"102836":{"type":"graphic_table","displayName":"Motor milestones for developmental surveillance","title":"Motor milestones for developmental surveillance at preventive care visits","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Motor milestones for developmental surveillance at preventive care visits</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age*</td> <td class=\"subtitle1\">Gross motor milestones</td> <td class=\"subtitle1\">Fine motor milestones</td> </tr> <tr> <td>2 months</td> <td> <ul> <li>Lifts head and chest in prone </li> </ul> </td> <td>&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">&ndash;</span></td> </tr> <tr> <td>4 months</td> <td> <ul> <li>Rolls over prone to supine </li> <li>Supports on elbows and wrists in prone </li> </ul> </td> <td> <ul> <li>Hands unfisted </li> <li>Plays with fingers in midline </li> <li>Grasps object </li> </ul> </td> </tr> <tr> <td>6 months</td> <td> <ul> <li>Rolls over supine to prone </li> <li>Sits without support </li> </ul> </td> <td> <ul> <li>Reaches for cubes and transfers </li> <li>Rakes small object with&nbsp;four fingers </li> </ul> </td> </tr> <tr> <td>9 months</td> <td> <ul> <li>Pulls to stand </li> <li>Comes to sit from lying </li> <li>Crawls </li> </ul> </td> <td> <ul> <li>Picks up small object with&nbsp;three fingers </li> </ul> </td> </tr> <tr> <td>12 months</td> <td> <ul> <li>Walks independently </li> <li>Stands </li> </ul> </td> <td> <ul> <li>Puts&nbsp;one block in a cup </li> <li>Bangs&nbsp;two objects together </li> <li>Picks up small object with two-finger pincer grasp </li> </ul> </td> </tr> <tr> <td>15 months</td> <td> <ul> <li>Walks backward </li> <li>Runs </li> </ul> </td> <td> <ul> <li>Scribbles in imitation </li> <li>Dumps small object from bottle, with demonstration </li> </ul> </td> </tr> <tr> <td>18 months</td> <td> <ul> <li>Walks up steps with hand held </li> </ul> </td> <td> <ul> <li>Dumps small object from bottle spontaneously </li> <li>Builds tower of&nbsp;two cubes </li> <li>Scribbles spontaneously </li> <li>Puts 10 blocks in a cup </li> </ul> </td> </tr> <tr> <td>24 months</td> <td> <ul> <li>Rides on toy without pedals </li> <li>Jumps up </li> </ul> </td> <td> <ul> <li>Builds tower and horizontal train with&nbsp;three blocks </li> </ul> </td> </tr> <tr> <td>30 months</td> <td> <ul> <li>Begins to walk up steps alternating feet </li> </ul> </td> <td> <ul> <li>Imitates horizontal and vertical lines </li> <li>Builds a train with a chimney with four blocks </li> </ul> </td> </tr> <tr> <td>3 years</td> <td> <ul> <li>Pedals; climbs on and off furniture </li> </ul> </td> <td> <ul> <li>Copies a circle drawing </li> <li>Draws a person with head and one other body part </li> <li>Builds a bridge with&nbsp;three blocks </li> </ul> </td> </tr> <tr> <td>4 years</td> <td> <ul> <li>Climbs stairs without support </li> <li>Skips on&nbsp;one foot </li> </ul> </td> <td> <ul> <li>Draws a person with&nbsp;six parts </li> <li>Draws a simple cross </li> <li>Buttons medium-sized buttons </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The mean ages at which typically developing children will achieve motor milestones are listed. Marked delay beyond these ages warrants attention but does not necessarily signify a neuromotor disease.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 131, Pages e2016-27, Copyright &copy; 2013 by the AAP.</div><div id=\"graphicVersion\">Graphic 102836 Version 4.0</div></div></div>"},"102840":{"type":"graphic_picture","displayName":"ATFL and syndesmosis surface anatomy","title":"Syndesmosis surface anatomy","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">Syndesmosis surface anatomy</div><div class=\"cntnt\"><img style=\"width:783px; height:585px;\" src=\"images/SM/102840_ATFL_syndsms_srfc_antmy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The distal-most location of the syndesmosis, the ATiFL, is approximately 1 inch proximal and slightly medial to the anterior talofibular ligament. There is usually no landmark to palpate, as the tibiotalar joint line and tibiotalar syndesmosis are not distinct in most individuals. The recommend approach to palpate the syndesmosis is to locate the anterio-medial tip of the lateral malleolus, and move proximally about an inch and slightly medially to the ATiFL, and continue palpation proximally along the interosseous membrane.</div><div class=\"graphic_reference\">Courtesy of Kevin deWeber, MD.</div><div id=\"graphicVersion\">Graphic 102840 Version 1.0</div></div></div>"},"102841":{"type":"graphic_picture","displayName":"Squeeze test for syndesmotic injury (high ankle sprain)","title":"Squeeze test for syndesmotic injury (high ankle sprain)","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Squeeze test for syndesmotic injury (high ankle sprain)</div><div class=\"cntnt\"><img style=\"width:586px; height:782px;\" src=\"images/SM/102841_Sqz_tst_hgh_ankl_sprn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform the squeeze test, place a heel of each hand just proximal to the midpoint of the calf, and compress the tibia and fibula by squeezing in an anteromedial to posterolateral direction. A positive test is marked by reproduction of pain in the distal syndesmosis, just above the ankle joint.</div><div class=\"graphic_reference\">Courtesy of Kevin deWeber, MD.</div><div id=\"graphicVersion\">Graphic 102841 Version 2.0</div></div></div>"},"102843":{"type":"graphic_table","displayName":"Neuroimaging characteristics of NMOSD","title":"Neuroimaging characteristics of neuromyelitis optica spectrum disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuroimaging characteristics of neuromyelitis optica spectrum disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Spinal cord MRI, acute</td> </tr> <tr> <td class=\"indent1\">LETM lesion associated with acute TM</td> </tr> <tr> <td class=\"indent2\">Increased signal on sagittal T2-weighted (standard T2-weighted, proton density, or STIR sequences) extending over three or more complete vertebral segments</td> </tr> <tr> <td class=\"indent2\">Central cord predominance (more than 70% of the lesion residing within the central gray matter)</td> </tr> <tr> <td class=\"indent2\">Gadolinium enhancement of the lesion on T1-weighted sequences (no specific distribution or pattern of enhancement is required)</td> </tr> <tr> <td class=\"indent1\">Other characteristic features that may be detected</td> </tr> <tr> <td class=\"indent2\">Rostral extension of the lesion into the brainstem</td> </tr> <tr> <td class=\"indent2\">Cord expansion/swelling</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Decreased signal on T1-weighted sequences corresponding to region of increased T2-weighted signal</td> </tr> <tr> <td class=\"subtitle1_single\">Spinal cord MRI, chronic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Longitudinally extensive cord atrophy (sharply demarcated atrophy extending over &#8805;3 complete, contiguous vertebral segments and caudal to a particular segment of the spinal cord), with or without focal or diffuse T2 signal change involving the atrophic segment</td> </tr> <tr> <td class=\"subtitle1_single\">Optic nerve MRI</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Unilateral or bilateral increased T2 signal or T1 gadolinium enhancement within optic nerve or optic chiasm; relatively long lesions (eg, those extending more than half the distance from orbit to chiasm) and those involving the posterior aspects of the optic nerves or the chiasm are associated with NMO</td> </tr> <tr> <td class=\"subtitle1_single\">Cerebral MRI: NMOSD-typical brain lesion patterns (increased signal on T2-weighted MRI sequences unless otherwise noted)</td> </tr> <tr> <td class=\"indent1\">Lesions involving the dorsal medulla (especially the area postrema), either small and localized, often bilateral, or contiguous with an upper cervical spinal cord lesion</td> </tr> <tr> <td class=\"indent1\">Periependymal surfaces of the fourth ventricle in the brainstem/cerebellum</td> </tr> <tr> <td class=\"indent1\">Lesions involving the hypothalamus, thalamus, or periependymal surfaces of the third ventricle</td> </tr> <tr> <td class=\"indent1\">Large, confluent, unilateral, or bilateral subcortical or deep white matter lesions</td> </tr> <tr> <td class=\"indent1\">Long (one-half of the length of the corpus callosum or greater), diffuse, heterogeneous, or edematous corpus callosum lesions</td> </tr> <tr> <td class=\"indent1\">Long corticospinal tract lesions, unilateral or bilateral, contiguously involving internal capsule and cerebral peduncle</td> </tr> <tr> <td class=\"indent1\">Extensive periependymal brain lesions, often with gadolinium enhancement</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LETM: longitudinally extensive transverse myelitis lesions; TM: transverse myelitis; NMOSD: neuromyelitis optica spectrum disorders; NMO: neuromyelitis optica; STIR: short tau inversion recovery.</div><div class=\"graphic_reference\">From: Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85:177. DOI: <a href=\"http://www.neurology.org/content/85/2/177.long\" target=\"_blank\">10.1212/WNL.0000000000001729</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 102843 Version 1.0</div></div></div>"},"102844":{"type":"graphic_picture","displayName":"Miliaria crystallina in infant","title":"Miliaria crystallina","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Miliaria crystallina</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/102844_Miliaria_crystallina_infnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small, clear vesicles on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 102844 Version 1.0</div></div></div>"},"102845":{"type":"graphic_picture","displayName":"Miliaria crystallina on neck","title":"Miliaria crystallina","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Miliaria crystallina</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/102845_Miliaria_crystlln_nck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple vesicles with clear fluid on the neck.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 102845 Version 1.0</div></div></div>"},"102846":{"type":"graphic_table","displayName":"Findings atypical for NMOSD","title":"Red flags: Findings atypical for neuromyelitis optica spectrum disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Red flags: Findings atypical for neuromyelitis optica spectrum disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Red flags (clinical/laboratory)</td> </tr> <tr> <td class=\"indent1\"><strong>1. Clinical features and laboratory findings</strong></td> </tr> <tr> <td class=\"indent3\">Progressive overall clinical course (neurologic deterioration unrelated to attacks; consider MS)</td> </tr> <tr> <td class=\"indent3\">Atypical time to attack nadir: Less than four hours (consider cord ischemia/infarction); continual worsening for more than four weeks from attack onset (consider sarcoidosis or neoplasm)</td> </tr> <tr> <td class=\"indent3\">Partial transverse myelitis, especially when not associated with LETM MRI lesion (consider MS)</td> </tr> <tr> <td class=\"indent3\">Presence of CSF oligoclonal bands (oligoclonal bands occur in &#60;20% of cases of NMO versus &#62;80% of MS)</td> </tr> <tr> <td class=\"indent1\"><strong>2. Comorbidities associated with neurologic syndromes that mimic NMOSD</strong></td> </tr> <tr> <td class=\"indent3\">Sarcoidosis, established or suggestive clinical, radiologic, or laboratory findings thereof (eg, mediastinal adenopathy, fever and night sweats, elevated serum angiotensin converting enzyme or interleukin-2 receptor levels)</td> </tr> <tr> <td class=\"indent3\">Cancer, established or with suggestive clinical, radiologic, or laboratory findings thereof; consider lymphoma or paraneoplastic disease (eg, collapsin response mediator protein-5 associated optic neuropathy and myelopathy or anti-Ma-associated diencephalic syndrome)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">Chronic infection, established or with suggestive clinical, radiologic, or laboratory findings thereof (eg, HIV, syphilis)</td> </tr> <tr> <td class=\"subtitle1_single\">Red flags (conventional neuroimaging)</td> </tr> <tr> <td class=\"indent1\"><strong>1. Brain</strong></td> </tr> <tr> <td class=\"indent2\">a. Imaging features (T2-weighted MRI) suggestive of MS (MS-typical)</td> </tr> <tr> <td class=\"indent4\">Lesions with orientation perpendicular to a lateral ventricular surface (Dawson fingers)</td> </tr> <tr> <td class=\"indent4\">Lesions adjacent to lateral ventricle in the inferior temporal lobe</td> </tr> <tr> <td class=\"indent4\">Juxtacortical lesions involving subcortical U-fibers</td> </tr> <tr> <td class=\"indent4\">Cortical lesions</td> </tr> <tr> <td class=\"indent2\">b. Imaging characteristics suggestive of diseases other than MS and NMOSD</td> </tr> <tr> <td class=\"indent4\">Lesions with persistent (&#62;3 months) gadolinium enhancement</td> </tr> <tr> <td class=\"indent1\"><strong>2. Spinal cord</strong></td> </tr> <tr> <td class=\"indent2\">Characteristics more suggestive of MS than NMOSD</td> </tr> <tr> <td class=\"indent3\">Lesions &#60;3 complete vertebral segments on sagittal T2-weighted sequences</td> </tr> <tr> <td class=\"indent3\">Lesions located predominantly (&#62;70%) in the peripheral cord on axial T2-weighted sequences</td> </tr> <tr> <td class=\"indent3\">Diffuse, indistinct signal change on T2-weighted sequences (as sometimes seen with longstanding or progressive MS)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These are some common or key findings that should prompt thorough investigation for competing differential diagnoses before making a diagnosis of NMOSD.</div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; LETM: longitudinally extensive transverse myelitis lesions; MS: multiple sclerosis; NMO: neuromyelitis optica; NMOSD: neuromyelitis optica spectrum disorders.</div><div class=\"graphic_reference\">From: Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85:177. DOI: <a href=\"http://www.neurology.org/content/85/2/177.long\" target=\"_blank\">10.1212/WNL.0000000000001729</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 102846 Version 1.0</div></div></div>"},"102847":{"type":"graphic_picture","displayName":"Miliaria rubra on infant","title":"Miliaria rubra","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Miliaria rubra</div><div class=\"cntnt\"><img style=\"width:724px; height:483px;\" src=\"images/DERM/102847_Miliaria_rubra_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Infant with widely spread, non-follicularly-based erythematous papules.</div><div class=\"graphic_reference\">Courtesy of Kenneth Greer, MD.</div><div id=\"graphicVersion\">Graphic 102847 Version 1.0</div></div></div>"},"102848":{"type":"graphic_picture","displayName":"Miliaria rubra on extremity","title":"Miliaria rubra","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Miliaria rubra</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/102848_Miliaria_rubra_extrmty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small erythematous papules and papulovesicles.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 102848 Version 1.0</div></div></div>"},"102849":{"type":"graphic_picture","displayName":"Miliaria profunda","title":"Miliaria profunda","html":"<div class=\"graphic\"><div style=\"width: 801px\" class=\"figure\"><div class=\"ttl\">Miliaria profunda</div><div class=\"cntnt\"><img style=\"width:781px; height:479px;\" src=\"images/DERM/102849_Miliaria_profunda.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple subtle skin-colored papules.</div><div class=\"graphic_reference\">Courtesy of Barbara Wilson, MD.</div><div id=\"graphicVersion\">Graphic 102849 Version 1.0</div></div></div>"},"102850":{"type":"graphic_picture","displayName":"Miliaria profunda histopathology","title":"Miliaria profunda","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Miliaria profunda</div><div class=\"cntnt\"><img style=\"width:521px; height:781px;\" src=\"images/DERM/102850_Miliaria_prfnd_hstpthlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathology of miliaria profunda. Spongiosis and inflammation around the eccrine duct.</div><div class=\"graphic_reference\">Courtesy of Barbara Wilson, MD.</div><div id=\"graphicVersion\">Graphic 102850 Version 1.0</div></div></div>"},"102855":{"type":"graphic_diagnosticimage","displayName":"Freiberg disease","title":"Freiberg disease","html":"<div class=\"graphic\"><div style=\"width: 780px\" class=\"figure\"><div class=\"ttl\">Freiberg disease</div><div class=\"cntnt\"><img style=\"width:760px; height:620px;\" src=\"images/EM/102855_Freiberg_dss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Anteroposterior radiograph of the foot demonstrating early Freiberg's of the second metatarsal head.<br />(B) Anteroposterior radiograph of the foot demonstrating late stage Freiberg's of the third metatarsal head.</div><div class=\"graphic_reference\">Reproduced from: Ayer A, Hennrikus W. Foot pain in the child and adolescent athlete. Pediatr Clin N AM 2014: 61:1185. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 102855 Version 1.0</div></div></div>"},"102858":{"type":"graphic_figure","displayName":"Biceps anatomy PI","title":"Biceps muscle and tendons","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Biceps muscle and tendons</div><div class=\"cntnt\"><img style=\"width:484px; height:576px;\" src=\"images/PI/102858_Biceps_anatomy_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 102858 Version 1.0</div></div></div>"},"102859":{"type":"graphic_diagnosticimage","displayName":"Iselin disease (fifth metatarsal traction apophysitis)","title":"Iselin disease (fifth metatarsal traction apophysitis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Iselin disease (fifth metatarsal traction apophysitis)</div><div class=\"cntnt\"><img style=\"width:272px; height:586px;\" src=\"images/EM/102859_Iselin_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oblique radiograph of the foot demonstrating Iselin's apophyisitis. Note the separation of the apophysis from the base of the fifth metatarsal.</div><div class=\"graphic_reference\">Reproduced from: Ayer A, Hennrikus W. Foot pain in the child and adolescent athlete. Pediatr Clin N AM 2014: 61:1185. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 102859 Version 2.0</div></div></div>"},"102862":{"type":"graphic_diagnosticimage","displayName":"Spinal cord and optic nerve MRI in NMOSD","title":"Spinal cord and optic nerve MRI patterns in neuromyelitis optica spectrum disorders","html":"<div class=\"graphic\"><div style=\"width: 951px\" class=\"figure\"><div class=\"ttl\">Spinal cord and optic nerve MRI patterns in neuromyelitis optica spectrum disorders</div><div class=\"cntnt\"><img style=\"width:931px; height:1086px;\" src=\"images/NEURO/102862_Spnl_crd_optc_nrv_MRI_NMOSD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spinal cord imaging in the context of acute myelitis in NMOSD usually reveals a LETM lesion extending over three or more vertebral segments. Sagittal T2-weighted MRI of the thoracic spinal cord (A) demonstrates a typical LETM lesion involving most of the thoracic spinal cord (arrows). LETM lesions have a predilection for the central cord, as shown by axial T2-weighted (B, arrowhead) and T1-weighted MRI with gadolinium (C, arrowhead). Cervical LETM may extend into the medulla, a characteristic NMOSD pattern demonstrated in D (arrows; sagittal T2-weighted MRI) and E (arrows; sagittal T1-weighted MRI with gadolinium). Acute LETM lesions can be associated with intralesional hypointensity as shown by sagittal T1-weighted MRI (F, arrow); in this example, a rim of gadolinium enhancement surrounds the hypointense region. Chronic sequelae of LETM may include longitudinally extensive segments of spinal cord atrophy as shown by T2-weighted MRI using sagittal (G, the two arrowheads indicate the atrophic segment and the top arrow indicates the normal diameter of unaffected cervical spinal cord) and axial planes (H, arrowhead shows an atrophic spinal cord). Fast spin echo fat-suppressed T2-weighted MRI in the axial (I) and coronal (J) planes shows increased signal throughout most the length of the left optic nerve, especially its posterior portion (arrows). Axial T1-weighted MRI with gadolinium shows enhancement of the optic chiasm (K, arrows). These images are from two different patients experiencing acute optic neuritis in the setting of NMOSD.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; LETM: longitudinally extensive transverse myelitis lesions; TM: transverse myelitis; NMOSD: neuromyelitis optica spectrum disorders; NMO: neuromyelitis optica.</div><div class=\"graphic_reference\">From: Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85:177. DOI: <a href=\"http://www.neurology.org/content/85/2/177.long\" spellcheck=\"true\" target=\"_blank\">10.1212/WNL.0000000000001729</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 102862 Version 2.0</div></div></div>"},"102863":{"type":"graphic_diagnosticimage","displayName":"Brainstem lesions in NMOSD","title":"Dorsal medulla, area postrema, and other brainstem lesions in neuromyelitis optica spectrum disorders","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Dorsal medulla, area postrema, and other brainstem lesions in neuromyelitis optica spectrum disorders</div><div class=\"cntnt\"><img style=\"width:458px; height:1087px;\" src=\"images/NEURO/102863_Brainstem_lsns_NMOSD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal T2-weighted FLAIR MRI shows a lesion in the dorsal medulla (A, arrow). Sagittal T2-weighted (B) and T1-weighted MRI with gadolinium (C) each demonstrate an acute lesion (arrows) associated with area postrema clinical syndrome. Axial T2-weighted FLAIR (D, arrows) and T1-weighted MRI with gadolinium (E, arrowheads) show dorsal medulla involvement in a patient with acute area postrema clinical syndrome. Axial T2-weighted FLAIR MRI shows periependymal lesions involving the pons (F, arrows) and dorsal midbrain (G, arrow). Sagittal T2-weighted FLAIR MRI shows increased signal surrounding the fourth ventricle (H, arrows).</div><div class=\"graphic_footnotes\">NMOSD: neuromyelitis optica spectrum disorders; FLAIR: fluid-attenuated inversion recovery; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">From: Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85:177. DOI: <a href=\"http://www.neurology.org/content/85/2/177.long\" spellcheck=\"true\" target=\"_blank\">10.1212/WNL.0000000000001729</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 102863 Version 3.0</div></div></div>"},"102864":{"type":"graphic_diagnosticimage","displayName":"Diencephalic and cerebral lesions in NMOSD","title":"Diencephalic and cerebral lesions in neuromyelitis optica spectrum disorders","html":"<div class=\"graphic\"><div style=\"width: 681px\" class=\"figure\"><div class=\"ttl\">Diencephalic and cerebral lesions in neuromyelitis optica spectrum disorders</div><div class=\"cntnt\"><img style=\"width:661px; height:1087px;\" src=\"images/NEURO/102864_Dncphlc_crbrl_lsns_NMOSD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A variety of brain lesion patterns are associated with neuromyelitis optica spectrum disorder. Axial T2-weighted FLAIR MRI from two patients demonstrates lesions involving the right thalamus (A, arrow) and the hypothalamus (B, arrows). Axial T2-weighted FLAIR MRI shows an extensive subcortical white matter lesion (C, arrow) that enhances after gadolinium administration on T1-weighted sequences (D, arrow). Chronic longitudinally extensive and linear corpus callosum lesions are depicted on sagittal T2-weighted FLAIR MRI (E, arrows). Coronal T2-weighted FLAIR MRI shows longitudinal involvement of the corticospinal tract extending to the cerebral peduncle and pons (F, arrows). Acute periependymal cerebral lesions from one patient are depicted using sagittal (G, arrow) and axial (H, arrows) T2-weighted FLAIR MRI and axial T1-weighted MRI with gadolinium (I, arrows).</div><div class=\"graphic_footnotes\">NMOSD: neuromyelitis optica spectrum disorders; FLAIR: fluid-attenuated inversion recovery.</div><div class=\"graphic_reference\">From: Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85:177. DOI: <a href=\"http://www.neurology.org/content/85/2/177.long\" spellcheck=\"true\" target=\"_blank\">10.1212/WNL.0000000000001729</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 102864 Version 1.0</div></div></div>"},"102865":{"type":"graphic_picture","displayName":"Miliaria rubra close view","title":"Miliaria rubra","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Miliaria rubra</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/102865_Miliaria_rubra_close.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules and papulovesicles. The erythema is subtle in this patient with dark skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 102865 Version 1.0</div></div></div>"},"102887":{"type":"graphic_picture","displayName":"Undebrided and debrided partial-thickness thermal burn","title":"Undebrided and debrided partial-thickness thermal burn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Undebrided and debrided partial-thickness thermal burn</div><div class=\"cntnt\"><img style=\"width:323px; height:1001px;\" src=\"images/EM/102887_Undbdbrdprtthckthrmbrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photographs above show a partial-thickness thermal burn before and after basic debridement. Topical antibiotic ointment and an appropriate dressing with a nonadherent first layer are applied following debridement.</div><div class=\"graphic_reference\">Courtesy of Arek Wiktor, MD, FACS.</div><div id=\"graphicVersion\">Graphic 102887 Version 3.0</div></div></div>"},"102891":{"type":"graphic_picture","displayName":"Early epithelialization of deep partial thickness thermal burn","title":"Early epithelialization of deep partial thickness thermal burn","html":"<div class=\"graphic\"><div style=\"width: 801px\" class=\"figure\"><div class=\"ttl\">Early epithelialization of deep partial thickness thermal burn</div><div class=\"cntnt\"><img style=\"width:781px; height:582px;\" src=\"images/EM/102891_Erlyepthllztndpthckbrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tiny opalescent \"islands\" of epithelium (skin buds) are apparent in this photograph of a deep partial thickness thermal burn of the arm in the early stages of epithelialization.</div><div class=\"graphic_reference\">Courtesy of Arek Wiktor, MD, FACS.</div><div id=\"graphicVersion\">Graphic 102891 Version 2.0</div></div></div>"},"102914":{"type":"graphic_table","displayName":"Medication considerations in athletes with URTIs","title":"Medication considerations in athletes with URTIs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medication considerations in athletes with URTIs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Risks and implications</td> <td class=\"subtitle1\">Our approach</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antibiotics</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Fluoroquinolones</td> <td>Tendinopathy/tendon rupture</td> <td>Avoid if possible, stop if symptoms of tendon pain arise</td> </tr> <tr> <td>Photosensitivity</td> <td>Emphasize use of sunscreen and protective clothing, particularly if participating in outdoor sports</td> </tr> <tr> <td>QTc prolongation &ndash; May fail electrocardiogram (EKG) screening (if required for clearance for participation)</td> <td>Reasonable to avoid where possible if athlete will have electrocardiogram (EKG) checked for clearance/eligibility</td> </tr> <tr> <td class=\"indent1\">Macrolides</td> <td>QTc prolongation &ndash; May fail EKG screening (if required for clearance for participation)</td> <td>Reasonable to avoid where possible if athlete will have electrocardiogram checked for clearance/eligibility</td> </tr> <tr> <td class=\"indent1\">Tetracyclines/sulfonamides</td> <td>Photosensitivity</td> <td>Emphasize use of sunscreen and protective clothing, particularly if participating in outdoor sports</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Any antibiotic</td> <td>Antibiotic-associated diarrhea &ndash; Decreased performance/increased risk for dehydration</td> <td>Use narrow-spectrum antibiotics, avoid extended courses</td> </tr> <tr class=\"divider_bottom\"> <td>Fatigue (possible) &ndash; Impaired performance</td> <td>When possible, avoid dosing antibiotics (eg, prophylactic antibiotics for acne) around the time of competition</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Medications used for symptom relief</td> </tr> <tr> <td class=\"indent1\">Expectorants</td> <td>None</td> <td>May be used</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Antihistamines</td> <td>Anticholinergic effects &ndash; Increased risk of dehydration/heat illness</td> <td>Advise to stay well-hydrated</td> </tr> <tr> <td>Sedation &ndash; Increased risk of injury</td> <td>Avoid in competition</td> </tr> <tr> <td class=\"indent1\">Antitussives</td> <td>Fatigue &ndash; Increased risk of injury</td> <td>Use with caution</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Oral decongestants</td> <td>May contain banned substances</td> <td>Avoid in competition</td> </tr> <tr> <td>Dehydration/hyperthermia</td> <td>Advise to stay well-hydrated</td> </tr> <tr> <td class=\"indent1\">Antipyretics</td> <td>Mask fever</td> <td>Should not be used to mask fever in order to allow participation in competition</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 102914 Version 1.0</div></div></div>"},"102921":{"type":"graphic_figure","displayName":"Pressure on coccyx during vaginal delivery (childbirth) ","title":"Pressure on coccyx during vaginal delivery (childbirth) ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pressure on coccyx during vaginal delivery (childbirth) </div><div class=\"cntnt\"><img style=\"width:438px; height:720px;\" src=\"images/PC/102921_Vaginal_delivery_childbirth_with_coccyx_labelled.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a vaginal delivery, injury from&nbsp;pressure exerted on the coccyx, especially during forceps delivery, can lead to coccydynia. </div><div class=\"graphic_reference\">Reproduced from: U.S. Department of Health and Human Services Office on Women's Health. Pregnancy: Labor and birth. Available at: <A spellcheck=true href=\"http://www.womenshealth.gov/pregnancy/childbirth-beyond/labor-birth.html\" target=_blank>http://www.womenshealth.gov/pregnancy/childbirth-beyond/labor-birth.html</A>&nbsp;(Accessed on July 23, 2015).</div><div id=\"graphicVersion\">Graphic 102921 Version 1.0</div></div></div>"},"102923":{"type":"graphic_table","displayName":"Defining potential life-ending clin practices","title":"Definitions of potential life-ending clinical practices; updated as of October 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions of potential life-ending clinical practices; updated as of&nbsp;October 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Term</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Status</td> </tr> <tr class=\"divider_bottom\"> <td>Terminating life-sustaining treatments</td> <td>When the physician withholds or withdraws life-sustaining treatments, such as a respirator, vasopressors, or artificial nutrition, from the patient with the patient or proxy's consent</td> <td>Legal and ethical in the United States and most other developed countries</td> </tr> <tr class=\"divider_bottom\"> <td>\"Double effect\" of opioids for pain or dyspnea</td> <td>When the physician administers narcotics or other medications to relieve pain or other symptoms \"foreseeing but not intending\" that this may cause respiratory depression or other side effects that might increase the risk of the patient's death</td> <td>Legal and ethical in the United States and most other developed countries</td> </tr> <tr class=\"divider_bottom\"> <td>Physician-assisted dying (also called physician-assisted suicide, physician aid in dying, patient-administered physician-hastened death, self-administered medical assistance in dying and medical aid in dying)</td> <td>When the physician provides medication, a prescription, and information on its use to a patient at his or her request with the understanding that the patient potentially intends to use them to end life</td> <td>Legal in Oregon, Montana, Washington, Vermont, California, Colorado, the District of Columbia, the Netherlands, Belgium, Luxemburg, Switzerland, Columbia, Canada, and 7 of 17 states in Germany</td> </tr> <tr> <td>Voluntary active euthanasia (also potentially called physician-administered hastened death, and clinician-assisted medical assistance in dying)</td> <td>When the physician or someone else administers medications, such as narcotics, or another intervention to intentionally cause the patient's death at the patient's explicit request with full informed consent</td> <td>Legal in the Netherlands, Luxemburg, Belgium, Columbia, and Canada (policy&nbsp;still under development&nbsp;in some provinces)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 102923 Version 6.0</div></div></div>"},"102924":{"type":"graphic_picture","displayName":"Cutis verticis gyrata secondary","title":"Secondary cutis verticis gyrata","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Secondary cutis verticis gyrata</div><div class=\"cntnt\"><img style=\"width:648px; height:432px;\" src=\"images/DERM/102924_Cutis_verticis_gyrata_sec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thickened and folded scalp area in a female infant with Turner syndrome.</div><div class=\"graphic_reference\">From: Debeer A, Steenkiste E, Devriendt K, Morren M. Scalp skin lesion in Turner syndrome: more than lymphedema? Clin Dysmorphol 2005; 14:149. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2005. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 102924 Version 1.0</div></div></div>"},"102936":{"type":"graphic_picture","displayName":"HCL peripheral blood","title":"Hairy cell leukemia in peripheral blood","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Hairy cell leukemia in peripheral blood</div><div class=\"cntnt\"><img style=\"width:716px; height:527px;\" src=\"images/HEME/102936_Hairy_cell_lkm_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral smear from a patient with hairy cell leukemia. Wright-Giemsa stain showing two hairy cells. The cells have abundant, irregularly distributed cytoplasm with irregular cytoplasmic outlines, giving the cells their \"hairy\" appearance. The nuclei vary from round to oval.</div><div class=\"graphic_reference\">This image was originally published in ASH Image Bank. Maslak P. Hairy cell leukemia - 2. ASH Image Bank. 2008; image number 00003741. Copyright &copy; the American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 102936 Version 4.0</div></div></div>"},"102940":{"type":"graphic_table","displayName":"Risk factors for CP","title":"Prenatal and perinatal factors associated with an increased risk of cerebral palsy*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prenatal and perinatal factors associated with an increased risk of cerebral palsy*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Estimated risk<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Prematurity</strong></td> </tr> <tr> <td class=\"indent1\">GA &#60;28 weeks</td> <td class=\"centered\">OR 60.9, 95% CI 34.3-108.0</td> </tr> <tr> <td class=\"indent1\">GA 28 to 31 weeks</td> <td class=\"centered\">OR 32.0, 95% CI 20.6-49.5</td> </tr> <tr> <td class=\"indent1\">GA 32 to 36 weeks</td> <td class=\"centered\">OR 5.0, 95% CI 2.9-8.6</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Low birth weight</strong></td> </tr> <tr> <td class=\"indent1\">&#60;1500 g</td> <td class=\"centered\">OR 44.5, 95% CI 35.6-55.5</td> </tr> <tr> <td class=\"indent1\">1500 to 2499 g</td> <td class=\"centered\">OR 7.6, 95% CI 6.0-9.7</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Intrauterine infection</strong></td> </tr> <tr> <td class=\"indent1\">Any maternal infection during pregnancy</td> <td class=\"centered\">OR 2.9, 95% CI 1.7-4.8</td> </tr> <tr> <td class=\"indent1\">Maternal chorioamnionitis</td> <td class=\"centered\">RR 1.9, 95% CI 1.5-2.5</td> </tr> <tr> <td><strong>Preeclampsia</strong></td> <td class=\"centered\">OR 1.9, 95% CI 1.5-2.5</td> </tr> <tr> <td><strong>Placental abruption</strong></td> <td class=\"centered\">OR 10.9, 95% CI 8.4-14.1</td> </tr> <tr> <td><strong>Multiple pregnancy</strong></td> <td class=\"centered\">OR 3.7, 95% CI 3.0-4.5</td> </tr> <tr> <td><strong>Heavy maternal alcohol consumption</strong></td> <td class=\"centered\">OR 3.3, 95% CI 1.3-8.5</td> </tr> <tr> <td><strong>Maternal smoking</strong></td> <td class=\"centered\">HR 1.8, 95% CI 1.1-2.9</td> </tr> <tr> <td><strong><span style=\"color: black;\">Maternal obesity (prepregnancy BMI &#8805;30)</span></strong></td> <td class=\"centered\"><span style=\"color: #0000ff;\"><span style=\"color: black;\">RR&nbsp;1.6, 95% CI 1.1-2.</span><span style=\"color: black;\">2</span></span></td> </tr> <tr> <td><strong>Small size for gestational age</strong></td> <td class=\"centered\">OR 3.7, 95% CI 3.1-4.4</td> </tr> <tr> <td><strong>Other congenital abnormalities</strong></td> <td class=\"centered\">OR 5.2, 95% CI 2.8-9.7</td> </tr> <tr> <td><strong>Apgar &#60;7 at 5 minutes</strong></td> <td class=\"centered\">OR 27.0, 95% CI 23.5-31.2</td> </tr> <tr> <td><strong>Neonatal infection</strong></td> <td class=\"centered\">OR 14.7, 95% CI 1.7-126.5</td> </tr> <tr> <td><strong><span style=\"color: black;\">Respiratory distress syndrome</span></strong></td> <td class=\"centered\"><span style=\"color: black;\">HR 2.1, 95% CI 1.4-3.1</span>&nbsp;</td> </tr> <tr> <td><strong>Requiring mechanical ventilation after birth</strong></td> <td class=\"centered\">OR 2.4, 95% CI 2.4-4.5</td> </tr> <tr> <td><strong>Requiring antibiotic therapy after birth</strong></td> <td class=\"centered\">OR 1.7, 95% CI 1.3-2.2</td> </tr> <tr> <td><strong>Neonatal seizures</strong></td> <td class=\"centered\">OR 7.4, 95% CI 4.8-11.6</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GA: gestational age; OR: odds ratio; RR: relative risk; HR: hazard ratio; BMI: body mass index; CP: cerebral palsy.<br />* This table summarizes prenatal and perinatal factors that have been reported to be associated with an increased risk of CP. Studies have identified associations with these factors and CP; however, in most cases a causal relationship has not been established. While the estimated risks associated with individual factors are presented, in many cases CP is multifactorial and multiple risk factors coexist. In most studies, prematurity and low birth weight are the strongest and most consistent predictors of CP.<br />¶ Baseline risk of CP is approximately 0.2 percent.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hirvonen M, Ojala R, Korhonen P, et al. Cerebral palsy among children born moderately and late preterm. Pediatrics 2014; 134:e1584.</LI>&#xD;&#xA;<LI>Hjern A, Thorngren-Jerneck K. Perinatal complications and socio-economic differences in cerebral palsy in Sweden - a national cohort study. BMC Pediatr 2008; 8:49. </LI>&#xD;&#xA;<LI>O'Leary CM, Watson L, D'Antoine H, et al. Heavy maternal alcohol consumption and cerebral palsy in the offspring. Dev Med Child Neurol 2012; 54:224. </LI>&#xD;&#xA;<LI>Streja E, Miller JE, Bech BH, et al. Congenital cerebral palsy and prenatal exposure to self-reported maternal infections, fever, or smoking. Am J Obstet Gynecol 2013; 209:332.e1. </LI>&#xD;&#xA;<LI>Croen LA, Grether JK, Curry CJ, Nelson KB. Congenital abnormalities among children with cerebral palsy: More evidence for prenatal antecedents. J Pediatr 2001; 138:804. </LI>&#xD;&#xA;<LI>Ahlin K, Himmelmann K, Hagberg G, et al. Cerebral palsy and perinatal infection in children born at term. Obstet Gynecol 2013; 122:41. </LI>&#xD;&#xA;<LI>Wu YW. Systematic review of chorioamnionitis and cerebral palsy. Ment Retard Dev Disabil Res Rev 2002; 8:25.</LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Thygesen SK, Olsen M, Østergaard JR, Sørensen HT. Respiratory distress syndrome in moderately late and late preterm infants and risk of cerebral palsy: a population-based cohort study. BMJ Open 2016; 6:e011643.</SPAN></LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Forthun I, Wilcox AJ, Strandberg-Larsen K, et al. Maternal Prepregnancy BMI and Risk of Cerebral Palsy in Offspring. Pediatrics 2016; 138.</SPAN></LI></OL></div><div id=\"graphicVersion\">Graphic 102940 Version 3.0</div></div></div>"},"102942":{"type":"graphic_table","displayName":"Genetic and metabolic motor disorders","title":"Genetic and metabolic disorders that may present with motor symptoms resembling cerebral palsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic and metabolic disorders that may present with motor symptoms resembling cerebral palsy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Type of motor disturbance</td> <td class=\"subtitle1\">Clinical and radiographic features</td> <td class=\"subtitle1\">Laboratory and diagnostic tests</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Organic acidemias</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/231670\" target=\"_blank\">Glutaric aciduria type 1</a></td> <td>Dystonia</td> <td> <ul> <li>Episodes of metabolic decompensation and encephalopathy often precipitated by infection and fever </li> <li>Rarely presents in the newborn period </li> <li>Microencephalic macrocephaly </li> <li>Seizures (approximately 20 percent) </li> <li>Cognitive function is preserved </li> <li>MRI findings include frontal and temporal atrophy </li> </ul> </td> <td> <ul> <li>Abnormal urinary organic acid analysis (elevated glutaric acid and 3-hydroxyglutaric acid) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://omim.org/entry/253270\" target=\"_blank\">Holocarboxylase synthetase deficiency</a></td> <td>Hypotonia</td> <td> <ul> <li>Ketoacidosis </li> <li>Dermatitis </li> <li>Alopecia </li> <li>Seizures </li> <li>Developmental delay </li> </ul> </td> <td> <ul> <li>Abnormal urinary organic acid analysis (elevated beta-hydroxyisovalerate, beta-methylcrotonylglycine, beta-hydroxypropionate, methylcitrate, and tiglylglycine) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Urea cycle disorders</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://omim.org/entry/207800\" target=\"_blank\">Arginase deficiency</a></td> <td>Spasticity</td> <td> <ul> <li>Hyperammonemia </li> <li>Encephalopathy </li> <li>Respiratory alkalosis </li> </ul> </td> <td> <ul> <li>Elevated ammonia level </li> <li>Abnormal quantitative plasma amino acid analysis (elevated arginine level) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Disorders of carbohydrate metabolism</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://omim.org/entry/312170\" target=\"_blank\">Pyruvate dehydrogenase deficiency</a></td> <td> <p>Spasticity</p> <p>Ataxia</p> Hypotonia</td> <td> <ul> <li>Lactic acidosis </li> <li>Seizures </li> <li>Intellectual disability </li> </ul> </td> <td> <ul> <li>Elevated lactate and pyruvate levels in blood and CSF </li> <li>Abnormal PDH enzymatic activity in cultured fibroblasts </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Peroxisomal disorders</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/214100\" target=\"_blank\">Zellweger syndrome</a></td> <td>Hypotonia</td> <td> <ul> <li>Craniofacial dysmorphism </li> <li>Hepatomegaly </li> <li>Neonatal seizures </li> <li>Profound developmental delay </li> <li>MRI findings include cortical and white matter abnormalities </li> <li>Neurologic deterioration is rapid and infants rarely survive beyond six months of age </li> </ul> </td> <td> <ul> <li>Elevated plasma VLCFA levels </li> <li>Elevated levels of phytanic acid, pristanic acid, and pipecolic acid in plasma and fibroblasts </li> <li>Reduced plasmalogen in erythrocytes </li> <li>Molecular genetic testing for mutations in the PEX1 or PEX6 genes may also be helpful </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/300100\" target=\"_blank\">Adrenoleukodystrophy</a> and adrenomyeloneuropathy</td> <td>Spasticity</td> <td>Clinical features vary by specific type, and may include: <ul class=\"decimal_heading\"> <li>Cognitive and behavioral abnormalities </li> <li>Adrenal insufficiency </li> <li>Hyperpigmented skin </li> <li>Gonadal dysfunction </li> <li>Neurologic deterioration progresses at a variable rate </li> </ul> </td> <td> <ul> <li>Elevated plasma VLCFA levels </li> <li>Molecular genetic testing for mutations in the ABCD1 gene may be helpful in cases with borderline VLCFA levels or&nbsp;atypical features, or in females </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://omim.org/entry/601539\" target=\"_blank\">Infantile Refsum disease</a></td> <td> <p>Hypotonia</p> Ataxia</td> <td> <ul> <li>Abnormalities of the optic nerve and disc </li> <li>Retinitis pigmentosa </li> <li>Sensorineural hearing loss </li> <li>Hepatomegaly and cirrhosis </li> <li>Neurologic deterioration is slower than in Zellweger syndrome or ALD </li> </ul> </td> <td> <ul> <li>Elevated plasma VLCFA levels, though less pronounced than in Zellweger syndrome and ALD </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Lipid storage disorders</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://omim.org/entry/257220\" target=\"_blank\">Niemann-Pick disease type C</a></td> <td> <p>Ataxia</p> Dystonia</td> <td> <ul> <li>Progressive neurodegeneration </li> <li>Hepatosplenomegaly </li> <li>Systemic involvement of liver, spleen, or lung precedes neurologic symptoms </li> <li>MRI shows cerebral and cerebellar atrophy and thinning of the corpus callosum </li> </ul> </td> <td> <ul> <li>Abnormal liver function tests </li> <li>Fibroblast cell culture with filipin staining </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Mitochondrial disorders</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/256000\" target=\"_blank\">Leigh syndrome</a></td> <td> <p>Ataxia</p> Dystonia</td> <td> <ul> <li>Progressive psychomotor regression </li> <li>Seizures </li> <li>External ophthalmoplegia </li> <li>Lactic acidosis </li> <li>Vomiting </li> <li>MRI shows abnormal white matter signal in the putamen, basal ganglia, and brainstem&nbsp;on T2 images </li> </ul> </td> <td> <ul> <li>Increased lactate levels in blood and CSF </li> <li>Genetic testing for specific mutations (&#62;20 have been described) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Others</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/105830\" target=\"_blank\">Angelman syndrome</a></td> <td>Ataxia</td> <td> <ul> <li>Profound intellectual disability</li> <li>Postnatal microcephaly</li> <li>Typical abnormal behaviors (paroxysmal laughter, easily excitable) </li> </ul> </td> <td> <ul> <li>Methylation studies and chromosome microarray to detect chromosome 15 anomalies and UBE3A mutations</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/208900\" target=\"_blank\">Ataxia-telangiectasia</a></td> <td>Ataxia</td> <td> <ul> <li>Progressive cerebellar ataxia </li> <li>Abnormal eye movements </li> <li>Oculocutaneous telangiectasias </li> <li>Immune deficiency </li> <li>Increased risk of malignancy </li> </ul> </td> <td> <ul> <li>Elevated serum alpha-fetoprotein level</li> <li>Low IgA and IgG levels</li> <li>Lymphopenia</li> <li>Genetic testing for mutation in the ATM gene</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/128230\" target=\"_blank\">Dopa-responsive dystonia</a></td> <td> <p>Focal dystonia</p> Spastic diplegia</td> <td> <ul> <li>Onset in early childhood </li> <li>Symptoms worsen with fatigue and exercise </li> </ul> </td> <td> <ul> <li>Positive response to a trial of levodopa </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/phenotypicSeries/PS303350\" spellcheck=\"true\" target=\"_blank\">Hereditary spastic paraplegia</a>&nbsp;</td> <td>Spastic paraplegia</td> <td> <ul> <li>Variable depending on specific mutation</li> </ul> </td> <td> <ul> <li>&#62;50 mutations have been identified</li> <li>Genetic testing is available for many</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/300322\" target=\"_blank\">Lesch-Nyhan syndrome</a></td> <td> <p>Choreoathetosis</p> <p>Dystonia</p> Spasticity</td> <td> <ul> <li>Self-mutilating behavior </li> <li>Urinary stones due to hyperuricemia </li> </ul> </td> <td> <ul> <li>Elevated uric acid level </li> <li>Abnormal enzymatic activity of HPRT in cultured fibroblasts </li> <li>Genetic testing for HPRT gene mutations </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/250100\" target=\"_blank\">Metachromatic leukodystrophy</a></td> <td> <p>Hypotonia</p> Ataxia</td> <td> <ul> <li>Regression of motor skills </li> <li>Seizures </li> <li>Optic atrophy </li> <li>Reduced or absent deep tendon reflexes </li> <li>Intellectual disability </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Deficient arylsulfatase A enzyme activity in leukocytes or cultured skin fibroblasts</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/247200\" target=\"_blank\">Miller-Dieker lissencephaly</a></td> <td>Hypotonia or spasticity</td> <td> <ul> <li>Lissencephaly </li> <li>Microcephaly </li> <li>Dysmorphic features </li> <li>Seizures </li> <li>Failure to thrive </li> </ul> </td> <td> <ul> <li>Cytogenetic testing for 17p13.3 microdeletion </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/312080\" target=\"_blank\">Pelizaeus-Merzbacher</a></td> <td> <p>Spasticity</p> <p>Ataxia</p> Athetosis</td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Nystagmus </li> <li>Cognitive impairment </li> <li>Onset in infancy </li> <li>Slowly progressive </li> <li>Language development may be normal </li> <li>MRI shows white matter abnormalities </li> </ul> </td> <td> <ul> <li>Genetic testing for mutations in PLP1 gene </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/607596\" target=\"_blank\">Pontocerebellar hypoplasias</a></td> <td> <p>Hypotonia</p> Dyskinesias</td> <td>Clinical features vary by specific type, and may include: <ul class=\"decimal_heading\"> <li>Progressive muscle atrophy </li> <li>Microcephaly </li> <li>Developmental delay </li> <li>MRI shows small cerebellum and brainstem including the pons </li> </ul> </td> <td> <ul> <li>Genetic testing for PCH gene mutations (mutations in &#62;10 genes have been described) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/312750\" target=\"_blank\">Rett syndrome</a></td> <td> <p>Dystonia</p> Spasticity</td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Occurs almost exclusively in females</li> <li>Normal development during first six months followed by regression and loss of milestones</li> <li>Loss of speech capability</li> <li>Stereotypic hand movements </li> </ul> <li>Seizures</li> <li>Autistic features </li> <p>&nbsp;</p> </td> <td> <ul> <li>Clinical diagnosis </li> <li>Genetic testing for MECP2 mutations may be helpful </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This list is not exhaustive. Refer to UpToDate topics on cerebral palsy for further details.</div><div class=\"graphic_footnotes\">VLCFA: very long chain fatty acids; PDH: pyruvate dehydrogenase; HPRT: hypoxanthine phosphoribosyltransferase; CSF: cerebrospinal fluid; PCH: pontocerebellar hypoplasias; MRI: magnetic resonance imaging; Ig: immunoglobulin; ATM: ataxia-telangiectasia mutated; ALD: adrenoleukodystrophy.</div><div id=\"graphicVersion\">Graphic 102942 Version 2.0</div></div></div>"},"102955":{"type":"graphic_algorithm","displayName":"Effect of sleep on UA mechanics and alveolar ventilation","title":"Effect of sleep on upper airway mechanics and alveolar ventilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of sleep on upper airway mechanics and alveolar ventilation</div><div class=\"cntnt\"><img style=\"width:281px; height:197px;\" src=\"images/SLEEP/102955_Effct_slp_UA_mchn_alvlr_vnt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that several sleep-related changes contribute to decreased alveolar ventilation and increased arterial PaCO<sub>2</sub>.</div><div class=\"graphic_footnotes\">VT: tidal volume; UA: upper airway; VA: alveolar ventilation.</div><div id=\"graphicVersion\">Graphic 102955 Version 1.0</div></div></div>"}};